<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="pt" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40197947</article-id><article-id pub-id-type="pmc">PMC12013738</article-id>
<article-id pub-id-type="other">00401</article-id><article-id pub-id-type="doi">10.36660/abc.20240529</article-id><article-categories><subj-group subj-group-type="heading"><subject>Artigo de Revis&#x000e3;o</subject></subj-group></article-categories><title-group><article-title>O Complexo Quebra-Cabe&#x000e7;a do Fen&#x000f3;tipo Hipertr&#x000f3;fico: Uma Abordagem Pr&#x000e1;tica para o Cl&#x000ed;nico</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7046-8707</contrib-id><name><surname>Felix</surname><given-names>Alex dos Santos</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0711-7995</contrib-id><name><surname>Barberato</surname><given-names>Silvio Henrique</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8809-8783</contrib-id><name><surname>de Melo</surname><given-names>Marcelo Dantas Tavares</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8812-2330</contrib-id><name><surname>Rosa</surname><given-names>S&#x000ed;lvia Aguiar</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3812-4872</contrib-id><name><surname>Cardim</surname><given-names>Nuno</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgname">Instituto Nacional de Cardiologia</institution>
<addr-line>
<named-content content-type="city">Rio de Janeiro</named-content>
<named-content content-type="state">RJ</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Instituto Nacional de Cardiologia, Rio de Janeiro, RJ &#x02013; Brasil</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">DASA - Diagn&#x000f3;sticos da Am&#x000e9;rica SA</institution>
<addr-line>
<named-content content-type="city">Rio de Janeiro</named-content>
<named-content content-type="state">RJ</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">DASA - Diagn&#x000f3;sticos da Am&#x000e9;rica SA, Rio de Janeiro, RJ &#x02013; Brasil</institution>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="orgname">Universidade do Estado do Rio de Janeiro</institution>
<addr-line>
<named-content content-type="city">Rio de Janeiro</named-content>
<named-content content-type="state">RJ</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ &#x02013; Brasil</institution>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="orgdiv1">Complexo Hospitalar Am&#x000e9;ricas - Vit&#x000f3;ria</institution>
<institution content-type="orgname">Samaritano Barra</institution>
<addr-line>
<named-content content-type="city">Rio de Janeiro</named-content>
<named-content content-type="state">RJ</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Complexo Hospitalar Am&#x000e9;ricas - Vit&#x000f3;ria / Samaritano Barra, Rio de Janeiro, RJ &#x02013; Brasil</institution>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="orgname">CardioEco Centro de Diagn&#x000f3;stico Cardiovascular</institution>
<addr-line>
<named-content content-type="city">Curitiba</named-content>
<named-content content-type="state">PR</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">CardioEco Centro de Diagn&#x000f3;stico Cardiovascular, Curitiba, PR &#x02013; Brasil</institution>
</aff><aff id="aff6">
<label>6</label>
<institution content-type="orgname">Quanta Diagn&#x000f3;stico - Ecocardiografia</institution>
<addr-line>
<named-content content-type="city">Curitiba</named-content>
<named-content content-type="state">PR</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Quanta Diagn&#x000f3;stico - Ecocardiografia, Curitiba, PR &#x02013; Brasil</institution>
</aff><aff id="aff7">
<label>7</label>
<institution content-type="orgname">Universidade Federal da Para&#x000ed;ba</institution>
<addr-line>
<named-content content-type="city">Jo&#x000e3;o Pessoa</named-content>
<named-content content-type="state">PB</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade Federal da Para&#x000ed;ba, Jo&#x000e3;o Pessoa, PB &#x02013; Brasil</institution>
</aff><aff id="aff8">
<label>8</label>
<institution content-type="orgname">Hospital of Santa Marta</institution>
<addr-line>
<named-content content-type="city">Lisboa</named-content>
</addr-line>
<country country="PT">Portugal</country>
<institution content-type="original">Hospital of Santa Marta, Lisboa &#x02013; Portugal</institution>
</aff><aff id="aff9">
<label>9</label>
<institution content-type="orgname">NOVA Medical School</institution>
<addr-line>
<named-content content-type="city">Lisboa</named-content>
</addr-line>
<country country="PT">Portugal</country>
<institution content-type="original">NOVA Medical School, Lisboa &#x02013; Portugal</institution>
</aff><aff id="aff10">
<label>10</label>
<institution content-type="orgname">Hospital CUF Descobertas</institution>
<addr-line>
<named-content content-type="city">Lisboa</named-content>
</addr-line>
<country country="PT">Portugal</country>
<institution content-type="original">Hospital CUF Descobertas, Lisboa &#x02013; Portugal</institution>
</aff><author-notes><corresp id="c01">
<label>Correspond&#x000ea;ncia</label>: Alex dos Santos Felix <bold>&#x02022;</bold> Instituto Nacional de Cardiologia - Rua das Laranjeiras, 374. CEP 20521290, Rio de Janeiro, RJ - Brasil. E-mail: <email>alexsfelix@gmail.com</email>
</corresp><fn fn-type="COI-statement"><p><bold>Potencial conflito de interesse:</bold> N&#x000e3;o h&#x000e1; conflito com o presente artigo</p></fn><fn fn-type="edited-by"><p><bold>Editor respons&#x000e1;vel pela revis&#x000e3;o:</bold> Gl&#x000e1;ucia Maria Moraes de Oliveira</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><volume>122</volume><issue>1</issue><elocation-id>e20240529</elocation-id><history><date date-type="received"><day>06</day><month>8</month><year>2024</year></date><date><day>15</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Este &#x000e9; um artigo de acesso aberto distribu&#x000ed;do sob os termos da licen&#x000e7;a de atribui&#x000e7;&#x000e3;o pelo Creative Commons</license-p></license></permissions><abstract abstract-type="graphical"><p>
<fig position="float" id="f01"><label>Figura Central:</label><caption><title>O Complexo Quebra-Cabe&#x000e7;a do Fen&#x000f3;tipo Hipertr&#x000f3;fico: Uma Abordagem Pr&#x000e1;tica para o Cl&#x000ed;nico-Geral</title><p>O diagn&#x000f3;stico correto de um paciente com fen&#x000f3;tipo hipertr&#x000f3;fico do ventr&#x000ed;culo esquerdo depende de uma abordagem integrativa, usando pistas da hist&#x000f3;ria cl&#x000ed;nica, exame f&#x000ed;sico e uso de imagens multimodais. VE: ventr&#x000ed;culo esquerdo; HVE: hipertrofia ventricular esquerda; CMH: cardiomiopatia hipertr&#x000f3;fica; LGE: realce tardio com gadol&#x000ed;nio; VD: ventr&#x000ed;culo direito.</p></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf01" position="float"/></fig>
</p></abstract><abstract><title>Resumo</title><p>A hipertrofia ventricular esquerda (HVE) &#x000e9; frequentemente observada na pr&#x000e1;tica cl&#x000ed;nica. No entanto, o fen&#x000f3;tipo hipertr&#x000f3;fico &#x000e9; uma manifesta&#x000e7;&#x000e3;o comum de diversas condi&#x000e7;&#x000f5;es, representando, portanto, um enigma para os m&#x000e9;dicos em termos de diagn&#x000f3;stico. Diferenciar as etiologias da HVE &#x000e9; fundamental para a tomada de decis&#x000e3;o terap&#x000ea;utica, pois diferentes abordagens devem ser implementadas para condi&#x000e7;&#x000f5;es distintas, como HVE secund&#x000e1;ria a altera&#x000e7;&#x000f5;es de carga, cardiomiopatia hipertr&#x000f3;fica (CMH) ou mimetizadores de CMH.</p><p>Em alguns casos, um diagn&#x000f3;stico incorreto ou tardio pode levar &#x000e0; progress&#x000e3;o da doen&#x000e7;a de base com perda adicional da capacidade funcional, alta morbidade e mortalidade.</p><p>O uso racional da multimodalidade de imagem cardiovascular &#x000e9; de extrema import&#x000e2;ncia quando s&#x000e3;o realizados em conjunto com uma avalia&#x000e7;&#x000e3;o cl&#x000ed;nica completa e correlacionados com os achados eletrocardiogr&#x000e1;ficos, fornecendo pistas para preencher lacunas. Na maioria das vezes, os exames de imagem s&#x000e3;o a pe&#x000e7;a que falta para resolver esse quebra-cabe&#x000e7;a desafiador.</p><p>Uma abordagem integral &#x000e9; de suma import&#x000e2;ncia na avalia&#x000e7;&#x000e3;o desses pacientes, pois, muitas vezes, s&#x000e3;o acompanhados por diversas especialidades, com manifesta&#x000e7;&#x000f5;es sist&#x000ea;micas variadas. Embora seja necess&#x000e1;ria uma equipe multidisciplinar para um acompanhamento otimizado desses pacientes, o agente mais importante nessa jornada &#x000e9; o cl&#x000ed;nico, cuja miss&#x000e3;o &#x000e9; reunir todos os sinais de alerta e coordenar todos os dados para um diagn&#x000f3;stico assertivo.</p><p>O objetivo desta revis&#x000e3;o &#x000e9; fornecer uma metodologia pragm&#x000e1;tica, destacando pistas importantes para discriminar as diversas condi&#x000e7;&#x000f5;es que resultam em HVE.</p></abstract><kwd-group><kwd>Hipertrofia Ventricular Esquerda</kwd><kwd>Diagn&#x000f3;stico</kwd><kwd>Diagn&#x000f3;stico Diferencial</kwd><kwd>T&#x000e9;cnicas de Imagem Card&#x000ed;aca</kwd><kwd>Testes de Fun&#x000e7;&#x000e3;o Card&#x000ed;aca</kwd></kwd-group><counts><fig-count count="18"/><table-count count="2"/><equation-count count="0"/><ref-count count="99"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introdu&#x000e7;&#x000e3;o</title><p>A hipertrofia ventricular esquerda (HVE) consiste no aumento da espessura da parede do ventr&#x000ed;culo esquerdo (VE), sendo frequentemente observada na pr&#x000e1;tica cl&#x000ed;nica. No entanto, o fen&#x000f3;tipo hipertr&#x000f3;fico &#x000e9; uma manifesta&#x000e7;&#x000e3;o comum de diversas condi&#x000e7;&#x000f5;es, representando, portanto, um enigma para os m&#x000e9;dicos em termos de diagn&#x000f3;stico.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> A diferencia&#x000e7;&#x000e3;o entre as etiologias da HVE (<xref rid="f02" ref-type="fig">Figura 1</xref>) &#x000e9; fundamental para a elabora&#x000e7;&#x000e3;o de abordagens precisas de tratamento. A HVE frequentemente se origina de mecanismos adaptativos secund&#x000e1;rios, como hipertens&#x000e3;o arterial (HA), estenose a&#x000f3;rtica (EA) e cora&#x000e7;&#x000e3;o de atleta, ou de diversos outros estados patol&#x000f3;gicos, abrangendo doen&#x000e7;as gen&#x000e9;ticas e adquiridas, que podem existir simultaneamente. A cardiomiopatia hipertr&#x000f3;fica (CMH) &#x000e9; caracterizada pelo espessamento da parede do VE (&#x02265; 15 mm em qualquer parte do VE) que n&#x000e3;o &#x000e9; atribu&#x000ed;do apenas a condi&#x000e7;&#x000f5;es de carga anormais. &#x000c9; crucial diferenciar (a) a variante sarcom&#x000e9;rica, respons&#x000e1;vel pela etiologia principal da HVE inexplicada (40-60%) de (b) outras formas de CMH (variantes de genes n&#x000e3;o sarcom&#x000e9;ricos ou etiologia gen&#x000e9;tica n&#x000e3;o elucidada) e (c) outras causas gen&#x000e9;ticas e n&#x000e3;o gen&#x000e9;ticas, coletivamente denominadas mimetizadores de CMH (genoc&#x000f3;pias ou fenoc&#x000f3;pias).<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref></sup> O objetivo deste artigo &#x000e9; fornecer uma metodologia pragm&#x000e1;tica para discriminar as diversas condi&#x000e7;&#x000f5;es que resultam em HVE. Essa diferencia&#x000e7;&#x000e3;o considera diversos fatores, incluindo o perfil cl&#x000ed;nico do paciente, hist&#x000f3;rico familiar, atributos do eletrocardiograma (ECG), perfil laboratorial, caracter&#x000ed;sticas da ecocardiografia (ECO) e da resson&#x000e2;ncia magn&#x000e9;tica card&#x000ed;aca (RMC) e, em casos selecionados, estudo gen&#x000e9;tico e at&#x000e9; bi&#x000f3;psia endomioc&#x000e1;rdica. O uso racional e abrangente da multimodalidade de imagem cardiovascular &#x000e9; de extrema import&#x000e2;ncia para determinar um diagn&#x000f3;stico espec&#x000ed;fico, fornecendo pistas para preencher lacunas. Na maioria das vezes, os exames de imagem s&#x000e3;o a pe&#x000e7;a que falta para resolver esse quebra-cabe&#x000e7;a desafiador.</p><p>
<fig position="float" id="f02"><label>Figura 1</label><caption><title>&#x02013; Quebra-cabe&#x000e7;a desafiador do diagn&#x000f3;stico diferencial em pacientes com fen&#x000f3;tipo hipertr&#x000f3;fico do ventr&#x000ed;culo esquerdo.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf02" position="float"/></fig>
</p><sec><title>Apresenta&#x000e7;&#x000e3;o cl&#x000ed;nica</title><p>Para auxiliar no diagn&#x000f3;stico diferencial da HVE, o cl&#x000ed;nico-geral deve considerar uma abordagem focada, levando em conta a idade na primeira apresenta&#x000e7;&#x000e3;o, os sintomas, o hist&#x000f3;rico pessoal e familiar e marcadores cl&#x000ed;nicos espec&#x000ed;ficos no exame f&#x000ed;sico (&#x0201c;redflags&#x0201d;) (<xref rid="t1" ref-type="table">Tabela 1</xref>). A principal etapa investigativa em adultos que apresentam HVE envolve a triagem de etiologias frequentes, principalmente condi&#x000e7;&#x000f5;es de sobrecarga de press&#x000e3;o, como HA e EA cr&#x000f4;nicas, ou adapta&#x000e7;&#x000f5;es fisiol&#x000f3;gicas associadas ao treinamento f&#x000ed;sico de alta performance (&#x0201c;cora&#x000e7;&#x000e3;o do atleta&#x0201d;). Indiv&#x000ed;duos com HVE podem ser assintom&#x000e1;ticos ou apresentar sintomas inespec&#x000ed;ficos, como dispneia ao esfor&#x000e7;o, fadiga, desconforto tor&#x000e1;cico, palpita&#x000e7;&#x000f5;es, s&#x000ed;ncope e/ou pr&#x000e9;-s&#x000ed;ncope. A investiga&#x000e7;&#x000e3;o de HVE &#x000e9; frequentemente precipitada por achados incidentais durante um ECG ou ECO, que geralmente s&#x000e3;o conduzidos para outros fins. Por outro lado, uma variedade de sintomas e sinais n&#x000e3;o card&#x000ed;acos podem ocasionalmente ser indicativos de diagn&#x000f3;sticos espec&#x000ed;ficos.</p><p>
<table-wrap position="float" id="t1"><label>Tabela 1</label><caption><title>&#x02013; Aspectos gen&#x000e9;ticos, epidemiol&#x000f3;gicos e cl&#x000ed;nicos de poss&#x000ed;vel diagn&#x000f3;stico diferencial do fen&#x000f3;tipo hipertr&#x000f3;fico do ventr&#x000ed;culo esquerdo</title></caption><table frame="hsides" rules="groups"><colgroup width="11%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Cardiomiopatia Hipertr&#x000f3;fica</th><th rowspan="1" colspan="1">Doen&#x000e7;a de Fabry</th><th rowspan="1" colspan="1">Amiloidose card&#x000ed;aca</th><th rowspan="1" colspan="1">Doen&#x000e7;a de Danon</th><th rowspan="1" colspan="1">Doen&#x000e7;a de Pompe</th><th rowspan="1" colspan="1">PRKAG2</th><th rowspan="1" colspan="1">RASopatias</th><th rowspan="1" colspan="1">Ataxia de Friedreich</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gen&#x000e9;tica</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Heran&#x000e7;a autoss&#x000f4;mica dominante</p></list-item><list-item><p>&#x02022; Grande variedade de muta&#x000e7;&#x000f5;es gen&#x000e9;ticas, as mais prevalentes: MYH7 (cadeia pesada de miosina card&#x000ed;aca beta) - 30-50%, MYBPC3 (prote&#x000ed;na C de liga&#x000e7;&#x000e3;o &#x000e0; miosina) - 20-40%, TNNT2 (troponina T card&#x000ed;aca) - 5-20%</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Heran&#x000e7;a ligada ao X</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000e3;o no gene GLA</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; ATTR heredit&#x000e1;rio (mutante ou familiar): doen&#x000e7;a autoss&#x000f4;mica dominante com penetr&#x000e2;ncia vari&#x000e1;vel</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000e3;o do gene transtirretina (TTR)</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Heran&#x000e7;a ligada ao cromossomo X</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000f5;es no gene da membrana associada ao lisossomo 2 (LAMP2)</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; doen&#x000e7;a de dep&#x000f3;sito lisossomal autoss&#x000f4;mica recessiva</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000f5;es no gene GAA</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Heran&#x000e7;a autoss&#x000f4;mica dominante</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000f5;es no gene PRKAG2</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Heran&#x000e7;a autoss&#x000f4;mica dominante</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000f5;es na via de sinaliza&#x000e7;&#x000e3;o RAS/MAPK</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Heran&#x000e7;a autoss&#x000f4;mica recessiva</p></list-item><list-item><p>&#x02022; Muta&#x000e7;&#x000f5;es no gene Frataxina (FXN)</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Aspectos cl&#x000ed;nicos epidemiol&#x000f3;gicos</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; HVE mais comum entre as causas gen&#x000e9;ticas</p></list-item><list-item><p>&#x02022; Pacientes jovens e mais velhos (ampla faixa et&#x000e1;ria)</p></list-item><list-item><p>&#x02022; Hist&#x000f3;ria de s&#x000ed;ncope</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Opacidade da c&#x000f3;rnea</p></list-item><list-item><p>&#x02022; Angioceratoma</p></list-item><list-item><p>&#x02022; Hipoidrose</p></list-item><list-item><p>&#x02022; Albumin&#x000fa;ria</p></list-item><list-item><p>&#x02022; Acroparestesia</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Adultos &#x0003e; 55 anos</p></list-item><list-item><p>&#x02022; S&#x000ed;ndrome do t&#x000fa;nel do carpo bilateral</p></list-item><list-item><p>&#x02022; Ruptura do tend&#x000e3;o do b&#x000ed;ceps</p></list-item><list-item><p>&#x02022; Polineuropatia perif&#x000e9;rica</p></list-item><list-item><p>&#x02022; Envolvimento sensorial, disfun&#x000e7;&#x000e3;o auton&#x000f4;mica</p></list-item><list-item><p>&#x02022; Hematomas na pele</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Indiv&#x000ed;duos do sexo masculino de 10 a 20 anos</p></list-item><list-item><p>&#x02022; Defici&#x000ea;ncia intelectual</p></list-item><list-item><p>&#x02022; Fraqueza muscular</p></list-item><list-item><p>&#x02022; Hepatomegalia</p></list-item><list-item><p>&#x02022; Mulheres com miocardiopatia quase exclusiva</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Crian&#x000e7;as (ao nascer e primeiro ano de vida) / Adolescentes</p></list-item><list-item><p>&#x02022; Fraqueza muscular</p></list-item><list-item><p>&#x02022; Macroglossia</p></list-item><list-item><p>&#x02022; Retinite pigmentar</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Pacientes jovens (d&#x000e9;cadas I-IV)</p></list-item><list-item><p>&#x02022; Mialgia</p></list-item><list-item><p>&#x02022; Epilepsia</p></list-item><list-item><p>&#x02022; Hipertens&#x000e3;o arterial de in&#x000ed;cio precoce</p></list-item><list-item><p>&#x02022; Pr&#x000e9;-excita&#x000e7;&#x000e3;o ventricular (pseudo Wolff-Parkinson-White)</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Crian&#x000e7;as/adolescentes e pacientes jovens &#x0003c; 20 anos</p></list-item><list-item><p>&#x02022; Dismorfismo facial</p></list-item><list-item><p>&#x02022; Lentigos m&#x000fa;ltiplos</p></list-item><list-item><p>&#x02022; Pectus carinatum</p></list-item><list-item><p>&#x02022; Surdez</p></list-item><list-item><p>&#x02022; Cifose</p></list-item><list-item><p>&#x02022; Hipertelorismo</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; &#x0003e; 15 anos</p></list-item><list-item><p>&#x02022; Ataxia sim&#x000e9;trica da marcha</p></list-item><list-item><p>&#x02022; Cifoescoliose</p></list-item><list-item><p>&#x02022; Neuropatia sensorial</p></list-item><list-item><p>&#x02022; Disartria</p></list-item><list-item><p>&#x02022; Surdez</p></list-item><list-item><p>&#x02022; Vertigem</p></list-item></list>
</td></tr></tbody></table></table-wrap>
</p><p>Em rela&#x000e7;&#x000e3;o &#x000e0; idade de in&#x000ed;cio, uma alta preval&#x000ea;ncia de doen&#x000e7;as de armazenamento de glicog&#x000ea;nio (por exemplo, doen&#x000e7;a de Pompe) e RASopatias (incluindo s&#x000ed;ndrome de Noonan) &#x000e9; observada como etiologia subjacente da HVE inexplicada em crian&#x000e7;as e adolescentes. J&#x000e1; em adultos com mais de 55 anos, a amiloidose card&#x000ed;aca (AC) pode ser encontrada com maior frequ&#x000ea;ncia, e estar ciente do poss&#x000ed;vel diagn&#x000f3;stico desta doen&#x000e7;a trat&#x000e1;vel &#x000e9; muito importante.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> A CMH representa a etiologia mais comum para HVE entre as causas gen&#x000e9;ticas em diversas faixas et&#x000e1;rias, abrangendo desde pacientes jovens at&#x000e9; idosos.<sup><xref rid="B4" ref-type="bibr">4</xref></sup></p><p>A HVE grave observada no nascimento ou durante o primeiro ano de vida, juntamente com fraqueza muscular, macroglossia e retinite pigmentar, deve levantar suspeita cl&#x000ed;nica de doen&#x000e7;a de Pompe. Em indiv&#x000ed;duos do sexo masculino com idade entre 10 e 20 anos que apresentam HVE importante, defici&#x000ea;ncia intelectual, fraqueza muscular e pr&#x000e9;-excita&#x000e7;&#x000e3;o ventricular, &#x000e9; necess&#x000e1;ria uma avalia&#x000e7;&#x000e3;o para doen&#x000e7;a de Danon. Da mesma forma, at&#x000e9; os 20 anos, a presen&#x000e7;a de dismorfismo facial, les&#x000f5;es lentiginosas multiplas, pectus carinatum, surdez, cifose e hipertelorismo deve alertar os m&#x000e9;dicos sobre a possibilidade de RASopatias, como a s&#x000ed;ndrome de Noonan e a s&#x000ed;ndrome de Noonan com lentiginose multipla. Em indiv&#x000ed;duos com mais de 15 anos, a ocorr&#x000ea;ncia simult&#x000e2;nea de sintomas neurol&#x000f3;gicos como ataxia, desequil&#x000ed;brio e altera&#x000e7;&#x000f5;es na marcha pode indicar ataxia de Friedreich. Al&#x000e9;m disso, doen&#x000e7;as mitocondriais, juntamente com HVE, frequentemente se manifestam com anormalidades sensoriais, bem como sintomas neurol&#x000f3;gicos e miop&#x000e1;ticos. Em indiv&#x000ed;duos com idade entre 30 e 40 anos, a doen&#x000e7;a de Fabry e a cardiomiopatia (CM) PRKAG2 devem ser inclu&#x000ed;das no diagn&#x000f3;stico diferencial.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> A manifesta&#x000e7;&#x000e3;o de sintomas gastrointestinais, dor neurop&#x000e1;tica, angioceratomas, hipoidrose, c&#x000f3;rnea verticilata, protein&#x000fa;ria, dist&#x000fa;rbios de condu&#x000e7;&#x000e3;o, ataque isqu&#x000ea;mico transit&#x000f3;rio juvenil ou criptog&#x000ea;nico, ou acidente vascular cerebral e perda auditiva, juntamente com hist&#x000f3;rico de transmiss&#x000e3;o heredit&#x000e1;ria ligada ao cromossomo X, levam &#x000e0; investiga&#x000e7;&#x000e3;o da doen&#x000e7;a de Fabry.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Em pacientes com mais de 55-60 anos, AC (transtirretina de cadeia leve ou de tipo selvagem) deve ser considerada, especialmente na presen&#x000e7;a de indicadores cl&#x000ed;nicos, como s&#x000ed;ndrome do t&#x000fa;nel do carpo, ruptura espont&#x000e2;nea do tend&#x000e3;o do b&#x000ed;ceps (sinal de Popeye), dor nas costas (indicativa de estenose espinhal), polineuropatia (manifestada como dor neurop&#x000e1;tica, dificuldades de locomo&#x000e7;&#x000e3;o ou quedas frequentes), intoler&#x000e2;ncia a medicamentos anti-hipertensivos ou para insufici&#x000ea;ncia card&#x000ed;aca devido &#x000e0; hipotens&#x000e3;o postural, baixa voltagem do QRS desproporcional &#x000e0; massa do VE no ECO, insufici&#x000ea;ncia card&#x000ed;aca com fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o preservada (ICFEp) e bradiarritmia.<sup><xref rid="B7" ref-type="bibr">7</xref></sup></p><p>Quando h&#x000e1; suspeita de etiologia gen&#x000e9;tica, &#x000e9; fundamental realizar uma investiga&#x000e7;&#x000e3;o detalhada do hist&#x000f3;rico familiar de tr&#x000ea;s gera&#x000e7;&#x000f5;es, com foco no diagn&#x000f3;stico de CMH, presen&#x000e7;a de morte s&#x000fa;bita, arritmia, implante de dispositivo intracard&#x000ed;aco e relatos de acidente vascular cerebral precoce.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> Muta&#x000e7;&#x000f5;es HCM e PRKAG2 s&#x000e3;o normalmente associadas &#x000e0; heran&#x000e7;a autoss&#x000f4;mica dominante. Um padr&#x000e3;o ligado ao X deve sugerir a possibilidade da doen&#x000e7;a de Fabry ou Danon, ao passo que um padr&#x000e3;o autoss&#x000f4;mico recessivo sugere ataxia de Friedreich<sup><xref rid="B8" ref-type="bibr">8</xref></sup> (<xref rid="t1" ref-type="table">Tabela 1</xref>). Durante o exame f&#x000ed;sico, a presen&#x000e7;a de sinais indicativos de obstru&#x000e7;&#x000e3;o din&#x000e2;mica da via de sa&#x000ed;da do VE (VSVE), como sopro sist&#x000f3;lico que aumenta na posi&#x000e7;&#x000e3;o ortost&#x000e1;tica ou pulso b&#x000ed;fido, pode sugerir obstru&#x000e7;&#x000e3;o intraventricular causada por CMH. Um hist&#x000f3;rico de implanta&#x000e7;&#x000e3;o de marcapasso, v&#x000e1;rios membros familiares afetados e a presen&#x000e7;a da s&#x000ed;ndrome de Wolff-Parkinson-White fundamentam o diagn&#x000f3;stico de PRKAG2, com a doen&#x000e7;a de Fabry como um poss&#x000ed;vel diagn&#x000f3;stico alternativo.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p><p>Dados cl&#x000ed;nicos isoladamente, embora informativos, s&#x000e3;o insuficientes para diferenciar a etiologia da HVE, e exames diagn&#x000f3;sticos adicionais s&#x000e3;o essenciais para confirmar a causa subjacente. No entanto, um julgamento cl&#x000ed;nico amplo e uma avalia&#x000e7;&#x000e3;o personalizada de cada paciente s&#x000e3;o fundamentais para orientar a sele&#x000e7;&#x000e3;o criteriosa de metodologias diagn&#x000f3;sticas apropriadas.</p><p>Em suma, com base nos crit&#x000e9;rios acima mencionados, tr&#x000ea;s principais achados devem levantar suspeitas e iniciar a investiga&#x000e7;&#x000e3;o de mimetizadores de CMH:</p><list list-type="simple"><list-item><p>&#x02022; Idade em que ocorre o in&#x000ed;cio da HVE, seja no in&#x000ed;cio ou em fase mais tardia da vida.</p></list-item><list-item><p>&#x02022; A presen&#x000e7;a de manifesta&#x000e7;&#x000f5;es extracard&#x000ed;acas.</p></list-item><list-item><p>&#x02022; Padr&#x000f5;es de heran&#x000e7;a que n&#x000e3;o s&#x000e3;o consistentes com a transmiss&#x000e3;o autoss&#x000f4;mica dominante.</p></list-item></list></sec><sec><title>Eletrocardiografia</title><p>Anomalias eletrocardiogr&#x000e1;ficas podem se manifestar anos antes do desenvolvimento de um fen&#x000f3;tipo hipertr&#x000f3;fico. Embora as altera&#x000e7;&#x000f5;es no ECG sejam geralmente inespec&#x000ed;ficas, elas podem fornecer dicas importantes para o diagn&#x000f3;stico, especialmente quando interpretadas em conjunto com outros achados cl&#x000ed;nicos e laboratoriais e correlacionadas com multimodalidade de imagem (<xref rid="f03" ref-type="fig">Figura 2</xref>). A CMH pode apresentar diversos padr&#x000f5;es, incluindo &#x0201c;strain&#x0201d; do VE , com e anormalidades nas ondas ST e T, embora, em alguns casos, o ECG possa ser normal.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Ondas T negativas profundas nas deriva&#x000e7;&#x000f5;es precordiais podem sugerir CMH apical. Um padr&#x000e3;o extremo de HVE sugere cardiomiopatias de Danon, Pompe e PRKAG2. Baixa voltagem do QRS (absoluta ou relativa, por exemplo, voltagem do QRS desproporcional &#x000e0; espessura da parede do VE), bloqueio atrioventricular e um padr&#x000e3;o de pseudoinfarto s&#x000e3;o caracter&#x000ed;sticas da AC. Um curto intervalo PR/pr&#x000e9;-excita&#x000e7;&#x000e3;o ventricular (principalmente em pacientes mais jovens) e bloqueios atrioventriculares (em pacientes adultos) s&#x000e3;o observados nas doen&#x000e7;as de Fabry, Danon e PRKAG2. Bloqueios bifasciculares tamb&#x000e9;m podem indicar doen&#x000e7;a de Fabry como poss&#x000ed;vel diagn&#x000f3;stico.<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p><p>
<fig position="float" id="f03"><label>Figura 2</label><caption><title>&#x02013; Pistas eletrocardiogr&#x000e1;ficas para o diagn&#x000f3;stico diferencial de HVE. CMH: miocardiopatia hipertr&#x000f3;fica; AV: atrioventricular; HA: hipertens&#x000e3;o arterial; EA: estenose a&#x000f3;rtica; HVE: hipertrofia ventricular esquerda.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf03" position="float"/></fig>
</p><p>Pacientes com HVE podem apresentar diversos tipos de arritmias, desde batimentos atriais e/ou ventriculares prematuros assintom&#x000e1;ticos at&#x000e9; arritmias ventriculares (AVs) possivelmente fatais. A fibrila&#x000e7;&#x000e3;o atrial (FA) &#x000e9; uma complica&#x000e7;&#x000e3;o comum na progress&#x000e3;o cl&#x000ed;nica da CMH, doen&#x000e7;a de Fabry e amiloidose. Da mesma forma, CMH sarcom&#x000e9;rica, doen&#x000e7;a de Danon e cardiomiopatias PRKAG2 est&#x000e3;o associadas a um risco de AVs possivelmente fatais.<sup><xref rid="B8" ref-type="bibr">8</xref></sup></p></sec><sec><title>Exames laboratoriais</title><p>No contexto de um fen&#x000f3;tipo hipertr&#x000f3;fico e suas manifesta&#x000e7;&#x000f5;es cl&#x000ed;nicas, exames laboratoriais de rotina e direcionados podem fornecer indica&#x000e7;&#x000f5;es para diagn&#x000f3;sticos espec&#x000ed;ficos. Embora n&#x000e3;o sejam espec&#x000ed;ficos, n&#x000ed;veis desproporcionalmente altos de pept&#x000ed;deo natriur&#x000e9;tico cerebral N-terminal (NT-proBNP) e pequenas eleva&#x000e7;&#x000f5;es na troponina s&#x000e9;rica podem indicar um diagn&#x000f3;stico de amiloidose ou formas espec&#x000ed;ficas de CMH sarcom&#x000e9;rica. N&#x000ed;veis s&#x000e9;ricos de creatina quinase (CK) persistentemente altos podem indicar doen&#x000e7;a de Pompe, doen&#x000e7;as neuromusculares ou cora&#x000e7;&#x000e3;o de atleta. Disfun&#x000e7;&#x000e3;o hep&#x000e1;tica, caracterizada por n&#x000ed;veis s&#x000e9;ricos elevados de transaminases hep&#x000e1;ticas, pode ser observada em cardiomiopatias de Pompe, Danon e PRKAG2. Imunoglobulina de cadeia leve em ensaios de imunofixa&#x000e7;&#x000e3;o s&#x000e9;rica e urin&#x000e1;ria e uma propor&#x000e7;&#x000e3;o anormal de cadeias leves livres s&#x000e3;o consistentes com o diagn&#x000f3;stico de amiloidose de cadeia leve (AL).<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Para a doen&#x000e7;a de Fabry, o &#x0201c;dry spot test&#x0201d; &#x000e9; uma ferramenta de triagem &#x000fa;til em homens, nos quais o diagn&#x000f3;stico &#x000e9; estabelecido por meio da avalia&#x000e7;&#x000e3;o da atividade da alfa-galactosidase A (&#x003b1;-GalA) e das medi&#x000e7;&#x000f5;es de liso-Gb3. Em pacientes do sexo feminino, geralmente s&#x000e3;o necess&#x000e1;rios exames gen&#x000e9;ticos para confirmar o diagn&#x000f3;stico.</p></sec><sec><title>Ecocardiograma</title><p>O ECO desempenha um papel fundamental no diagn&#x000f3;stico e tratamento da HVE, n&#x000e3;o apenas devido &#x000e0; sua ampla disponibilidade, natureza n&#x000e3;o invasiva e relativa acessibilidade, mas principalmente devido &#x000e0;s informa&#x000e7;&#x000f5;es abrangentes que fornece. Essas informa&#x000e7;&#x000f5;es incluem visualiza&#x000e7;&#x000e3;o anat&#x000f4;mica de estruturas (fen&#x000f3;tipo de HVE, espessura das paredes do VE e distribui&#x000e7;&#x000e3;o geom&#x000e9;trica de hipertrofia), avalia&#x000e7;&#x000e3;o da fun&#x000e7;&#x000e3;o ventricular esquerda e direita (VD) e avalia&#x000e7;&#x000f5;es hemodin&#x000e2;micas (como press&#x000e3;o diast&#x000f3;lica final do VE, press&#x000e3;o sist&#x000f3;lica da art&#x000e9;ria pulmonar, volume sist&#x000f3;lico e colapsibilidade da veia cava). O ECO tamb&#x000e9;m &#x000e9; valioso para identificar obstru&#x000e7;&#x000f5;es fixas, como EA, ou obstru&#x000e7;&#x000f5;es din&#x000e2;micas do VE, como CMH obstrutiva.<sup><xref rid="B12" ref-type="bibr">12</xref></sup></p><p>Avan&#x000e7;os recentes em t&#x000e9;cnicas ecocardiogr&#x000e1;ficas, particularmente na an&#x000e1;lise de deforma&#x000e7;&#x000e3;o mioc&#x000e1;rdica, aumentaram nossa compreens&#x000e3;o da fisiopatologia, da mec&#x000e2;nica mioc&#x000e1;rdica e da fun&#x000e7;&#x000e3;o mioc&#x000e1;rdica al&#x000e9;m da fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o. A ecocardiografia com &#x0201c;speckle tracking&#x0201d;(STE) surgiu como uma ferramenta sens&#x000ed;vel para a detec&#x000e7;&#x000e3;o precoce de doen&#x000e7;as mioc&#x000e1;rdicas, uma vez que o <italic toggle="yes">strain</italic> longitudinal global (GLS) geralmente se deteriora antes que a fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o do VE (FEVE) diminua em v&#x000e1;rios contextos cl&#x000ed;nicos, com a vantagem de ser menos dependente da carga. &#x000c9; importante para o diagn&#x000f3;stico de doen&#x000e7;as card&#x000ed;acas subcl&#x000ed;nicas em parentes gen&#x000f3;tipo-positivos de pacientes com CMH, ataxia de Friedreich e AC, bem como para o monitoramento de pacientes com doen&#x000e7;as metab&#x000f3;licas, infiltrativas ou de armazenamento mioc&#x000e1;rdico. O STE auxilia na caracteriza&#x000e7;&#x000e3;o dos padr&#x000f5;es de envolvimento mioc&#x000e1;rdico, atuando como uma esp&#x000e9;cie de &#x0201c;impress&#x000e3;o digital&#x0201d; visual, servindo como uma &#x0201c;ferramenta de caracteriza&#x000e7;&#x000e3;o tecidual&#x0201d; baseada no ECO (<xref rid="f04" ref-type="fig">Figura 3</xref>).<sup><xref rid="B13" ref-type="bibr">13</xref></sup> H&#x000e1; uma forte correla&#x000e7;&#x000e3;o entre os valores de GLS e o realce tardio de gadol&#x000ed;nio (LGE) na resson&#x000e2;ncia magn&#x000e9;tica card&#x000ed;aca (RMC), apontando para fibrose mioc&#x000e1;rdica e maior risco de mortalidade e AVs malignas em pacientes com CMH.<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref></sup> Este par&#x000e2;metro tamb&#x000e9;m tem valor progn&#x000f3;stico em doen&#x000e7;as infiltrativas como AC.<sup><xref rid="B16" ref-type="bibr">16</xref></sup></p><p>
<fig position="float" id="f04"><label>Figura 3</label><caption><title>&#x02013; Padr&#x000f5;es de deforma&#x000e7;&#x000e3;o longitudinal no fen&#x000f3;tipo hipertr&#x000f3;fico do ventr&#x000ed;culo esquerdo (VE) (display param&#x000e9;trico em &#x0201c;bulls-eye&#x0201d;). A) Cardiomiopatia hipertr&#x000f3;fica (CMH) mostrando altera&#x000e7;&#x000f5;es de deforma&#x000e7;&#x000e3;o regionais conforme a distribui&#x000e7;&#x000e3;o da hipertrofia (neste caso uma CMH assim&#x000e9;trica septal), B)- Amiloidose card&#x000ed;aca, com padr&#x000e3;o &#x0201c;cherry on top&#x0201d;, um &#x0201c;redflag&#x0201d; ecocardiogr&#x000e1;fico para seu diagn&#x000f3;stico, C) Doen&#x000e7;a de Fabry, com altera&#x000e7;&#x000e3;o t&#x000ed;pica de deforma&#x000e7;&#x000e3;o na parede &#x000e2;ntero-lateral basal, D) Cardiomiopatia PRKAG2, com hipertrofia biventricular maci&#x000e7;a neste caso, com altera&#x000e7;&#x000e3;o global acentuada na GLS mostrando padr&#x000e3;o difuso, E) Ataxia de Friedreich, com hipertrofia conc&#x000ea;ntrica do VE, mostrando altera&#x000e7;&#x000e3;o de deforma&#x000e7;&#x000e3;o principalmente nos segmentos basal e medial, destacando que o padr&#x000e3;o &#x0201c;cherry on top&#x0201d; (apical sparing) relativo n&#x000e3;o &#x000e9; espec&#x000ed;fico para o diagn&#x000f3;stico de AC (este caso: cortesia - Dr. Thiago Santos Rosa - Brasil).</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf04" position="float"/></fig>
</p><p>O <italic toggle="yes">&#x0201c;myocardial work&#x0201d;</italic> foi recentemente descrito como uma nova ferramenta ecocardiogr&#x000e1;fica promissora para avalia&#x000e7;&#x000e3;o da mec&#x000e2;nica mioc&#x000e1;rdica, incorporando a p&#x000f3;s-carga (press&#x000e3;o arterial) como estimativa da press&#x000e3;o do VE e utilizando a deforma&#x000e7;&#x000e3;o longitudinal (LS) para criar um loop &#x0201c;press&#x000e3;o x deforma&#x000e7;&#x000e3;o&#x0201d;, gerado por um software espec&#x000ed;fico.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> O valor adicional desta t&#x000e9;cnica em rela&#x000e7;&#x000e3;o aos par&#x000e2;metros ecocardiogr&#x000e1;ficos convencionais para avalia&#x000e7;&#x000e3;o de cardiomiopatias ainda precisa ser comprovado em estudos maiores, mas alguns dados demonstram valor progn&#x000f3;stico para avalia&#x000e7;&#x000e3;o de CMH<sup><xref rid="B18" ref-type="bibr">18</xref></sup> e AC,<sup><xref rid="B19" ref-type="bibr">19</xref></sup> por exemplo.</p><p>Embora ainda n&#x000e3;o esteja universalmente dispon&#x000ed;vel, a ecocardiografia tridimensional (3DE) tornou-se uma ferramenta valiosa para avaliar doen&#x000e7;as mioc&#x000e1;rdicas, especialmente medi&#x000e7;&#x000f5;es volum&#x000e9;tricas diretas de c&#x000e2;maras card&#x000ed;acas. Fornece valores precisos de FE e massa do VE, correlacionando-se bem com a RMC considerada padr&#x000e3;o ouro.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> O 3DE tamb&#x000e9;m permite a medi&#x000e7;&#x000e3;o tridimensional da deforma&#x000e7;&#x000e3;o mioc&#x000e1;rdica, menos afetada por limita&#x000e7;&#x000f5;es t&#x000e9;cnicas, como movimento fora do plano, e permite a avalia&#x000e7;&#x000e3;o simult&#x000e2;nea de todo o VE, o que &#x000e9; &#x000fa;til para an&#x000e1;lise de sincroniza&#x000e7;&#x000e3;o.</p><p>O ECO com contraste que utiliza agentes de realce ultrassonogr&#x000e1;ficos &#x000e9; importante para a delimita&#x000e7;&#x000e3;o da borda do VE, especialmente em pacientes com janelas ac&#x000fa;sticas sub&#x000f3;timas. Aumenta a sensibilidade na detec&#x000e7;&#x000e3;o de condi&#x000e7;&#x000f5;es como CMH apical, aneurismas apicais e na diferencia&#x000e7;&#x000e3;o de trombos intracavit&#x000e1;rios e em outras estruturas, como tend&#x000f5;es ou trabecula&#x000e7;&#x000f5;es.<sup><xref rid="B21" ref-type="bibr">21</xref></sup></p></sec><sec><title>Resson&#x000e2;ncia magn&#x000e9;tica cardiovascular</title><p>A RMC assumiu um papel inquestion&#x000e1;vel na avalia&#x000e7;&#x000e3;o da HVE, principalmente devido &#x000e0; avalia&#x000e7;&#x000e3;o da morfologia card&#x000ed;aca, fun&#x000e7;&#x000e3;o e caracteriza&#x000e7;&#x000e3;o tecidual.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Embora a RMC possa fornecer pistas essenciais para o diagn&#x000f3;stico final em entidades com anormalidades extremas na caracteriza&#x000e7;&#x000e3;o do tecido, como AC ou doen&#x000e7;a de Fabry, a grande sobreposi&#x000e7;&#x000e3;o de achados de imagem em muitas entidades torna necess&#x000e1;ria uma integra&#x000e7;&#x000e3;o abrangente dos achados de imagem no contexto cl&#x000ed;nico. Nenhum achado de imagem deve ser interpretado isoladamente, sem considera&#x000e7;&#x000e3;o da hist&#x000f3;ria cl&#x000ed;nica, dados eletrocardiogr&#x000e1;ficos e hist&#x000f3;ria familiar.<sup><xref rid="B22" ref-type="bibr">22</xref></sup></p><p>Al&#x000e9;m da avalia&#x000e7;&#x000e3;o anat&#x000f4;mica e funcional do VE, a principal vantagem da RMC em rela&#x000e7;&#x000e3;o ao ECO &#x000e9; a possibilidade de caracteriza&#x000e7;&#x000e3;o tecidual. T&#x000e9;cnicas de mapeamento param&#x000e9;trico que medem os tempos de relaxamento T1 e T2 t&#x000ea;m sido cada vez mais incorporadas aos protocolos de aquisi&#x000e7;&#x000e3;o, permitindo a avalia&#x000e7;&#x000e3;o quantitativa de componentes intracelulares e extracelulares.<sup><xref rid="B23" ref-type="bibr">23</xref></sup>Imagens com LGE podem identificar fibrose de substitui&#x000e7;&#x000e3;o e possuem valor progn&#x000f3;stico bem estabelecido, embora sejam menos sens&#x000ed;veis para detectar deposi&#x000e7;&#x000e3;o difusa de col&#x000e1;geno intersticial do que as t&#x000e9;cnicas de mapeamento T1.<sup><xref rid="B24" ref-type="bibr">24</xref></sup></p></sec><sec><title>Diagn&#x000f3;stico de hipertrofia ventricular esquerda</title><p>Embora as diretrizes cl&#x000ed;nicas estabele&#x000e7;am valores de refer&#x000ea;ncia normais para a massa do VE de acordo com o g&#x000ea;nero,<sup><xref rid="B25" ref-type="bibr">25</xref></sup> desafios t&#x000e9;cnicos podem causar variabilidade e dificultar a medi&#x000e7;&#x000e3;o ecocardiogr&#x000e1;fica da espessura da parede do VE. Janela ac&#x000fa;stica sub&#x000f3;tima, medi&#x000e7;&#x000f5;es incorretas (obl&#x000ed;quas ou encurtadas, uso de janela apical &#x02013; baixa resolu&#x000e7;&#x000e3;o lateral) e inclus&#x000e3;o de estruturas de confus&#x000e3;o podem afetar a precis&#x000e3;o. Algumas estruturas, como uma banda moderadora proeminente do VD, aparelho subvalvar tricusp&#x000ed;deo, crista supraventricular ou falsos tend&#x000f5;es fibromusculares do VE inseridos no septo interventricular, podem ser erroneamente interpretadas como parte do septo, superestimando sua espessura. Em pacientes pedi&#x000e1;tricos, os escores Z, que representam o n&#x000fa;mero de desvios padr&#x000e3;o dos valores m&#x000e9;dios, s&#x000e3;o usados como padr&#x000f5;es de refer&#x000ea;ncia. Esses escores ajustam a massa do VE e a espessura da parede conforme a idade e o tamanho corporal da crian&#x000e7;a, proporcionando uma avalia&#x000e7;&#x000e3;o mais personalizada nessa popula&#x000e7;&#x000e3;o.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> Os limiares para portadores de variantes gen&#x000e9;ticas patog&#x000ea;nicas podem ser menores<sup><xref rid="B12" ref-type="bibr">12</xref></sup> e algumas apresenta&#x000e7;&#x000f5;es podem causar confus&#x000e3;o e diagn&#x000f3;sticos incorretos, como fen&#x000f3;tipos tardios e j&#x000e1; dilatados.<sup><xref rid="B26" ref-type="bibr">26</xref></sup> Para garantir um diagn&#x000f3;stico preciso, &#x000e9; essencial correlacionar essas medidas com o hist&#x000f3;rico cl&#x000ed;nico, a presen&#x000e7;a de outras doen&#x000e7;as card&#x000ed;acas estruturais associadas, os valores de GLS e a fun&#x000e7;&#x000e3;o diast&#x000f3;lica. Em certos casos, uma RMC pode ser necess&#x000e1;ria para confirmar o diagn&#x000f3;stico.</p></sec><sec><title>Cardiomiopatia hipertr&#x000f3;fica</title><p>A CMH &#x000e9; definida por um aumento da espessura da parede do VE &#x02265; 15 mm ou &#x02265; 13 mm (em indiv&#x000ed;duos com gen&#x000f3;tipo positivo ou parentes de pacientes com CMH), na aus&#x000ea;ncia de condi&#x000e7;&#x000f5;es que justifiquem HVE secund&#x000e1;ria, como HA grave, EA ou coarcta&#x000e7;&#x000e3;o da aorta, e excluindo quaisquer doen&#x000e7;as sist&#x000ea;micas infiltrativas.<sup><xref rid="B27" ref-type="bibr">27</xref></sup> &#x000c9; crucial reconhecer que a CMH n&#x000e3;o &#x000e9; meramente uma doen&#x000e7;a mioc&#x000e1;rdica. Outras caracter&#x000ed;sticas que justificam o diagn&#x000f3;stico incluem anormalidades da VM e do aparelho subvalvar, como alongamento do folheto mitral, hipertrofia do m&#x000fa;sculo papilar, cordas da VM secund&#x000e1;rias anormais e feixes musculares (<xref rid="f05" ref-type="fig">Figura 4</xref>).<sup><xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref></sup></p><p>
<fig position="float" id="f05"><label>Figura 4</label><caption><title>&#x02013; Pistas ecocardiogr&#x000e1;ficas para o diagn&#x000f3;stico diferencial do fen&#x000f3;tipo hipertr&#x000f3;fico do ventr&#x000ed;culo esquerdo. CMH: cardiomiopatia hipertr&#x000f3;fica; SAM: movimento anterior sist&#x000f3;lico da valva mitral; RM: regurgita&#x000e7;&#x000e3;o mitral; VD: ventr&#x000ed;culo direito.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf05" position="float"/></fig>
</p><p>A HVE septal assim&#x000e9;trica &#x000e9; o padr&#x000e3;o mais cl&#x000e1;ssico de CMH, mas outras express&#x000f5;es fenot&#x000ed;picas, como apical, conc&#x000ea;ntrica, de parede lateral, m&#x000e9;dio-ventricular, e apresenta&#x000e7;&#x000f5;es menos t&#x000ed;picas envolvendo qualquer segmento do VE, s&#x000e3;o comuns. Os crit&#x000e9;rios cl&#x000e1;ssicos para diagn&#x000f3;stico de CMH, que s&#x000e3;o os mesmos utilizados no ECO e na RMC,<sup><xref rid="B8" ref-type="bibr">8</xref></sup> foram recentemente questionados (&#x0201c;uma medida serve para todos&#x0201d;?). No futuro, provavelmente g&#x000ea;nero, superf&#x000ed;cie corporal e ra&#x000e7;a ser&#x000e3;o considerados para a defini&#x000e7;&#x000e3;o de novos limiares. Em especial, esses crit&#x000e9;rios podem n&#x000e3;o ser preenchidos na variante apical, caracterizada pela perda ou revers&#x000e3;o do estreitamento mioc&#x000e1;rdico apical usual. Por exemplo, novos valores de corte e crit&#x000e9;rios diagn&#x000f3;sticos foram recentemente sugeridos para a detec&#x000e7;&#x000e3;o de CMH apical, sendo o limite superior do normal apical de 11 mm ou 5,6 mm/m<sup><xref rid="B2" ref-type="bibr">2</xref></sup>.<sup><xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B30" ref-type="bibr">30</xref></sup></p><p>A hipertrofia do VD tamb&#x000e9;m &#x000e9; frequente em pacientes com CMH, sendo encontrada em 30-44% dos casos, geralmente junto da HVE.<sup><xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref></sup> A obstru&#x000e7;&#x000e3;o din&#x000e2;mica do VD pode ocorrer, seja intraventricular ou na via de sa&#x000ed;da do VD.<sup><xref rid="B33" ref-type="bibr">33</xref></sup> Os &#x000ed;ndices ecocardiogr&#x000e1;ficos convencionais da fun&#x000e7;&#x000e3;o sist&#x000f3;lica do VD, como excurs&#x000e3;o sist&#x000f3;lica do plano anular tric&#x000fa;spide (TAPSE), fra&#x000e7;&#x000e3;o de varia&#x000e7;&#x000e3;o de &#x000e1;rea (FAC) e velocidades do Doppler tecidual, s&#x000e3;o tipicamente normais, mas a disfun&#x000e7;&#x000e3;o sist&#x000f3;lica subcl&#x000ed;nica pode ser identificada por meio de altera&#x000e7;&#x000f5;es na LS do VD.<sup><xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref></sup></p><p>O ECO tamb&#x000e9;m desempenhou um papel importante na avalia&#x000e7;&#x000e3;o de risco e estratifica&#x000e7;&#x000e3;o de pacientes com CMH,<sup><xref rid="B36" ref-type="bibr">36</xref></sup> sendo que estudos demonstraram maior mortalidade em pacientes com CMH com espessura do septo do VE &#x02265; 30 mm, aneurisma apical ou disfun&#x000e7;&#x000e3;o do VE (FEVE &#x0003c; 50%).<sup><xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B37" ref-type="bibr">37</xref></sup> GLS 2D do VE correlaciona-se fortemente com fibrose em pacientes com CMH. Os valores absolutos de GLS e dispers&#x000e3;o mec&#x000e2;nica t&#x000ea;m uma boa correla&#x000e7;&#x000e3;o com a porcentagem de LGE e s&#x000e3;o preditores independentes de AVs.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> No estudo de Reant et al.,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> valores absolutos de GLS &#x0003c; 15,4% foram associados &#x000e0; insufici&#x000ea;ncia card&#x000ed;aca, morte e interna&#x000e7;&#x000f5;es hospitalares em uma coorte de pacientes com CMH. O gr&#x000e1;fico param&#x000e9;trico da LS 2D derivado do STE2D (<italic toggle="yes">&#x0201c;bulls-eye&#x0201d;</italic>) pode oferecer uma vis&#x000e3;o geral intuitiva da deforma&#x000e7;&#x000e3;o mioc&#x000e1;rdica global e regional do VE na CMH e &#x000e9; caracterizado por valores de deforma&#x000e7;&#x000e3;o segmentar severamente reduzidos nas paredes mais hipertrofiadas, geralmente mais pronunciados do que outras etiologias, como hipertens&#x000e3;o ou HVE secund&#x000e1;ria &#x000e0; EA.<sup><xref rid="B38" ref-type="bibr">38</xref></sup></p><p>A avalia&#x000e7;&#x000e3;o hemodin&#x000e2;mica para identificar pacientes com obstru&#x000e7;&#x000e3;o da VSVE &#x000e9; crucial para o tratamento de pacientes com CMH. Aproximadamente um ter&#x000e7;o dos pacientes com CMH apresentam obstru&#x000e7;&#x000e3;o da VSVE em repouso (&#x0003e; 30 mmHg), sendo que o outro ter&#x000e7;o apresenta obstru&#x000e7;&#x000e3;o latente, revelada por meio de manobras provocativas &#x000e0; beira do leito (Valsalva, ficar em p&#x000e9;, agachar-elevar, inala&#x000e7;&#x000e3;o de nitrito de amila) ou ecocardiografia de exerc&#x000ed;cio.<sup><xref rid="B39" ref-type="bibr">39</xref></sup>A regurgita&#x000e7;&#x000e3;o mitral &#x000e9; um achado comum em pacientes com CMH, especialmente em pacientes com movimento mitral anterior sist&#x000f3;lico (SAM), e pode ser um determinante importante dos sintomas. &#x000c9; muito importante destacar que o SAM n&#x000e3;o &#x000e9; resultado unicamente de hipertrofia assim&#x000e9;trica septal (altas velocidades da VSVE e efeito Venturi) e, de fato, anormalidades prim&#x000e1;rias do aparelho da VM, como hipertrofia e deslocamento anterior dos m&#x000fa;sculos papilares, alongamento dos folhetos e altera&#x000e7;&#x000e3;o na inser&#x000e7;&#x000e3;o cordal, podem ter um grande papel na obstru&#x000e7;&#x000e3;o da VSVE (<xref rid="f06" ref-type="fig">Figura 5</xref>).<sup><xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B40" ref-type="bibr">40</xref></sup></p><p>
<fig position="float" id="f06"><label>Figura 5</label><caption><title>&#x02013; Exemplo de paciente com Cardiomiopatia Hipertr&#x000f3;fica Obstrutiva. A) espessura do septo: 4,1 cm, B) Padr&#x000e3;o de deforma&#x000e7;&#x000e3;o longitudinal &#x0201c;bulls-eye&#x0201d; mostrando altera&#x000e7;&#x000e3;o regional principalmente nos segmentos septais e, C) Aquisi&#x000e7;&#x000e3;o de eco transtor&#x000e1;cico (ETT) 3D, imagens 3D renderizadas longitudinais mostrando movimento sist&#x000f3;lico anterior (SAM) da valva mitral na s&#x000ed;stole (*), D) Aquisi&#x000e7;&#x000e3;o de ETT 3D, imagens 3D coloridas renderizadas (vis&#x000e3;o longitudinal) mostrando regurgita&#x000e7;&#x000e3;o mitral secund&#x000e1;ria a SAM (*), E) Doppler cont&#x000ed;nuo mostrando gradiente de pico tardio em repouso na via de sa&#x000ed;da do ventr&#x000ed;culo esquerdo de 96 mmHg, padr&#x000e3;o cl&#x000e1;ssico em forma de adaga, F) Aquisi&#x000e7;&#x000e3;o de ETT 3D, imagens 3D renderizadas (vis&#x000e3;o de eixo curto) mostrando anomalia dos m&#x000fa;sculos papilares com quatro cabe&#x000e7;as (*) e posicionados anteriormente, G) RMC mostrando hipertrofia septal maci&#x000e7;a, e H) imagens com realce tardio com gadol&#x000ed;nio mostrando fibrose septal com padr&#x000e3;o de parede m&#x000e9;dia.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf06" position="float"/></fig>
</p><p>A CMH geralmente se apresenta com FEVE normal ou aumentada, o fen&#x000f3;tipo cl&#x000e1;ssico da ICFEp, associada &#x000e0; disfun&#x000e7;&#x000e3;o diast&#x000f3;lica em v&#x000e1;rios graus. Alguns pacientes podem apresentar aneurismas apicais e disfun&#x000e7;&#x000e3;o progressiva do VE, o que pode levar &#x000e0; doen&#x000e7;a card&#x000ed;aca terminal ou &#x000e0; variante CMH <italic toggle="yes">&#x0201c;burned-out&#x0201d;</italic>, associada a um pior progn&#x000f3;stico.<sup><xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref></sup></p><p>A RMC tamb&#x000e9;m permite uma caracteriza&#x000e7;&#x000e3;o anat&#x000f4;mica detalhada em rela&#x000e7;&#x000e3;o ao padr&#x000e3;o de HVE, varia&#x000e7;&#x000f5;es no aparelho da VM e suas contribui&#x000e7;&#x000f5;es para a obstru&#x000e7;&#x000e3;o da VSVE.<sup><xref rid="B43" ref-type="bibr">43</xref></sup>Considerando esta avalia&#x000e7;&#x000e3;o detalhada, a RMC desempenha um papel importante no planejamento de terapias de redu&#x000e7;&#x000e3;o septal.<sup><xref rid="B44" ref-type="bibr">44</xref></sup></p><p>Em rela&#x000e7;&#x000e3;o &#x000e0; caracteriza&#x000e7;&#x000e3;o tecidual, T1 nativo e VEC correlacionam-se com fibrose difusa, elevada mesmo em &#x000e1;reas sem LGE.<sup><xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref></sup> A fibrose de substitui&#x000e7;&#x000e3;o t&#x000ed;pica com padr&#x000e3;o de parede m&#x000e9;dia, mais frequente em &#x000e1;reas hipertr&#x000f3;ficas, &#x000e9; bem descrita com LGE, com valor progn&#x000f3;stico bem reconhecido.<sup><xref rid="B47" ref-type="bibr">47</xref></sup>Com avan&#x000e7;os recentes, <italic toggle="yes">&#x0201c;diffusion tensor acquisition&#x0201d;</italic> permite estudar a desorganiza&#x000e7;&#x000e3;o dos mi&#x000f3;citos, um marcador prematuro da doen&#x000e7;a,<sup><xref rid="B48" ref-type="bibr">48</xref></sup> e a RMC de perfus&#x000e3;o sob estresse permite o estudo da disfun&#x000e7;&#x000e3;o microvascular.<sup><xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref></sup></p></sec><sec><title>Mimetizadores de CMH</title><sec><title>Amiloidose card&#x000ed;aca</title><p>A AC &#x000e9; uma CM infiltrativa causada pela deposi&#x000e7;&#x000e3;o extracelular de fibrilas amiloides, com fen&#x000f3;tipo cl&#x000e1;ssico de HVE (&#x0201c;pseudo-hipertrofia&#x0201d;) e ICFEp. O ECO, particularmente nos est&#x000e1;gios iniciais,<sup><xref rid="B51" ref-type="bibr">51</xref></sup> carece especificidade para distinguir precisamente doen&#x000e7;as card&#x000ed;acas infiltrativas ou hipertr&#x000f3;ficas amiloides de n&#x000e3;o amiloides, refor&#x000e7;ando a necessidade de correla&#x000e7;&#x000e3;o com outros (&#x0201c;redflags&#x0201d;) cl&#x000ed;nicos e complementa&#x000e7;&#x000e3;o com outras modalidades de imagem. Os achados cl&#x000e1;ssicos do ECO podem ser observados apenas em est&#x000e1;gios avan&#x000e7;ados de infiltra&#x000e7;&#x000e3;o amiloide, com aumento biatrial, espessamento das v&#x000e1;lvulas e do septo interatrial, derrame pleural e peric&#x000e1;rdico, baixas velocidades mioc&#x000e1;rdicas e hipertrofia biventricular com apar&#x000ea;ncia brilhante. Geralmente, esses pacientes apresentam FEVE preservada e disfun&#x000e7;&#x000e3;o diast&#x000f3;lica acentuada com aumento das press&#x000f5;es de enchimento do VE (disfun&#x000e7;&#x000e3;o diast&#x000f3;lica tipo II-III), embora a FEVE reduzida seja um achado frequente na doen&#x000e7;a em est&#x000e1;gio avan&#x000e7;ado.<sup><xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref></sup> &#x000c9; importante observar que pacientes com AC podem apresentar redu&#x000e7;&#x000e3;o do d&#x000e9;bito sist&#x000f3;lico mesmo antes de uma redu&#x000e7;&#x000e3;o na FEVE, causada por diferentes fatores, incluindo altera&#x000e7;&#x000e3;o na deforma&#x000e7;&#x000e3;o mioc&#x000e1;rdica, desempenho diast&#x000f3;lico do VE prejudicado, disfun&#x000e7;&#x000e3;o mec&#x000e2;nica atrial e volumes reduzidos do VE devido ao espessamento da parede.<sup><xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref></sup></p><p>O ECO &#x000e9; um instrumento vital para o diagn&#x000f3;stico precoce de AC, particularmente em pacientes com fen&#x000f3;tipo hipertr&#x000f3;fico (definido como espessura da parede do VE &#x02265; 12 mm) combinado com outros &#x0201c;redflags&#x0201d; cl&#x000ed;nicos ou ecocardiogr&#x000e1;ficos. Esses achados (<xref rid="f05" ref-type="fig">Figura 4</xref>) devem levar o cl&#x000ed;nico a direcionar esses pacientes para um caminho investigativo especializado. Esse caminho normalmente inclui RMC, cintilografia com marcadores &#x000f3;sseos e quantifica&#x000e7;&#x000e3;o de cadeias leves livres no soro, juntamente com testes de imunofixa&#x000e7;&#x000e3;o no soro e na urina. Essas modalidades diagn&#x000f3;sticas ajudam a confirmar o diagn&#x000f3;stico de AC, diferenciando os tipos de imunoglobulina de cadeia leve (AL) monoclonal dos tipos de transtirretina (ATTR) e avaliam o estadiamento da doen&#x000e7;a e o progn&#x000f3;stico.<sup><xref rid="B56" ref-type="bibr">56</xref></sup></p><p>A GLS &#x000e9; notavelmente prejudicada em pacientes com AC, demonstrando uma forte correla&#x000e7;&#x000e3;o com a extens&#x000e3;o da carga amiloide, conforme demonstrado em estudos que comparam a GLS com o LGE e o volume extracelular (VEC) medido por RMC.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B54" ref-type="bibr">54</xref></sup> Um padr&#x000e3;o regional caracter&#x000ed;stico de deforma&#x000e7;&#x000e3;o longitudinal preservada nos segmentos apicais, formando um gradiente basal-apical ou um padr&#x000e3;o de preserva&#x000e7;&#x000e3;o apical relativa (RASp), foi identificado na AC (<xref rid="f07" ref-type="fig">Figura 6</xref>). Existem muitas maneiras de identificar esse padr&#x000e3;o por STE, usando diferentes f&#x000f3;rmulas e crit&#x000e9;rios quantitativos ou mesmo considerando uma apar&#x000ea;ncia visual de &#x0201c;cherry on top&#x0201d; um sinal visual qualitativo derivado da an&#x000e1;lise param&#x000e9;trica do LS (&#x0201c;bulls eye&#x0201d;). O RASp demonstrou boa precis&#x000e3;o na distin&#x000e7;&#x000e3;o de AC de outras causas de HVE e doen&#x000e7;as mioc&#x000e1;rdicas.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref></sup>Embora o RASp n&#x000e3;o seja espec&#x000ed;fico para o diagn&#x000f3;stico de AC<sup><xref rid="B59" ref-type="bibr">59</xref></sup> e possa ser encontrado em outras causas de HVE, ele pode ser usado como um valioso <italic toggle="yes">redflag</italic> ecocardiogr&#x000e1;fico para garantir investiga&#x000e7;&#x000e3;o adicional em pacientes com hist&#x000f3;rico cl&#x000ed;nico compat&#x000ed;vel<sup><xref rid="B60" ref-type="bibr">60</xref></sup> e tamb&#x000e9;m para determinar o progn&#x000f3;stico nesses pacientes.<sup><xref rid="B61" ref-type="bibr">61</xref></sup> &#x000c9; importante enfatizar que o RASp pode ser observado em diferentes tipos de AC, incluindo AL, ATTR heredit&#x000e1;rio e amiloidose ATTR de tipo selvagem, e n&#x000e3;o &#x000e9; &#x000fa;til para distingui-los. Esse padr&#x000e3;o pode n&#x000e3;o estar presente em uma propor&#x000e7;&#x000e3;o significativa de pacientes, porque nos est&#x000e1;gios iniciais da doen&#x000e7;a apenas graus leves de infiltra&#x000e7;&#x000e3;o amiloide em segmentos basais podem estar presentes. Por outro lado, um padr&#x000e3;o difuso de envolvimento do mioc&#x000e1;rdio pode ocorrer na doen&#x000e7;a em est&#x000e1;gio avan&#x000e7;ado, sem um gradiente significativo entre o &#x000e1;pice e a base do cora&#x000e7;&#x000e3;o.<sup><xref rid="B62" ref-type="bibr">62</xref></sup> Considerando a queda desproporcional e precoce da GLS e a FE relativamente preservada em pacientes com AC, a raz&#x000e3;o da FEVE dividida pela GLS apresentou boa acur&#x000e1;cia para diferenciar a AC da CMH, com ponto de corte de 4,1.<sup><xref rid="B63" ref-type="bibr">63</xref></sup></p><p>
<fig position="float" id="f07"><label>Figura 6</label><caption><title>&#x02013; Exemplo de paciente com Amiloidose Card&#x000ed;aca. A) ECG com baixa voltagem nas deriva&#x000e7;&#x000f5;es frontais, bloqueio atrioventricular de primeiro grau e padr&#x000e3;o de &#x0201c;pseudoinfarto&#x0201d; nas deriva&#x000e7;&#x000f5;es precordiais, B) um sinal cl&#x000ed;nico de ruptura do tend&#x000e3;o do b&#x000ed;ceps, C) 4 c&#x000e2;maras apicais mostrando aumento biatrial, espessamento do septo interatrial e das v&#x000e1;lvulas atrioventriculares, hipertrofia conc&#x000ea;ntrica do ventr&#x000ed;culo esquerdo (VE), D) Strain atrial com componente de reservat&#x000f3;rio reduzido (+15%) geralmente causado por miopatia atrial e disfun&#x000e7;&#x000e3;o diast&#x000f3;lica, E) Strain longitudinal (LS) do VE em formato de &#x0201c;bulls-eye&#x0201d; (exibi&#x000e7;&#x000e3;o param&#x000e9;trica) mostrando Strain regional alterada nos segmentos basal e medial, relativamente preservada nos segmentos apicais (&#x0201c;cherry on top&#x0201d;). F) LS do ventr&#x000ed;culo direito (VD) reduzida (Strain da parede livre = -13%) mostrando infiltra&#x000e7;&#x000e3;o de amiloide na parede do VD, G) RMC mostrando espessamento da parede biventricular, septo interatrial, aumento biatrial, H) RMC com realce tardio de gadol&#x000ed;nio mostrando padr&#x000e3;o global subendoc&#x000e1;rdico, com cin&#x000e9;tica de gadol&#x000ed;nio alterada.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf07" position="float"/></fig>
</p><p>O strain mioc&#x000e1;rdico do VD &#x000e9; tipicamente prejudicado em pacientes com AC, o que pode ser uma caracter&#x000ed;stica diagn&#x000f3;stica &#x000fa;til para diferenciar a AC de outras causas de fen&#x000f3;tipos hipertr&#x000f3;ficos. Curiosamente, um padr&#x000e3;o de preserva&#x000e7;&#x000e3;o apical relativa do VD, semelhante ao observado no VE, tamb&#x000e9;m foi identificado nesses pacientes. A identifica&#x000e7;&#x000e3;o desse padr&#x000e3;o do VD, juntamente com os achados do VE, aumenta a especificidade diagn&#x000f3;stica para AC, conforme citado em algumas publica&#x000e7;&#x000f5;es.<sup><xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref></sup></p><p>A RMC &#x000e9; particularmente &#x000fa;til para a AC, uma vez que os valores T1 s&#x000e3;o notavelmente extremos e o LGE tem cin&#x000e9;tica t&#x000ed;pica (<xref rid="f09" ref-type="fig">Figura 7</xref>).<sup><xref rid="B22" ref-type="bibr">22</xref></sup> O mioc&#x000e1;rdio amiloid&#x000f3;tico tem uma avidez singular pelo gadol&#x000ed;nio, levando a um &#x0201c;ponto nulo&#x0201d; mioc&#x000e1;rdico antes do pool sangu&#x000ed;neo do VE. Como contraste extracelular, o gadol&#x000ed;nio se acumula na presen&#x000e7;a de expans&#x000e3;o do espa&#x000e7;o extracelular secund&#x000e1;ria &#x000e0; deposi&#x000e7;&#x000e3;o de amiloide.<sup><xref rid="B66" ref-type="bibr">66</xref></sup> O padr&#x000e3;o do LGE &#x000e9; tipicamente global e subendoc&#x000e1;rdico, tornando-se transmural em est&#x000e1;gios avan&#x000e7;ados.<sup><xref rid="B67" ref-type="bibr">67</xref></sup>Devido ao ac&#x000fa;mulo extracelular de fibrilas amiloides, o VEC aumenta acentuadamente, frequentemente acima de 40%.<sup><xref rid="B68" ref-type="bibr">68</xref></sup></p><p>
<fig position="float" id="f09"><label>Figura 7</label><caption><title>&#x02013; Uso da resson&#x000e2;ncia magn&#x000e9;tica card&#x000ed;aca (RMC) em pacientes com fen&#x000f3;tipo hipertr&#x000f3;fico do ventr&#x000ed;culo esquerdo (VE), com imagens de ECG, cine RMC, realce tardio com gadol&#x000ed;nio (LGE) e mapeamento de sequ&#x000ea;ncia T1. Em A) um paciente com cardiomiopatia hipertr&#x000f3;fica septal assim&#x000e9;trica, em B) um paciente com cardiomiopatia hipertr&#x000f3;fica apical, C) um paciente com amiloidose card&#x000ed;aca (AC) ATTR, D) um paciente com doen&#x000e7;a de Fabry. As setas mostram &#x000e1;reas de fibrose e o (*) aponta para um padr&#x000e3;o difuso t&#x000ed;pico na AC. Vale ressaltar que o mapeamento T1 mostra um aumento do T1 nativo no paciente com AC (C) e um tempo T1 reduzido em um paciente com doen&#x000e7;a de Fabry (D).</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf08" position="float"/></fig>
</p><p>Quando utilizada isoladamente, a RMC n&#x000e3;o permite uma distin&#x000e7;&#x000e3;o precisa entre amiloidose AL e ATTR, embora cada tipo tenham algumas caracter&#x000ed;sticas espec&#x000ed;ficas: O LGE do VD fica aparente na maioria dos pacientes com amiloidose ATTR, mas apenas em cerca de 70% dos pacientes com amiloidose AL; a massa do VE e o VEC s&#x000e3;o maiores no tipo ATTR, enquanto T1 e T2 nativos s&#x000e3;o maiores na amiloidose AL secund&#x000e1;ria &#x000e0; toxicidade da cadeia leve nos cardiomi&#x000f3;citos.<sup><xref rid="B67" ref-type="bibr">67</xref>,<xref rid="B68" ref-type="bibr">68</xref></sup>Al&#x000e9;m disso, o c&#x000e1;lculo do VEC no f&#x000ed;gado e no ba&#x000e7;o pode identificar envolvimento sist&#x000ea;mico na AL, o que &#x000e9; muito raro na ATTR.<sup><xref rid="B69" ref-type="bibr">69</xref></sup></p><p>A combina&#x000e7;&#x000e3;o de imagens multimodais e a observa&#x000e7;&#x000e3;o de suas caracter&#x000ed;sticas podem fornecer pistas importantes para identificar poss&#x000ed;veis diagn&#x000f3;sticos diferenciais. Caracter&#x000ed;sticas da amiloidose na RMC com grau 0 ou 1 na cintilografia &#x000f3;ssea apontam para o diagn&#x000f3;stico de amiloidose AL, ou raramente, variantes TTR, AApoAI e AApoAIV-amiloidose.<sup><xref rid="B70" ref-type="bibr">70</xref></sup> Quando combinada com estudos de prote&#x000ed;nas monoclonais normais, a presen&#x000e7;a de caracter&#x000ed;sticas na RMC mostra alta especificidade para o diagn&#x000f3;stico de AC ATTR.<sup><xref rid="B71" ref-type="bibr">71</xref></sup></p></sec><sec><title>Doen&#x000e7;a de Fabry</title><p>A doen&#x000e7;a de Fabry &#x000e9; uma doen&#x000e7;a rara de armazenamento lisossomal causada por uma defici&#x000ea;ncia de &#x003b1;-GalA. A HVE &#x000e9; a principal manifesta&#x000e7;&#x000e3;o card&#x000ed;aca da doen&#x000e7;a de Fabry, sendo respons&#x000e1;vel por 0,9% dos casos de CMH.<sup><xref rid="B72" ref-type="bibr">72</xref></sup> Nos homens, o ac&#x000fa;mulo cr&#x000f4;nico de globotriaosilceramida &#x000e9; respons&#x000e1;vel por 2% da hipertrofia card&#x000ed;aca total, mas seu armazenamento desencadeia a express&#x000e3;o da prote&#x000ed;na sarcom&#x000e9;rica via hipertrofia dos mi&#x000f3;citos. Por outro lado, nas mulheres, a HVE consiste em hipertrofia equilibrada de esfingolip&#x000ed;deos e mi&#x000f3;citos em propor&#x000e7;&#x000e3;o. Muitas vezes, &#x000e9; subdiagnosticada e pode levar a desfechos ruins se n&#x000e3;o for tratada. O envolvimento card&#x000ed;aco &#x000e9; o fator progn&#x000f3;stico mais crucial na doen&#x000e7;a de Fabry e impacta significativamente a qualidade de vida.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Altera&#x000e7;&#x000f5;es card&#x000ed;acas na doen&#x000e7;a de Fabry podem ser sutis em pacientes jovens, mas eles geralmente desenvolvem ICFEp, arritmias e HVE mimetizando CMH mais tardiamente, geralmente ap&#x000f3;s os 30 anos nos homens e os 40 anos nas mulheres. O diagn&#x000f3;stico precoce &#x000e9; vital, especialmente porque a terapia de reposi&#x000e7;&#x000e3;o enzim&#x000e1;tica est&#x000e1; dispon&#x000ed;vel e pode limitar a progress&#x000e3;o da doen&#x000e7;a.<sup><xref rid="B73" ref-type="bibr">73</xref></sup></p><p>As caracter&#x000ed;sticas ecocardiogr&#x000e1;ficas t&#x000ed;picas da doen&#x000e7;a de Fabry s&#x000e3;o HVE conc&#x000ea;ntrica com FE preservada e hipertrofia desproporcional dos m&#x000fa;sculos papilares (<xref rid="f05" ref-type="fig">Figura 4</xref>). Entretanto, alguns pacientes podem apresentar HVE assim&#x000e9;trica e at&#x000e9; mesmo obstru&#x000e7;&#x000e3;o din&#x000e2;mica da VSVE, levando ao diagn&#x000f3;stico incorreto de CMH. Pode ocorrer dilata&#x000e7;&#x000e3;o da raiz a&#x000f3;rtica e espessamento das v&#x000e1;lvulas mitral e a&#x000f3;rtica, geralmente sem disfun&#x000e7;&#x000e3;o significativa. A hipertrofia do VD com fun&#x000e7;&#x000e3;o sist&#x000f3;lica preservada &#x000e9; comum em pacientes com doen&#x000e7;a de Fabry e HVE, e esses pacientes geralmente apresentam melhor fun&#x000e7;&#x000e3;o sist&#x000f3;lica em compara&#x000e7;&#x000e3;o aos pacientes com AC com n&#x000ed;veis semelhantes de espessamento da parede do VD.<sup><xref rid="B74" ref-type="bibr">74</xref></sup> A GLS &#x000e9; significativamente reduzida em pacientes com doen&#x000e7;a de Fabry evidente, e as altera&#x000e7;&#x000f5;es de deforma&#x000e7;&#x000e3;o regional s&#x000e3;o frequentemente mais pronunciadas na parede &#x000ed;nfero-lateral basal, correlacionando-se com LGE nessa regi&#x000e3;o na RMC. Para portadores de variantes patog&#x000ea;nicas do gene GLA, GLS facilita a detec&#x000e7;&#x000e3;o precoce do envolvimento card&#x000ed;aco, independentemente da HVE.<sup><xref rid="B75" ref-type="bibr">75</xref></sup></p><p>A RMC mostra T1 nativo baixo,<sup><xref rid="B76" ref-type="bibr">76</xref></sup> o que &#x000e9; caracter&#x000ed;stico, refletindo a deposi&#x000e7;&#x000e3;o de esfingolip&#x000ed;deos. Uma vez que o armazenamento &#x000e9; principalmente um fen&#x000f4;meno intracelular, o espa&#x000e7;o extracelular &#x000e9; poupado pelo ac&#x000fa;mulo, resultando em um VEC normal medido pelo contraste pr&#x000e9; e p&#x000f3;s T1.<sup><xref rid="B76" ref-type="bibr">76</xref></sup> De fato, a RMC pode retratar as tr&#x000ea;s fases da hist&#x000f3;ria natural da doen&#x000e7;a. Na fase de acumula&#x000e7;&#x000e3;o inicial, um T1 nativo baixo &#x000e9; observado na aus&#x000ea;ncia de HVE. A progress&#x000e3;o da doen&#x000e7;a &#x000e9; documentada pelo aparecimento de hipertrofia, inflama&#x000e7;&#x000e3;o e LGE principalmente na parede &#x000ed;nfero-lateral basal. Por fim, na presen&#x000e7;a de LGE extenso, h&#x000e1; uma pseudonormaliza&#x000e7;&#x000e3;o do T1<sup><xref rid="B76" ref-type="bibr">76</xref></sup> nativo.</p></sec><sec><title>S&#x000ed;ndrome de Noonan</title><p>A s&#x000ed;ndrome de Noonan &#x000e9; uma doen&#x000e7;a gen&#x000e9;tica autoss&#x000f4;mica dominante, parte de um grupo conhecido como RASopatias, que afeta v&#x000e1;rios sistemas do corpo. Possui diversas caracter&#x000ed;sticas, incluindo anormalidades card&#x000ed;acas cong&#x000ea;nitas, baixa estatura, pesco&#x000e7;o alado, dismorfismo craniofacial, malforma&#x000e7;&#x000f5;es esquel&#x000e9;ticas, di&#x000e1;tese hemorr&#x000e1;gica, hipertelorismo e defici&#x000ea;ncia intelectual leve. Muta&#x000e7;&#x000f5;es que causam a s&#x000ed;ndrome de Noonan afetam genes que codificam prote&#x000ed;nas da via RAS-MAPK (prote&#x000ed;na quinase ativada por mit&#x000f3;geno). Isso leva &#x000e0; desregula&#x000e7;&#x000e3;o de processos celulares cr&#x000ed;ticos, incluindo prolifera&#x000e7;&#x000e3;o, diferencia&#x000e7;&#x000e3;o, sobreviv&#x000ea;ncia e metabolismo, caracter&#x000ed;sticos das RASopatias.</p><p>Em mais de 80% dos pacientes com s&#x000ed;ndrome de Noonan, s&#x000e3;o observadas anormalidades card&#x000ed;acas, com estenose pulmonar prevalente em aproximadamente 50% dos casos e CMH ocorrendo em 25%.<sup><xref rid="B77" ref-type="bibr">77</xref></sup>Al&#x000e9;m disso, a s&#x000ed;ndrome de Noonan est&#x000e1; associada a um amplo espectro de outras malforma&#x000e7;&#x000f5;es card&#x000ed;acas.<sup><xref rid="B78" ref-type="bibr">78</xref></sup>A HVE geralmente se manifesta de forma precoce e &#x000e9; normalmente diagnosticada nos primeiros seis meses de vida.<sup><xref rid="B79" ref-type="bibr">79</xref></sup>A HVE observada na s&#x000ed;ndrome de Noonan pode se apresentar como conc&#x000ea;ntrica ou assim&#x000e9;trica, &#x000e0;s vezes acompanhada de obstru&#x000e7;&#x000e3;o din&#x000e2;mica da VSVE. Anomalias da VM e complica&#x000e7;&#x000f5;es subvalvares, como SAM, inser&#x000e7;&#x000e3;o an&#x000f4;mala da VM levando &#x000e0; obstru&#x000e7;&#x000e3;o suba&#x000f3;rtica e degenera&#x000e7;&#x000e3;o mixomatosa, resultando em prolapso da v&#x000e1;lvula, s&#x000e3;o comumente observadas em pacientes com s&#x000ed;ndrome de Noonan e CMH.<sup><xref rid="B80" ref-type="bibr">80</xref></sup> A presen&#x000e7;a de CMH na s&#x000ed;ndrome de Noonan influencia significativamente com a evolu&#x000e7;&#x000e3;o dos pacientes, correlacionando-se com aumento da morbidade e mortalidade.<sup><xref rid="B81" ref-type="bibr">81</xref></sup> A progress&#x000e3;o da HVE &#x000e9; vari&#x000e1;vel; em alguns casos, pode surgir mais tarde na inf&#x000e2;ncia e progredir lentamente, permanecer est&#x000e1;vel por v&#x000e1;rios anos ou evoluir rapidamente durante a inf&#x000e2;ncia. Em um subconjunto de pacientes, representando 17% de uma coorte de 46 indiv&#x000ed;duos acompanhados por sete anos, foram observadas regress&#x000e3;o e estabiliza&#x000e7;&#x000e3;o da HVE.<sup><xref rid="B82" ref-type="bibr">82</xref></sup></p></sec><sec><title>Doen&#x000e7;a de Pompe</title><p>A doen&#x000e7;a de Pompe &#x000e9; classificada como uma doen&#x000e7;a de dep&#x000f3;sito lisossomal autoss&#x000f4;mica recessiva de incid&#x000ea;ncia rara, decorrente de muta&#x000e7;&#x000f5;es no gene da &#x003b1;-glicosidase &#x000e1;cida. Essa altera&#x000e7;&#x000e3;o gen&#x000e9;tica resulta em um ac&#x000fa;mulo de glicog&#x000ea;nio lisossomal em v&#x000e1;rios tecidos, principalmente no mioc&#x000e1;rdio, no sistema respirat&#x000f3;rio e nos m&#x000fa;sculos esquel&#x000e9;ticos. O in&#x000ed;cio da doen&#x000e7;a de Pompe varia, com um poss&#x000ed;vel diagn&#x000f3;stico ao nascimento, na inf&#x000e2;ncia ou na idade adulta. A forma cl&#x000e1;ssica da doen&#x000e7;a, observada predominantemente em lactentes, &#x000e9; caracterizada por r&#x000e1;pida progress&#x000e3;o e geralmente se apresenta com CMH, muitas vezes com progn&#x000f3;stico desfavor&#x000e1;vel. Nesses casos, beb&#x000ea;s n&#x000e3;o tratados frequentemente sucumbem &#x000e0; insufici&#x000ea;ncia cardiorrespirat&#x000f3;ria no primeiro ano de vida. Fenotipicamente, a doen&#x000e7;a de Pompe &#x000e9; marcada por HVE, predominantemente com espessamento septal assim&#x000e9;trico, embora tamb&#x000e9;m seja observada hipertrofia conc&#x000ea;ntrica envolvendo as paredes septal e livre do VE e do VD. Na RMC, o LGE &#x000e9; raro e pode ser visto no subendoc&#x000e1;rdio das paredes lateral e anterior. A hipertrofia septal grave leva, geralmente, &#x000e0; SAM e obstru&#x000e7;&#x000e3;o da VSVE, exacerbando os sintomas cl&#x000ed;nicos. Essas patologias podem evoluir para disfun&#x000e7;&#x000e3;o diast&#x000f3;lica e sist&#x000f3;lica, culminando em IC. Notavelmente, observou-se que a terapia de reposi&#x000e7;&#x000e3;o enzim&#x000e1;tica induz a regress&#x000e3;o r&#x000e1;pida da HVE e melhora a fun&#x000e7;&#x000e3;o ventricular sist&#x000f3;lica, conforme avaliado pela an&#x000e1;lise de deforma&#x000e7;&#x000e3;o mioc&#x000e1;rdica.<sup><xref rid="B83" ref-type="bibr">83</xref></sup></p></sec><sec><title>Cardiomiopatia PRKAG2</title><p>A CM PRKAG2, uma doen&#x000e7;a autoss&#x000f4;mica dominante de armazenamento de glicog&#x000ea;nio que afeta principalmente o m&#x000fa;sculo card&#x000ed;aco e o sistema de condu&#x000e7;&#x000e3;o, apresenta um perfil cl&#x000ed;nico e progn&#x000f3;stico &#x000fa;nicos. A CM PRKAG2 &#x000e9; caracterizado por HVE, s&#x000ed;ndrome de Wolff-Parkinson-White e doen&#x000e7;a progressiva do sistema de condu&#x000e7;&#x000e3;o.<sup><xref rid="B84" ref-type="bibr">84</xref></sup>A CMH em pacientes com muta&#x000e7;&#x000f5;es no gene PRKAG2 geralmente surge na adolesc&#x000ea;ncia ou na idade adulta, com poucos casos relatados na inf&#x000e2;ncia. A CM PRKAG2 est&#x000e1; associada a piores desfechos em compara&#x000e7;&#x000e3;o &#x000e0; CMH sarcom&#x000e9;rica, com pacientes potencialmente apresentando insufici&#x000ea;ncia card&#x000ed;aca precoce e morte s&#x000fa;bita.<sup><xref rid="B85" ref-type="bibr">85</xref></sup> O fen&#x000f3;tipo ecocardiogr&#x000e1;fico frequentemente mostra HVE conc&#x000ea;ntrica, FEVE preservada, disfun&#x000e7;&#x000e3;o diast&#x000f3;lica e, menos comumente, hipertrofia do VD (<xref rid="f08" ref-type="fig">Figura 8</xref>).<sup><xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref></sup> A obstru&#x000e7;&#x000e3;o da VSVE &#x000e9; rara nesses pacientes, comparando-se aos pacientes com CMH sarcom&#x000e9;rica. Um estudo mostrou que pacientes com CM PRKAG2 podem ter GLS mais preservada, associada &#x000e0; bradicardia, embora tenham massa do VE e espessamento das paredes ventriculares semelhantes.<sup><xref rid="B88" ref-type="bibr">88</xref></sup></p><p>
<fig position="float" id="f08"><label>Figura 8</label><caption><title>&#x02013; Exemplo de um paciente jovem (homem de 25 anos) com cardiomiopatia PRKAG2. Em A) vis&#x000e3;o paraesternal do eixo longo mostrando um ventr&#x000ed;culo esquerdo (VE) remodelado com hipertrofia. Em B) ECG mostrando ondas delta, intervalo PR curto (s&#x000ed;ndrome de Wolff-Parkinson-White) e padr&#x000e3;o de hipertrofia do VE. Em C) vis&#x000e3;o de eixo curto representando hipertrofia conc&#x000ea;ntrica do VE. Em D) strain longitudinal (LS) do VE, Bulls-eye (display param&#x000e9;trico) mostrando altera&#x000e7;&#x000e3;o difusa da deforma&#x000e7;&#x000e3;o mioc&#x000e1;rdica. E) hipertrofia conc&#x000ea;ntrica biventricular e um DCI nas cavidades direitas. F) Strain longitudinal do ventr&#x000ed;culo direito alterado (strain m&#x000e9;dio de parede livre = -9,33%).</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf09" position="float"/></fig>
</p></sec><sec><title>Ataxia de Friedreich</title><p>A ataxia de Friedreich &#x000e9; uma doen&#x000e7;a degenerativa autoss&#x000f4;mica recessiva, que afeta o gene da frataxina, levando ao armazenamento de ferro mitocondrial e afetando o metabolismo da glicose, o sistema nervoso e o cora&#x000e7;&#x000e3;o.<sup><xref rid="B89" ref-type="bibr">89</xref></sup> A doen&#x000e7;a card&#x000ed;aca geralmente se manifesta como fen&#x000f3;tipo de CMH que pode evoluir para cardiomiopatia dilatada, a causa mais importante de morte.<sup><xref rid="B90" ref-type="bibr">90</xref></sup>O envolvimento mioc&#x000e1;rdico pode ser detectado subclinicamente antes do desenvolvimento de HVE ou redu&#x000e7;&#x000e3;o da FEVE, seja por STE<sup><xref rid="B91" ref-type="bibr">91</xref></sup> ou RMC.<sup><xref rid="B92" ref-type="bibr">92</xref></sup></p><p>As caracter&#x000ed;sticas ecocardiogr&#x000e1;ficas t&#x000ed;picas s&#x000e3;o HVE conc&#x000ea;ntrica sem obstru&#x000e7;&#x000e3;o da VSVE ou m&#x000e9;dio-ventricular (embora tamb&#x000e9;m possa ocorrer hipertrofia assim&#x000e9;trica), com disfun&#x000e7;&#x000e3;o do VE (FE reduzida) e insufici&#x000ea;ncia card&#x000ed;aca em doen&#x000e7;a avan&#x000e7;ada<sup><xref rid="B93" ref-type="bibr">93</xref></sup> com reserva de perfus&#x000e3;o alterada.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> O aspecto morfol&#x000f3;gico da HVE nesses pacientes pode assemelhar-se &#x000e0; AC, mesmo com uma textura granular brilhante do mioc&#x000e1;rdio, mas geralmente n&#x000e3;o h&#x000e1; aumento biatrial, derrame peric&#x000e1;rdico ou disfun&#x000e7;&#x000e3;o diast&#x000f3;lica grave em pacientes com ataxia de Friedreich.<sup><xref rid="B94" ref-type="bibr">94</xref></sup></p></sec><sec><title>Doen&#x000e7;a de Danon</title><p>A doen&#x000e7;a de Danon &#x000e9; uma doen&#x000e7;a gen&#x000e9;tica rara, dominante, ligada ao cromossomo X, que se manifesta com a tr&#x000ed;ade cl&#x000ed;nica de cardiomiopatia, miopatia esquel&#x000e9;tica e defici&#x000ea;ncia intelectual. &#x000c9; causada por muta&#x000e7;&#x000f5;es no gene da membrana associada ao lisossomo 2 (LAMP2). A cardiomiopatia de Danon &#x000e9; progressiva e geralmente se manifesta como fen&#x000f3;tipo hipertr&#x000f3;fico, com altera&#x000e7;&#x000f5;es do strain radial, circunferencial e longitudinal nos est&#x000e1;gios iniciais, com fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o preservada (ICFEp). Com a progress&#x000e3;o da fibrose, esses pacientes podem evoluir com decl&#x000ed;nio da fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o, piora dos sintomas e fen&#x000f3;tipo dilatado, principalmente em pacientes do sexo masculino.<sup><xref rid="B95" ref-type="bibr">95</xref></sup> A extens&#x000e3;o e a gravidade da cardiomiopatia s&#x000e3;o os principais fatores progn&#x000f3;sticos. A maioria dos pacientes &#x000e9; assintom&#x000e1;tica durante a inf&#x000e2;ncia, progredindo para um est&#x000e1;gio sintom&#x000e1;tico durante a adolesc&#x000ea;ncia e culminando em insufici&#x000ea;ncia card&#x000ed;aca fulminante e morte s&#x000fa;bita na idade adulta.<sup><xref rid="B96" ref-type="bibr">96</xref></sup> Os achados na RMC desempenham um papel fundamental no diagn&#x000f3;stico desta doen&#x000e7;a e geralmente incluem HVE acentuada, que pode ser conc&#x000ea;ntrica ou assim&#x000e9;trica, e padr&#x000f5;es distintos de LGE que diferem de outras formas de cardiomiopatia hipertr&#x000f3;fica. Geralmente, o LGE poupa o septo m&#x000e9;dio e exibe um gradiente da base para o &#x000e1;pice com envolvimento do &#x000e1;pice.<sup><xref rid="B97" ref-type="bibr">97</xref>,<xref rid="B98" ref-type="bibr">98</xref></sup> Al&#x000e9;m disso, a RMC pode revelar T1 nativo e VEC elevados, sugerindo fibrose mioc&#x000e1;rdica.<sup><xref rid="B98" ref-type="bibr">98</xref>,<xref rid="B99" ref-type="bibr">99</xref></sup></p></sec></sec></sec><sec sec-type="conclusions"><title>Conclus&#x000e3;o</title><p>A associa&#x000e7;&#x000e3;o das diferentes pe&#x000e7;as do quebra-cabe&#x000e7;a da HVE (hist&#x000f3;rico pessoal e familiar do paciente, apresenta&#x000e7;&#x000e3;o cl&#x000ed;nica, achados do exame f&#x000ed;sico, caracter&#x000ed;sticas do ECG e informa&#x000e7;&#x000f5;es obtidas em exames de multimodadlidade de imagem card&#x000ed;aca) pode identificar <italic toggle="yes">redflags</italic> espec&#x000ed;ficos que ajudam o cl&#x000ed;nico a diferenciar as causas de fen&#x000f3;tipos hipertr&#x000f3;ficos.</p><p>Essa abordagem sistem&#x000e1;tica permite diagn&#x000f3;sticos mais precisos e estrat&#x000e9;gias de tratamento personalizadas. No entanto, &#x000e9; importante observar que exames diagn&#x000f3;sticos adicionais, como testes gen&#x000e9;ticos, teste de exerc&#x000ed;cio cardiopulmonar e bi&#x000f3;psia endomioc&#x000e1;rdica, podem ser necess&#x000e1;rios para confirmar a etiologia subjacente. O julgamento cl&#x000ed;nico e a avalia&#x000e7;&#x000e3;o individualizada do paciente continuam sendo cruciais no processo de diagn&#x000f3;stico.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Vincula&#x000e7;&#x000e3;o acad&#x000ea;mica:</bold> N&#x000e3;o h&#x000e1; vincula&#x000e7;&#x000e3;o deste estudo a programas de p&#x000f3;s-gradua&#x000e7;&#x000e3;o.</p></fn><fn fn-type="other"><p><bold>Aprova&#x000e7;&#x000e3;o &#x000e9;tica e consentimento informado:</bold> Este artigo n&#x000e3;o cont&#x000e9;m estudos com humanos ou animais realizados por nenhum dos autores.</p></fn><fn fn-type="financial-disclosure"><p><bold>Fontes de financiamento:</bold> O presente estudo n&#x000e3;o teve fontes de financiamento externas.</p></fn></fn-group><ref-list><title>Refer&#x000ea;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardim</surname><given-names>N</given-names></name>
<name><surname>Galderisi</surname><given-names>M</given-names></name>
<name><surname>Edvardsen</surname><given-names>T</given-names></name>
<name><surname>Plein</surname><given-names>S</given-names></name>
<name><surname>Popescu</surname><given-names>BA</given-names></name>
<name><surname>D'Andrea</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Role of Multimodality Cardiac Imaging in the Management of Patients with Hypertrophic Cardiomyopathy: An Expert Consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2015</year><volume>16</volume><issue>3</issue><fpage>280</fpage><pub-id pub-id-type="doi">10.1093/ehjci/jeu291</pub-id><pub-id pub-id-type="pmid">25650407</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elliott</surname><given-names>PM</given-names></name>
<name><surname>Anastasakis</surname><given-names>A</given-names></name>
<name><surname>Borger</surname><given-names>MA</given-names></name>
<name><surname>Borggrefe</surname><given-names>M</given-names></name>
<name><surname>Cecchi</surname><given-names>F</given-names></name>
<name><surname>Charron</surname><given-names>P</given-names></name>
<etal>et al</etal>
</person-group><article-title>2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><issue>39</issue><fpage>2733</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu284</pub-id><pub-id pub-id-type="pmid">25173338</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ommen</surname><given-names>SR</given-names></name>
<name><surname>Ho</surname><given-names>CY</given-names></name>
<name><surname>Asif</surname><given-names>IM</given-names></name>
<name><surname>Balaji</surname><given-names>S</given-names></name>
<name><surname>Burke</surname><given-names>MA</given-names></name>
<name><surname>Day</surname><given-names>SM</given-names></name>
<etal>et al</etal>
</person-group><article-title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</article-title><source>Circulation</source><year>2024</year><volume>149</volume><issue>23</issue><fpage>e1239</fpage><lpage>e1311</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001250</pub-id><pub-id pub-id-type="pmid">38718139</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Limongelli</surname><given-names>G</given-names></name>
<name><surname>Monda</surname><given-names>E</given-names></name>
<name><surname>Tramonte</surname><given-names>S</given-names></name>
<name><surname>Gragnano</surname><given-names>F</given-names></name>
<name><surname>Masarone</surname><given-names>D</given-names></name>
<name><surname>Frisso</surname><given-names>G</given-names></name>
<etal>et al</etal>
</person-group><article-title>Prevalence and Clinical Significance of Red Flags in Patients with Hypertrophic Cardiomyopathy</article-title><source>Int J Cardiol</source><year>2020</year><volume>299</volume><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2019.06.073</pub-id><pub-id pub-id-type="pmid">31303393</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rapezzi</surname><given-names>C</given-names></name>
<name><surname>Arbustini</surname><given-names>E</given-names></name>
<name><surname>Caforio</surname><given-names>AL</given-names></name>
<name><surname>Charron</surname><given-names>P</given-names></name>
<name><surname>Gimeno-Blanes</surname><given-names>J</given-names></name>
<name><surname>Heli&#x000f6;</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Diagnostic Work-Up in Cardiomyopathies: Bridging the Gap between Clinical Phenotypes and Final Diagnosis. A Position Statement from the ESC Working Group on Myocardial and Pericardial Diseases</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>19</issue><fpage>1448</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs397</pub-id><pub-id pub-id-type="pmid">23211230</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pieroni</surname><given-names>M</given-names></name>
<name><surname>Moon</surname><given-names>JC</given-names></name>
<name><surname>Arbustini</surname><given-names>E</given-names></name>
<name><surname>Barriales-Villa</surname><given-names>R</given-names></name>
<name><surname>Camporeale</surname><given-names>A</given-names></name>
<name><surname>Vujkovac</surname><given-names>AC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>77</volume><issue>7</issue><fpage>922</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.12.024</pub-id><pub-id pub-id-type="pmid">33602475</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kittleson</surname><given-names>MM</given-names></name>
<name><surname>Maurer</surname><given-names>MS</given-names></name>
<name><surname>Ambardekar</surname><given-names>AV</given-names></name>
<name><surname>Bullock-Palmer</surname><given-names>RP</given-names></name>
<name><surname>Chang</surname><given-names>PP</given-names></name>
<name><surname>Eisen</surname><given-names>HJ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association</article-title><source>Circulation</source><year>2020</year><volume>142</volume><issue>1</issue><fpage>e7</fpage><lpage>e22</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000792</pub-id><pub-id pub-id-type="pmid">32476490</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arbelo</surname><given-names>E</given-names></name>
<name><surname>Protonotarios</surname><given-names>A</given-names></name>
<name><surname>Gimeno</surname><given-names>JR</given-names></name>
<name><surname>Arbustini</surname><given-names>E</given-names></name>
<name><surname>Barriales-Villa</surname><given-names>R</given-names></name>
<name><surname>Basso</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>2023 ESC Guidelines for the Management of Cardiomyopathies</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><issue>37</issue><fpage>3503</fpage><lpage>3626</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad194</pub-id><pub-id pub-id-type="pmid">37622657</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sweet</surname><given-names>ME</given-names></name>
<name><surname>Mestroni</surname><given-names>L</given-names></name>
<name><surname>Taylor</surname><given-names>MRG</given-names></name>
</person-group><article-title>Genetic Infiltrative Cardiomyopathies</article-title><source>Heart Fail Clin</source><year>2018</year><volume>14</volume><issue>2</issue><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.hfc.2017.12.003</pub-id><pub-id pub-id-type="pmid">29525649</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dores</surname><given-names>H</given-names></name>
<name><surname>Toste</surname><given-names>A</given-names></name>
<name><surname>Cardim</surname><given-names>N</given-names></name>
<collab>Portuguese Registry of Hypertrophic Cardiomyopathy</collab>
</person-group><article-title>Hypertrophic Cardiomyopathy in Patients with a Normal Electrocardiogram: A View from the East Side of the Atlantic Ocean</article-title><source>Int J Cardiol</source><year>2023</year><volume>390</volume><size units="pages">131260</size><pub-id pub-id-type="doi">10.1016/j.ijcard.2023.131260</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azevedo</surname><given-names>O</given-names></name>
<name><surname>Marques</surname><given-names>N</given-names></name>
<name><surname>Reis</surname><given-names>L</given-names></name>
<name><surname>Cruz</surname><given-names>I</given-names></name>
<name><surname>Craveiro</surname><given-names>N</given-names></name>
<name><surname>Antunes</surname><given-names>H</given-names></name>
<etal>et al</etal>
</person-group><article-title>Predictors of Fabry Disease in Patients with Hypertrophic Cardiomyopathy: How to Guide the Diagnostic Strategy?</article-title><source>Am Heart J</source><year>2020</year><volume>226</volume><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2020.04.006</pub-id><pub-id pub-id-type="pmid">32531501</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maron</surname><given-names>BJ</given-names></name>
<name><surname>Desai</surname><given-names>MY</given-names></name>
<name><surname>Nishimura</surname><given-names>RA</given-names></name>
<name><surname>Spirito</surname><given-names>P</given-names></name>
<name><surname>Rakowski</surname><given-names>H</given-names></name>
<name><surname>Towbin</surname><given-names>JA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review</article-title><source>J Am Coll Cardiol</source><year>2022</year><volume>79</volume><issue>4</issue><fpage>372</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.12.002</pub-id><pub-id pub-id-type="pmid">35086660</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phelan</surname><given-names>D</given-names></name>
<name><surname>Collier</surname><given-names>P</given-names></name>
<name><surname>Thavendiranathan</surname><given-names>P</given-names></name>
<name><surname>Popovic</surname><given-names>ZB</given-names></name>
<name><surname>Hanna</surname><given-names>M</given-names></name>
<name><surname>Plana</surname><given-names>JC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Relative Apical Sparing of Longitudinal Strain using Two-Dimensional Speckle-Tracking Echocardiography is both Sensitive and Specific for the Diagnosis of Cardiac Amyloidosis</article-title><source>Heart</source><year>2012</year><volume>98</volume><issue>19</issue><fpage>1442</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2012-302353</pub-id><pub-id pub-id-type="pmid">22865865</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reant</surname><given-names>P</given-names></name>
<name><surname>Mirabel</surname><given-names>M</given-names></name>
<name><surname>Lloyd</surname><given-names>G</given-names></name>
<name><surname>Peyrou</surname><given-names>J</given-names></name>
<name><surname>Lopez Ayala</surname><given-names>JM</given-names></name>
<name><surname>Dickie</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Global Longitudinal Strain is Associated with Heart Failure Outcomes in Hypertrophic Cardiomyopathy</article-title><source>Heart</source><year>2016</year><volume>102</volume><issue>10</issue><fpage>741</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2015-308576</pub-id><pub-id pub-id-type="pmid">26857213</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haland</surname><given-names>TF</given-names></name>
<name><surname>Almaas</surname><given-names>VM</given-names></name>
<name><surname>Hasselberg</surname><given-names>NE</given-names></name>
<name><surname>Saberniak</surname><given-names>J</given-names></name>
<name><surname>Leren</surname><given-names>IS</given-names></name>
<name><surname>Hopp</surname><given-names>E</given-names></name>
<etal>et al</etal>
</person-group><article-title>Strain Echocardiography is Related to Fibrosis and Ventricular Arrhythmias in Hypertrophic Cardiomyopathy</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2016</year><volume>17</volume><issue>6</issue><fpage>613</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jew005</pub-id><pub-id pub-id-type="pmid">26873460</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huntjens</surname><given-names>PR</given-names></name>
<name><surname>Zhang</surname><given-names>KW</given-names></name>
<name><surname>Soyama</surname><given-names>Y</given-names></name>
<name><surname>Karmpalioti</surname><given-names>M</given-names></name>
<name><surname>Lenihan</surname><given-names>DJ</given-names></name>
<name><surname>Gorcsan</surname><given-names>J</given-names><suffix>3rd</suffix></name>
</person-group><article-title>Prognostic Utility of Echocardiographic Atrial and Ventricular Strain Imaging in Patients with Cardiac Amyloidosis</article-title><source>JACC Cardiovasc Imaging</source><year>2021</year><volume>14</volume><issue>8</issue><fpage>1508</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2021.01.016</pub-id><pub-id pub-id-type="pmid">33744146</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russell</surname><given-names>K</given-names></name>
<name><surname>Eriksen</surname><given-names>M</given-names></name>
<name><surname>Aaberge</surname><given-names>L</given-names></name>
<name><surname>Wilhelmsen</surname><given-names>N</given-names></name>
<name><surname>Skulstad</surname><given-names>H</given-names></name>
<name><surname>Remme</surname><given-names>EW</given-names></name>
<etal>et al</etal>
</person-group><article-title>A Novel Clinical Method for Quantification of Regional Left Ventricular Pressure-Strain Loop Area: A Non-Invasive Index of Myocardial Work</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>6</issue><fpage>724</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs016</pub-id><pub-id pub-id-type="pmid">22315346</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hiemstra</surname><given-names>YL</given-names></name>
<name><surname>van der Bijl</surname><given-names>P</given-names></name>
<name><surname>El Mahdiui</surname><given-names>M</given-names></name>
<name><surname>Bax</surname><given-names>JJ</given-names></name>
<name><surname>Delgado</surname><given-names>V</given-names></name>
<name><surname>Marsan</surname><given-names>NA</given-names></name>
</person-group><article-title>Myocardial Work in Nonobstructive Hypertrophic Cardiomyopathy: Implications for Outcome</article-title><source>J Am Soc Echocardiogr</source><year>2020</year><volume>33</volume><issue>10</issue><fpage>1201</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1016/j.echo.2020.05.010</pub-id><pub-id pub-id-type="pmid">32680744</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clemmensen</surname><given-names>TS</given-names></name>
<name><surname>Eiskj&#x000e6;r</surname><given-names>H</given-names></name>
<name><surname>Ladefoged</surname><given-names>B</given-names></name>
<name><surname>Mikkelsen</surname><given-names>F</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>J</given-names></name>
<name><surname>Granstam</surname><given-names>SO</given-names></name>
<etal>et al</etal>
</person-group><article-title>Prognostic Implications of Left Ventricular Myocardial Work Indices in Cardiac Amyloidosis</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2021</year><volume>22</volume><issue>6</issue><fpage>695</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeaa097</pub-id><pub-id pub-id-type="pmid">32529207</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dorosz</surname><given-names>JL</given-names></name>
<name><surname>Lezotte</surname><given-names>DC</given-names></name>
<name><surname>Weitzenkamp</surname><given-names>DA</given-names></name>
<name><surname>Allen</surname><given-names>LA</given-names></name>
<name><surname>Salcedo</surname><given-names>EE</given-names></name>
</person-group><article-title>Performance of 3-Dimensional Echocardiography in Measuring Left Ventricular Volumes and Ejection Fraction: A Systematic Review and Meta-Analysis</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><issue>20</issue><fpage>1799</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.01.037</pub-id><pub-id pub-id-type="pmid">22575319</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hampson</surname><given-names>R</given-names></name>
<name><surname>Senior</surname><given-names>R</given-names></name>
<name><surname>Ring</surname><given-names>L</given-names></name>
<name><surname>Robinson</surname><given-names>S</given-names></name>
<name><surname>Augustine</surname><given-names>DX</given-names></name>
<name><surname>Becher</surname><given-names>H</given-names></name>
<etal>et al</etal>
</person-group><article-title>Contrast Echocardiography: A Practical Guideline from the British Society of Echocardiography</article-title><source>Echo Res Pract</source><year>2023</year><volume>10</volume><issue>1</issue><size units="pages">23</size><pub-id pub-id-type="doi">10.1186/s44156-023-00034-9</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosa</surname><given-names>SA</given-names></name>
<name><surname>Thomas</surname><given-names>B</given-names></name>
<name><surname>Pieroni</surname><given-names>M</given-names></name>
<name><surname>Maurizi</surname><given-names>N</given-names></name>
<name><surname>Zampieri</surname><given-names>M</given-names></name>
<name><surname>Cappelli</surname><given-names>F</given-names></name>
<etal>et al</etal>
</person-group><article-title>Role of Cardiovascular Magnetic Resonance in the Clinical Evaluation of Left Ventricular Hypertrophy: A 360&#x000b0; Panorama</article-title><source>Int J Cardiovasc Imaging</source><year>2023</year><volume>39</volume><issue>4</issue><fpage>793</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1007/s10554-022-02774-x</pub-id><pub-id pub-id-type="pmid">36543912</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Messroghli</surname><given-names>DR</given-names></name>
<name><surname>Moon</surname><given-names>JC</given-names></name>
<name><surname>Ferreira</surname><given-names>VM</given-names></name>
<name><surname>Grosse-Wortmann</surname><given-names>L</given-names></name>
<name><surname>He</surname><given-names>T</given-names></name>
<name><surname>Kellman</surname><given-names>P</given-names></name>
<etal>et al</etal>
</person-group><article-title>Clinical Recommendations for Cardiovascular Magnetic Resonance Mapping of T1, T2, T2* and Extracellular Volume: A Consensus Statement by the Society for Cardiovascular Magnetic Resonance (SCMR) Endorsed by the European Association for Cardiovascular Imaging (EACVI)</article-title><source>J Cardiovasc Magn Reson</source><year>2017</year><volume>19</volume><issue>1</issue><size units="pages">75</size><pub-id pub-id-type="doi">10.1186/s12968-017-0389-8</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iles</surname><given-names>LM</given-names></name>
<name><surname>Ellims</surname><given-names>AH</given-names></name>
<name><surname>Llewellyn</surname><given-names>H</given-names></name>
<name><surname>Hare</surname><given-names>JL</given-names></name>
<name><surname>Kaye</surname><given-names>DM</given-names></name>
<name><surname>McLean</surname><given-names>CA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Histological Validation of Cardiac Magnetic Resonance Analysis of Regional and Diffuse Interstitial Myocardial Fibrosis</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeu182</pub-id><pub-id pub-id-type="pmid">25354866</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lang</surname><given-names>RM</given-names></name>
<name><surname>Badano</surname><given-names>LP</given-names></name>
<name><surname>Mor-Avi</surname><given-names>V</given-names></name>
<name><surname>Afilalo</surname><given-names>J</given-names></name>
<name><surname>Armstrong</surname><given-names>A</given-names></name>
<name><surname>Ernande</surname><given-names>L</given-names></name>
<etal>et al</etal>
</person-group><article-title>Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title><source>J Am Soc Echocardiogr</source><year>2015</year><volume>28</volume><issue>1</issue><fpage>1</fpage><lpage>39</lpage><comment>e14</comment><pub-id pub-id-type="doi">10.1016/j.echo.2014.10.003</pub-id><pub-id pub-id-type="pmid">25559473</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marian</surname><given-names>AJ</given-names></name>
<name><surname>Braunwald</surname><given-names>E</given-names></name>
</person-group><article-title>Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><issue>7</issue><fpage>749</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311059</pub-id><pub-id pub-id-type="pmid">28912181</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>F</given-names></name>
<name><surname>Sim&#x000f5;es</surname><given-names>MV</given-names></name>
<name><surname>Correia</surname><given-names>EB</given-names></name>
<name><surname>Marcondes-Braga</surname><given-names>FG</given-names></name>
<name><surname>Coelho-Filho</surname><given-names>OR</given-names></name>
<name><surname>Mesquita</surname><given-names>CT</given-names></name>
<etal>et al</etal>
</person-group><article-title>Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024</article-title><source>Arq Bras Cardiol</source><year>2024</year><volume>121</volume><issue>7</issue><elocation-id>e202400415</elocation-id><pub-id pub-id-type="doi">10.36660/abc.20240415</pub-id><pub-id pub-id-type="pmid">39082572</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sherrid</surname><given-names>MV</given-names></name>
<name><surname>Balaram</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>B</given-names></name>
<name><surname>Axel</surname><given-names>L</given-names></name>
<name><surname>Swistel</surname><given-names>DG</given-names></name>
</person-group><article-title>The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>67</volume><issue>15</issue><fpage>1846</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.01.071</pub-id><pub-id pub-id-type="pmid">27081025</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barberato</surname><given-names>SH</given-names></name>
<name><surname>Romano</surname><given-names>MMD</given-names></name>
<name><surname>Beck</surname><given-names>ALS</given-names></name>
<name><surname>Rodrigues</surname><given-names>ACT</given-names></name>
<name><surname>Almeida</surname><given-names>ALC</given-names></name>
<name><surname>Assun&#x000e7;&#x000e3;o</surname><given-names>BMBL</given-names></name>
<etal>et al</etal>
</person-group><article-title>Position Statement on Indications of Echocardiography in Adults - 2019</article-title><source>Arq Bras Cardiol</source><year>2019</year><volume>113</volume><issue>1</issue><fpage>135</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.5935/abc.20190129</pub-id><pub-id pub-id-type="pmid">31411301</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>RK</given-names></name>
<name><surname>Shiwani</surname><given-names>H</given-names></name>
<name><surname>Rosmini</surname><given-names>S</given-names></name>
<name><surname>Augusto</surname><given-names>JB</given-names></name>
<name><surname>Burke</surname><given-names>L</given-names></name>
<name><surname>Jiang</surname><given-names>Y</given-names></name>
<etal>et al</etal>
</person-group><article-title>Improved Diagnostic Criteria for Apical Hypertrophic Cardiomyopathy</article-title><source>JACC Cardiovasc Imaging</source><year>2024</year><volume>17</volume><issue>5</issue><fpage>501</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2023.07.012</pub-id><pub-id pub-id-type="pmid">37831014</pub-id>
</element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McKenna</surname><given-names>WJ</given-names></name>
<name><surname>Kleinebenne</surname><given-names>A</given-names></name>
<name><surname>Nihoyannopoulos</surname><given-names>P</given-names></name>
<name><surname>Foale</surname><given-names>R</given-names></name>
</person-group><article-title>Echocardiographic Measurement of Right Ventricular Wall Thickness in Hypertrophic Cardiomyopathy: Relation to Clinical and Prognostic Features</article-title><source>J Am Coll Cardiol</source><year>1988</year><volume>11</volume><issue>2</issue><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(88)90101-5</pub-id><pub-id pub-id-type="pmid">2963057</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maron</surname><given-names>MS</given-names></name>
<name><surname>Hauser</surname><given-names>TH</given-names></name>
<name><surname>Dubrow</surname><given-names>E</given-names></name>
<name><surname>Horst</surname><given-names>TA</given-names></name>
<name><surname>Kissinger</surname><given-names>KV</given-names></name>
<name><surname>Udelson</surname><given-names>JE</given-names></name>
<etal>et al</etal>
</person-group><article-title>Right Ventricular Involvement in Hypertrophic Cardiomyopathy</article-title><source>Am J Cardiol</source><year>2007</year><volume>100</volume><issue>8</issue><fpage>1293</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2007.05.061</pub-id><pub-id pub-id-type="pmid">17920373</pub-id>
</element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimizu</surname><given-names>M</given-names></name>
<name><surname>Kawai</surname><given-names>H</given-names></name>
<name><surname>Yokota</surname><given-names>Y</given-names></name>
<name><surname>Yokoyama</surname><given-names>M</given-names></name>
</person-group><article-title>Echocardiographic Assessment of Right Ventricular Obstruction in Hypertrophic Cardiomyopathy</article-title><source>Circ J</source><year>2003</year><volume>67</volume><issue>10</issue><fpage>855</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1253/circj.67.855</pub-id><pub-id pub-id-type="pmid">14578619</pub-id>
</element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosca</surname><given-names>M</given-names></name>
<name><surname>Calin</surname><given-names>A</given-names></name>
<name><surname>Beladan</surname><given-names>CC</given-names></name>
<name><surname>Enache</surname><given-names>R</given-names></name>
<name><surname>Mateescu</surname><given-names>AD</given-names></name>
<name><surname>Gurzun</surname><given-names>MM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Right Ventricular Remodeling, Its Correlates, and Its Clinical Impact in Hypertrophic Cardiomyopathy</article-title><source>J Am Soc Echocardiogr</source><year>2015</year><volume>28</volume><issue>11</issue><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/j.echo.2015.07.015</pub-id><pub-id pub-id-type="pmid">26296986</pub-id>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JH</given-names></name>
<name><surname>Park</surname><given-names>JH</given-names></name>
</person-group><article-title>Strain Analysis of the Right Ventricle Using Two-Dimensional Echocardiography</article-title><source>J Cardiovasc Imaging</source><year>2018</year><volume>26</volume><issue>3</issue><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.4250/jcvi.2018.26.e11</pub-id><pub-id pub-id-type="pmid">30310878</pub-id>
</element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spirito</surname><given-names>P</given-names></name>
<name><surname>Maron</surname><given-names>BJ</given-names></name>
</person-group><article-title>Relation between Extent of Left Ventricular Hypertrophy and Occurrence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>1990</year><volume>15</volume><issue>7</issue><fpage>1521</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(90)92820-r</pub-id><pub-id pub-id-type="pmid">2140576</pub-id>
</element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maron</surname><given-names>BJ</given-names></name>
<name><surname>Rowin</surname><given-names>EJ</given-names></name>
<name><surname>Maron</surname><given-names>MS</given-names></name>
</person-group><article-title>Evolution of Risk Stratification And Sudden Death Prevention in Hypertrophic Cardiomyopathy: Twenty Years with the Implantable Cardioverter-Defibrillator</article-title><source>Heart Rhythm</source><year>2021</year><volume>18</volume><issue>6</issue><fpage>1012</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2021.01.019</pub-id><pub-id pub-id-type="pmid">33508516</pub-id>
</element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>D</given-names></name>
<name><surname>Hu</surname><given-names>K</given-names></name>
<name><surname>Nordbeck</surname><given-names>P</given-names></name>
<name><surname>Ertl</surname><given-names>G</given-names></name>
<name><surname>St&#x000f6;rk</surname><given-names>S</given-names></name>
<name><surname>Weidemann</surname><given-names>F</given-names></name>
</person-group><article-title>Longitudinal Strain Bull's Eye Plot Patterns in Patients with Cardiomyopathy and Concentric Left Ventricular Hypertrophy</article-title><source>Eur J Med Res</source><year>2016</year><volume>21</volume><issue>1</issue><size units="pages">21</size><pub-id pub-id-type="doi">10.1186/s40001-016-0216-y</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maron</surname><given-names>MS</given-names></name>
<name><surname>Olivotto</surname><given-names>I</given-names></name>
<name><surname>Zenovich</surname><given-names>AG</given-names></name>
<name><surname>Link</surname><given-names>MS</given-names></name>
<name><surname>Pandian</surname><given-names>NG</given-names></name>
<name><surname>Kuvin</surname><given-names>JT</given-names></name>
<etal>et al</etal>
</person-group><article-title>Hypertrophic Cardiomyopathy is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>21</issue><fpage>2232</fpage><lpage>2239</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.644682</pub-id><pub-id pub-id-type="pmid">17088454</pub-id>
</element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ommen</surname><given-names>SR</given-names></name>
</person-group><article-title>Hypertrophic Cardiomyopathy</article-title><source>Curr Probl Cardiol</source><year>2011</year><volume>36</volume><issue>11</issue><fpage>409</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.cpcardiol.2011.06.001</pub-id><pub-id pub-id-type="pmid">21962729</pub-id>
</element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hebl</surname><given-names>VB</given-names></name>
<name><surname>Miranda</surname><given-names>WR</given-names></name>
<name><surname>Ong</surname><given-names>KC</given-names></name>
<name><surname>Hodge</surname><given-names>DO</given-names></name>
<name><surname>Bos</surname><given-names>JM</given-names></name>
<name><surname>Gentile</surname><given-names>F</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Natural History of Nonobstructive Hypertrophic Cardiomyopathy</article-title><source>Mayo Clin Proc</source><year>2016</year><volume>91</volume><issue>3</issue><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2016.01.002</pub-id><pub-id pub-id-type="pmid">26944240</pub-id>
</element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Berger</surname><given-names>AE</given-names></name>
<name><surname>Johns</surname><given-names>RA</given-names></name>
<name><surname>Gao</surname><given-names>L</given-names></name>
</person-group><article-title>Survival and Prognostic Factors in Hypertrophic Cardiomyopathy: A Meta-Analysis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><size units="pages">11957</size><pub-id pub-id-type="doi">10.1038/s41598-017-12289-4</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quarta</surname><given-names>G</given-names></name>
<name><surname>Aquaro</surname><given-names>GD</given-names></name>
<name><surname>Pedrotti</surname><given-names>P</given-names></name>
<name><surname>Pontone</surname><given-names>G</given-names></name>
<name><surname>Dellegrottaglie</surname><given-names>S</given-names></name>
<name><surname>Iacovoni</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy: the Importance of Clinical Context</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2018</year><volume>19</volume><issue>6</issue><fpage>601</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jex323</pub-id><pub-id pub-id-type="pmid">29309572</pub-id>
</element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alenezi</surname><given-names>F</given-names></name>
<name><surname>Alajmi</surname><given-names>H</given-names></name>
<name><surname>Agarwal</surname><given-names>R</given-names></name>
<name><surname>Zwischenberger</surname><given-names>BA</given-names></name>
</person-group><article-title>Role of Cardiac Magnetic Resonance (CMR) in Planning Ventricular Septal Myomectomy in Patients with Hypertrophic Obstructive Cardiomyopathy (HOCM)</article-title><source>J Card Surg</source><year>2022</year><volume>37</volume><issue>12</issue><fpage>4186</fpage><lpage>4189</lpage><pub-id pub-id-type="doi">10.1111/jocs.17090</pub-id><pub-id pub-id-type="pmid">36434805</pub-id>
</element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellims</surname><given-names>AH</given-names></name>
<name><surname>Iles</surname><given-names>LM</given-names></name>
<name><surname>Ling</surname><given-names>LH</given-names></name>
<name><surname>Chong</surname><given-names>B</given-names></name>
<name><surname>Macciocca</surname><given-names>I</given-names></name>
<name><surname>Slavin</surname><given-names>GS</given-names></name>
<etal>et al</etal>
</person-group><article-title>A Comprehensive Evaluation of Myocardial Fibrosis in Hypertrophic Cardiomyopathy with Cardiac Magnetic Resonance Imaging: Linking Genotype with Fibrotic Phenotype</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2014</year><volume>15</volume><issue>10</issue><fpage>1108</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeu077</pub-id><pub-id pub-id-type="pmid">24819852</pub-id>
</element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>CY</given-names></name>
<name><surname>Abbasi</surname><given-names>SA</given-names></name>
<name><surname>Neilan</surname><given-names>TG</given-names></name>
<name><surname>Shah</surname><given-names>RV</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Heydari</surname><given-names>B</given-names></name>
<etal>et al</etal>
</person-group><article-title>T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers with and without Left Ventricular Hypertrophy</article-title><source>Circ Cardiovasc Imaging</source><year>2013</year><volume>6</volume><issue>3</issue><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.112.000333</pub-id><pub-id pub-id-type="pmid">23549607</pub-id>
</element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>RH</given-names></name>
<name><surname>Maron</surname><given-names>BJ</given-names></name>
<name><surname>Olivotto</surname><given-names>I</given-names></name>
<name><surname>Pencina</surname><given-names>MJ</given-names></name>
<name><surname>Assenza</surname><given-names>GE</given-names></name>
<name><surname>Haas</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Prognostic Value of quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients with Hypertrophic Cardiomyopathy</article-title><source>Circulation</source><year>2014</year><volume>130</volume><issue>6</issue><fpage>484</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.007094</pub-id><pub-id pub-id-type="pmid">25092278</pub-id>
</element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>PF</given-names></name>
<name><surname>Kilner</surname><given-names>PJ</given-names></name>
<name><surname>McGill</surname><given-names>LA</given-names></name>
<name><surname>Nielles-Vallespin</surname><given-names>S</given-names></name>
<name><surname>Scott</surname><given-names>AD</given-names></name>
<name><surname>Ho</surname><given-names>SY</given-names></name>
<etal>et al</etal>
</person-group><article-title>In Vivo Cardiovascular Magnetic Resonance Diffusion Tensor Imaging Shows Evidence of Abnormal Myocardial Laminar Orientations and Mobility in Hypertrophic Cardiomyopathy</article-title><source>J Cardiovasc Magn Reson</source><year>2014</year><volume>16</volume><issue>1</issue><size units="pages">87</size><pub-id pub-id-type="doi">10.1186/s12968-014-0087-8</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguiar Rosa</surname><given-names>S</given-names></name>
<name><surname>Thomas</surname><given-names>B</given-names></name>
<name><surname>Fiarresga</surname><given-names>A</given-names></name>
<name><surname>Papoila</surname><given-names>AL</given-names></name>
<name><surname>Alves</surname><given-names>M</given-names></name>
<name><surname>Pereira</surname><given-names>R</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Impact of Ischemia Assessed by Magnetic Resonance on Functional, Arrhythmic, and Imaging Features of Hypertrophic Cardiomyopathy</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><size units="pages">761860</size><pub-id pub-id-type="doi">10.3389/fcvm.2021.761860</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Camaioni</surname><given-names>C</given-names></name>
<name><surname>Knott</surname><given-names>KD</given-names></name>
<name><surname>Augusto</surname><given-names>JB</given-names></name>
<name><surname>Seraphim</surname><given-names>A</given-names></name>
<name><surname>Rosmini</surname><given-names>S</given-names></name>
<name><surname>Ricci</surname><given-names>F</given-names></name>
<etal>et al</etal>
</person-group><article-title>Inline Perfusion Mapping Provides Insights into the Disease Mechanism in Hypertrophic Cardiomyopathy</article-title><source>Heart</source><year>2020</year><volume>106</volume><issue>11</issue><fpage>824</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2019-315848</pub-id><pub-id pub-id-type="pmid">31822572</pub-id>
</element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SP</given-names></name>
<name><surname>Park</surname><given-names>JB</given-names></name>
<name><surname>Kim</surname><given-names>HK</given-names></name>
<name><surname>Kim</surname><given-names>YJ</given-names></name>
<name><surname>Grogan</surname><given-names>M</given-names></name>
<name><surname>Sohn</surname><given-names>DW</given-names></name>
</person-group><article-title>Contemporary Imaging Diagnosis of Cardiac Amyloidosis</article-title><source>J Cardiovasc Imaging</source><year>2019</year><volume>27</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.4250/jcvi.2019.27.e9</pub-id><pub-id pub-id-type="pmid">30701710</pub-id>
</element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dorbala</surname><given-names>S</given-names></name>
<name><surname>Cuddy</surname><given-names>S</given-names></name>
<name><surname>Falk</surname><given-names>RH</given-names></name>
</person-group><article-title>How to Image Cardiac Amyloidosis: A Practical Approach</article-title><source>JACC Cardiovasc Imaging</source><year>2020</year><volume>13</volume><issue>6</issue><fpage>1368</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2019.07.015</pub-id><pub-id pub-id-type="pmid">31607664</pub-id>
</element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sim&#x000f5;es</surname><given-names>MV</given-names></name>
<name><surname>Fernandes</surname><given-names>F</given-names></name>
<name><surname>Marcondes-Braga</surname><given-names>FG</given-names></name>
<name><surname>Scheinberg</surname><given-names>P</given-names></name>
<name><surname>Correia</surname><given-names>EB</given-names></name>
<name><surname>Rohde</surname><given-names>LEP</given-names></name>
<etal>et al</etal>
</person-group><article-title>Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021</article-title><source>Arq Bras Cardiol</source><year>2021</year><volume>117</volume><issue>3</issue><fpage>561</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.36660/abc.20210718</pub-id><pub-id pub-id-type="pmid">34550244</pub-id>
</element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knight</surname><given-names>DS</given-names></name>
<name><surname>Zumbo</surname><given-names>G</given-names></name>
<name><surname>Barcella</surname><given-names>W</given-names></name>
<name><surname>Steeden</surname><given-names>JA</given-names></name>
<name><surname>Muthurangu</surname><given-names>V</given-names></name>
<name><surname>Martinez-Naharro</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles</article-title><source>JACC Cardiovasc Imaging</source><year>2019</year><volume>12</volume><issue>5</issue><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2018.02.016</pub-id><pub-id pub-id-type="pmid">29680336</pub-id>
</element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matteo</surname><given-names>S</given-names></name>
<name><surname>Anna</surname><given-names>C</given-names></name>
<name><surname>Federico</surname><given-names>S</given-names></name>
<name><surname>Daniele</surname><given-names>M</given-names></name>
<name><surname>Gioele</surname><given-names>F</given-names></name>
<name><surname>Beatrice</surname><given-names>DP</given-names></name>
<etal>et al</etal>
</person-group><article-title>Stroke Volume and Myocardial Contraction Fraction in Transthyretin Amyloidosis Cardiomyopathy: A Systematic Review</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><size units="pages">1085824</size><pub-id pub-id-type="doi">10.3389/fcvm.2023.1085824</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merlo</surname><given-names>M</given-names></name>
<name><surname>Pagura</surname><given-names>L</given-names></name>
<name><surname>Porcari</surname><given-names>A</given-names></name>
<name><surname>Cameli</surname><given-names>M</given-names></name>
<name><surname>Vergaro</surname><given-names>G</given-names></name>
<name><surname>Musumeci</surname><given-names>B</given-names></name>
<etal>et al</etal>
</person-group><article-title>Unmasking the Prevalence of Amyloid Cardiomyopathy in the Real World: Results from Phase 2 of the AC-TIVE Study, an Italian Nationwide Survey</article-title><source>Eur J Heart Fail</source><year>2022</year><volume>24</volume><issue>8</issue><fpage>1377</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2504</pub-id><pub-id pub-id-type="pmid">35417089</pub-id>
</element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>D</given-names></name>
<name><surname>Hu</surname><given-names>K</given-names></name>
<name><surname>Niemann</surname><given-names>M</given-names></name>
<name><surname>Herrmann</surname><given-names>S</given-names></name>
<name><surname>Cikes</surname><given-names>M</given-names></name>
<name><surname>St&#x000f6;rk</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis from other Causes of Concentric Left Ventricular Hypertrophy</article-title><source>Circ Cardiovasc Imaging</source><year>2013</year><volume>6</volume><issue>6</issue><fpage>1066</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.113.000683</pub-id><pub-id pub-id-type="pmid">24100046</pub-id>
</element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almeida</surname><given-names>ALC</given-names></name>
<name><surname>Melo</surname><given-names>MDT</given-names></name>
<name><surname>Bihan</surname><given-names>DCSL</given-names></name>
<name><surname>Vieira</surname><given-names>MLC</given-names></name>
<name><surname>Pena</surname><given-names>JLB</given-names></name>
<name><surname>Del Castillo</surname><given-names>JM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Position Statement on the Use of Myocardial Strain in Cardiology Routines by the Brazilian Society of Cardiology's Department Of Cardiovascular Imaging - 2023</article-title><source>Arq Bras Cardiol</source><year>2023</year><volume>120</volume><issue>12</issue><elocation-id>e20230646</elocation-id><pub-id pub-id-type="doi">10.36660/abc.20230646</pub-id><pub-id pub-id-type="pmid">38232246</pub-id>
</element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barberato</surname><given-names>SH</given-names></name>
<name><surname>Beck</surname><given-names>ALS</given-names></name>
<name><surname>Hotta</surname><given-names>VT</given-names></name>
<name><surname>Rassi</surname><given-names>DC</given-names></name>
</person-group><article-title>A Critical Review of Echocardiographic Findings for Diagnosing Cardiac Amyloidosis</article-title><source>Int J Cardiovasc Sci</source><year>2024</year><volume>37</volume><elocation-id>e20240047</elocation-id><pub-id pub-id-type="doi">10.36660/ijcs.20240047</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cotella</surname><given-names>J</given-names></name>
<name><surname>Randazzo</surname><given-names>M</given-names></name>
<name><surname>Maurer</surname><given-names>MS</given-names></name>
<name><surname>Helmke</surname><given-names>S</given-names></name>
<name><surname>Scherrer-Crosbie</surname><given-names>M</given-names></name>
<name><surname>Soltani</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Limitations of Apical Sparing Pattern in Cardiac Amyloidosis: A Multicentre Echocardiographic Study</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2024</year><volume>25</volume><issue>6</issue><fpage>754</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeae021</pub-id><pub-id pub-id-type="pmid">38243591</pub-id>
</element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>AKBB</given-names></name>
<name><surname>Cavalcanti</surname><given-names>LTB</given-names></name>
<name><surname>Barberato</surname><given-names>SH</given-names></name>
<name><surname>Felix</surname><given-names>AS</given-names></name>
<name><surname>Melo</surname><given-names>MDT</given-names></name>
</person-group><article-title>The Role of Strain in the Prognosis of Transthyretin Amyloidosis</article-title><source>Int J Cardiovasc Sci</source><year>2024</year><volume>37</volume><elocation-id>e20240082</elocation-id><pub-id pub-id-type="doi">10.36660/ijcs.20240082</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ternacle</surname><given-names>J</given-names></name>
<name><surname>Bodez</surname><given-names>D</given-names></name>
<name><surname>Guellich</surname><given-names>A</given-names></name>
<name><surname>Audureau</surname><given-names>E</given-names></name>
<name><surname>Rappeneau</surname><given-names>S</given-names></name>
<name><surname>Lim</surname><given-names>P</given-names></name>
<etal>et al</etal>
</person-group><article-title>Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis</article-title><source>JACC Cardiovasc Imaging</source><year>2016</year><volume>9</volume><issue>2</issue><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2015.05.014</pub-id><pub-id pub-id-type="pmid">26777222</pub-id>
</element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pagourelias</surname><given-names>ED</given-names></name>
<name><surname>Mirea</surname><given-names>O</given-names></name>
<name><surname>Duchenne</surname><given-names>J</given-names></name>
<name><surname>Van Cleemput</surname><given-names>J</given-names></name>
<name><surname>Delforge</surname><given-names>M</given-names></name>
<name><surname>Bogaert</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters</article-title><source>Circ Cardiovasc Imaging</source><year>2017</year><volume>10</volume><issue>3</issue><elocation-id>e005588</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.116.005588</pub-id><pub-id pub-id-type="pmid">28298286</pub-id>
</element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urbano-Moral</surname><given-names>JA</given-names></name>
<name><surname>Gangadharamurthy</surname><given-names>D</given-names></name>
<name><surname>Comenzo</surname><given-names>RL</given-names></name>
<name><surname>Pandian</surname><given-names>NG</given-names></name>
<name><surname>Patel</surname><given-names>AR</given-names></name>
</person-group><article-title>Three-Dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters</article-title><source>Rev Esp Cardiol</source><year>2015</year><volume>68</volume><issue>8</issue><fpage>657</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.rec.2015.01.009</pub-id><pub-id pub-id-type="pmid">26092748</pub-id>
</element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arvidsson</surname><given-names>S</given-names></name>
<name><surname>Henein</surname><given-names>MY</given-names></name>
<name><surname>Wikstr&#x000f6;m</surname><given-names>G</given-names></name>
<name><surname>Suhr</surname><given-names>OB</given-names></name>
<name><surname>Lindqvist</surname><given-names>P</given-names></name>
</person-group><article-title>Right Ventricular Involvement In Transthyretin Amyloidosis</article-title><source>Amyloid</source><year>2018</year><volume>25</volume><issue>3</issue><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1080/13506129.2018.1493989</pub-id><pub-id pub-id-type="pmid">30193533</pub-id>
</element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>JA</given-names></name>
<name><surname>Kim</surname><given-names>HW</given-names></name>
<name><surname>Shah</surname><given-names>D</given-names></name>
<name><surname>Fine</surname><given-names>N</given-names></name>
<name><surname>Kim</surname><given-names>KY</given-names></name>
<name><surname>Wendell</surname><given-names>DC</given-names></name>
<etal>et al</etal>
</person-group><article-title>CMR Imaging with Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis</article-title><source>JACC Cardiovasc Imaging</source><year>2014</year><volume>7</volume><issue>2</issue><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2013.09.019</pub-id><pub-id pub-id-type="pmid">24412191</pub-id>
</element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fontana</surname><given-names>M</given-names></name>
<name><surname>Pica</surname><given-names>S</given-names></name>
<name><surname>Reant</surname><given-names>P</given-names></name>
<name><surname>Abdel-Gadir</surname><given-names>A</given-names></name>
<name><surname>Treibel</surname><given-names>TA</given-names></name>
<name><surname>Banypersad</surname><given-names>SM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis</article-title><source>Circulation</source><year>2015</year><volume>132</volume><issue>16</issue><fpage>1570</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.016567</pub-id><pub-id pub-id-type="pmid">26362631</pub-id>
</element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>JA</given-names></name>
<name><surname>Kerwin</surname><given-names>MJ</given-names></name>
<name><surname>Salerno</surname><given-names>M</given-names></name>
</person-group><article-title>Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis</article-title><source>JACC Cardiovasc Imaging</source><year>2020</year><volume>13</volume><issue>6</issue><fpage>1299</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2020.03.010</pub-id><pub-id pub-id-type="pmid">32498919</pub-id>
</element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chacko</surname><given-names>L</given-names></name>
<name><surname>Boldrini</surname><given-names>M</given-names></name>
<name><surname>Martone</surname><given-names>R</given-names></name>
<name><surname>Law</surname><given-names>S</given-names></name>
<name><surname>Martinez-Naharrro</surname><given-names>A</given-names></name>
<name><surname>Hutt</surname><given-names>DF</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid</article-title><source>Circ Cardiovasc Imaging</source><year>2021</year><elocation-id>CIRCIMAGING121012506</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.121.012506</pub-id><pub-id pub-id-type="pmid">33876651</pub-id>
</element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ioannou</surname><given-names>A</given-names></name>
<name><surname>Patel</surname><given-names>RK</given-names></name>
<name><surname>Razvi</surname><given-names>Y</given-names></name>
<name><surname>Porcari</surname><given-names>A</given-names></name>
<name><surname>Knight</surname><given-names>D</given-names></name>
<name><surname>Martinez-Naharro</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis</article-title><source>JACC Cardiovasc Imaging</source><year>2023</year><volume>16</volume><issue>4</issue><fpage>464</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2022.07.008</pub-id><pub-id pub-id-type="pmid">36648052</pub-id>
</element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chatzantonis</surname><given-names>G</given-names></name>
<name><surname>Bietenbeck</surname><given-names>M</given-names></name>
<name><surname>Elsanhoury</surname><given-names>A</given-names></name>
<name><surname>Tsch&#x000f6;pe</surname><given-names>C</given-names></name>
<name><surname>Pieske</surname><given-names>B</given-names></name>
<name><surname>Tauscher</surname><given-names>G</given-names></name>
<etal>et al</etal>
</person-group><article-title>Diagnostic Value of Cardiovascular Magnetic Resonance in Comparison to Endomyocardial Biopsy In Cardiac Amyloidosis: A Multi-Centre Study</article-title><source>Clin Res Cardiol</source><year>2021</year><volume>110</volume><issue>4</issue><fpage>555</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1007/s00392-020-01771-1</pub-id><pub-id pub-id-type="pmid">33170349</pub-id>
</element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azevedo</surname><given-names>O</given-names></name>
<name><surname>Cordeiro</surname><given-names>F</given-names></name>
<name><surname>Gago</surname><given-names>MF</given-names></name>
<name><surname>Miltenberger-Miltenyi</surname><given-names>G</given-names></name>
<name><surname>Ferreira</surname><given-names>C</given-names></name>
<name><surname>Sousa</surname><given-names>N</given-names></name>
<etal>et al</etal>
</person-group><article-title>Fabry Disease and the Heart: A Comprehensive Review</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>9</issue><size units="pages">4434</size><pub-id pub-id-type="doi">10.3390/ijms22094434</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Germain</surname><given-names>DP</given-names></name>
<name><surname>Elliott</surname><given-names>PM</given-names></name>
<name><surname>Falissard</surname><given-names>B</given-names></name>
<name><surname>Fomin</surname><given-names>VV</given-names></name>
<name><surname>Hilz</surname><given-names>MJ</given-names></name>
<name><surname>Jovanovic</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Male Patients with Fabry Disease: A Systematic Literature Review by a European Panel of Experts</article-title><source>Mol Genet Metab Rep</source><year>2019</year><volume>19</volume><size units="pages">100454</size><pub-id pub-id-type="doi">10.1016/j.ymgmr.2019.100454</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graziani</surname><given-names>F</given-names></name>
<name><surname>Laurito</surname><given-names>M</given-names></name>
<name><surname>Pieroni</surname><given-names>M</given-names></name>
<name><surname>Pennestr&#x000ec;</surname><given-names>F</given-names></name>
<name><surname>Lanza</surname><given-names>GA</given-names></name>
<name><surname>Coluccia</surname><given-names>V</given-names></name>
<etal>et al</etal>
</person-group><article-title>Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study</article-title><source>J Am Soc Echocardiogr</source><year>2017</year><volume>30</volume><issue>3</issue><fpage>282</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.echo.2016.11.014</pub-id><pub-id pub-id-type="pmid">28069318</pub-id>
</element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perry</surname><given-names>R</given-names></name>
<name><surname>Shah</surname><given-names>R</given-names></name>
<name><surname>Saiedi</surname><given-names>M</given-names></name>
<name><surname>Patil</surname><given-names>S</given-names></name>
<name><surname>Ganesan</surname><given-names>A</given-names></name>
<name><surname>Linhart</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease</article-title><source>JACC Cardiovasc Imaging</source><year>2019</year><volume>12</volume><issue>7 Pt 1</issue><fpage>1230</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2018.11.039</pub-id><pub-id pub-id-type="pmid">31272606</pub-id>
</element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nordin</surname><given-names>S</given-names></name>
<name><surname>Kozor</surname><given-names>R</given-names></name>
<name><surname>Medina-Menacho</surname><given-names>K</given-names></name>
<name><surname>Abdel-Gadir</surname><given-names>A</given-names></name>
<name><surname>Baig</surname><given-names>S</given-names></name>
<name><surname>Sado</surname><given-names>DM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Proposed Stages of Myocardial Phenotype Development in Fabry Disease</article-title><source>JACC Cardiovasc Imaging</source><year>2019</year><volume>12</volume><issue>8 Pt 2</issue><fpage>1673</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2018.03.020</pub-id><pub-id pub-id-type="pmid">29778854</pub-id>
</element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burch</surname><given-names>M</given-names></name>
<name><surname>Sharland</surname><given-names>M</given-names></name>
<name><surname>Shinebourne</surname><given-names>E</given-names></name>
<name><surname>Smith</surname><given-names>G</given-names></name>
<name><surname>Patton</surname><given-names>M</given-names></name>
<name><surname>McKenna</surname><given-names>W</given-names></name>
</person-group><article-title>Cardiologic Abnormalities in Noonan Syndrome: Phenotypic Diagnosis and Echocardiographic Assessment of 118 Patients</article-title><source>J Am Coll Cardiol</source><year>1993</year><volume>22</volume><issue>4</issue><fpage>1189</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(93)90436-5</pub-id><pub-id pub-id-type="pmid">8409059</pub-id>
</element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>AE</given-names></name>
<name><surname>Basson</surname><given-names>CT</given-names></name>
<name><surname>Goldmuntz</surname><given-names>E</given-names></name>
<name><surname>Magoulas</surname><given-names>PL</given-names></name>
<name><surname>McDermott</surname><given-names>DA</given-names></name>
<name><surname>McDonald-McGinn</surname><given-names>DM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Adults with Genetic Syndromes and Cardiovascular Abnormalities: Clinical History and Management</article-title><source>Genet Med</source><year>2008</year><volume>10</volume><issue>7</issue><fpage>469</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1097/gim.0b013e3181772111</pub-id><pub-id pub-id-type="pmid">18580689</pub-id>
</element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gelb</surname><given-names>BD</given-names></name>
<name><surname>Roberts</surname><given-names>AE</given-names></name>
<name><surname>Tartaglia</surname><given-names>M</given-names></name>
</person-group><article-title>Cardiomyopathies in Noonan Syndrome and the other RASopathies</article-title><source>Prog Pediatr Cardiol</source><year>2015</year><volume>39</volume><issue>1</issue><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.ppedcard.2015.01.002</pub-id><pub-id pub-id-type="pmid">26380542</pub-id>
</element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marino</surname><given-names>B</given-names></name>
<name><surname>Gagliardi</surname><given-names>MG</given-names></name>
<name><surname>Digilio</surname><given-names>MC</given-names></name>
<name><surname>Polletta</surname><given-names>B</given-names></name>
<name><surname>Grazioli</surname><given-names>S</given-names></name>
<name><surname>Agostino</surname><given-names>D</given-names></name>
<etal>et al</etal>
</person-group><article-title>Noonan Syndrome: Structural Abnormalities of the Mitral Valve Causing Subaortic Obstruction</article-title><source>Eur J Pediatr</source><year>1995</year><volume>154</volume><issue>12</issue><fpage>949</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1007/BF01958636</pub-id><pub-id pub-id-type="pmid">8801101</pub-id>
</element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilkinson</surname><given-names>JD</given-names></name>
<name><surname>Lowe</surname><given-names>AM</given-names></name>
<name><surname>Salbert</surname><given-names>BA</given-names></name>
<name><surname>Sleeper</surname><given-names>LA</given-names></name>
<name><surname>Colan</surname><given-names>SD</given-names></name>
<name><surname>Cox</surname><given-names>GF</given-names></name>
<etal>et al</etal>
</person-group><article-title>Outcomes in Children with Noonan Syndrome and Hypertrophic Cardiomyopathy: A Study from the Pediatric Cardiomyopathy Registry</article-title><source>Am Heart J</source><year>2012</year><volume>164</volume><issue>3</issue><fpage>442</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2012.04.018</pub-id><pub-id pub-id-type="pmid">22980313</pub-id>
</element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prendiville</surname><given-names>TW</given-names></name>
<name><surname>Gauvreau</surname><given-names>K</given-names></name>
<name><surname>Tworog-Dube</surname><given-names>E</given-names></name>
<name><surname>Patkin</surname><given-names>L</given-names></name>
<name><surname>Kucherlapati</surname><given-names>RS</given-names></name>
<name><surname>Roberts</surname><given-names>AE</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiovascular Disease in Noonan Syndrome</article-title><source>Arch Dis Child</source><year>2014</year><volume>99</volume><issue>7</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2013-305047</pub-id><pub-id pub-id-type="pmid">24534818</pub-id>
</element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scheffers</surname><given-names>LE</given-names></name>
<name><surname>Kok</surname><given-names>R</given-names></name>
<name><surname>van den Berg</surname><given-names>LE</given-names></name>
<name><surname>van den Hout</surname><given-names>JMP</given-names></name>
<name><surname>Boersma</surname><given-names>E</given-names></name>
<name><surname>van Capelle</surname><given-names>CI</given-names></name>
<etal>et al</etal>
</person-group><article-title>Effects of Enzyme Replacement Therapy on Cardiac Function in Classic Infantile Pompe Disease</article-title><source>Int J Cardiol</source><year>2023</year><volume>380</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2023.03.010</pub-id><pub-id pub-id-type="pmid">36893858</pub-id>
</element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pena</surname><given-names>JLB</given-names></name>
<name><surname>Santos</surname><given-names>WC</given-names></name>
<name><surname>Siqueira</surname><given-names>MHA</given-names></name>
<name><surname>Sampaio</surname><given-names>IH</given-names></name>
<name><surname>Moura</surname><given-names>ICG</given-names></name>
<name><surname>Sternick</surname><given-names>EB</given-names></name>
</person-group><article-title>Glycogen Storage Cardiomyopathy (PRKAG2): Diagnostic Findings of Standard and Advanced Echocardiography Techniques</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2021</year><volume>22</volume><issue>7</issue><fpage>800</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeaa176</pub-id><pub-id pub-id-type="pmid">32747946</pub-id>
</element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Bai</surname><given-names>R</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Zhao</surname><given-names>R</given-names></name>
<name><surname>Wan</surname><given-names>D</given-names></name>
<etal>et al</etal>
</person-group><article-title>Identification of a Novel de Novo Mutation Associated with PRKAG2 Cardiac Syndrome and Early Onset of Heart Failure</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>5</issue><elocation-id>e64603</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0064603</pub-id><pub-id pub-id-type="pmid">23741347</pub-id>
</element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yogasundaram</surname><given-names>H</given-names></name>
<name><surname>Paterson</surname><given-names>ID</given-names></name>
<name><surname>Graham</surname><given-names>M</given-names></name>
<name><surname>Sergi</surname><given-names>C</given-names></name>
<name><surname>Oudit</surname><given-names>GY</given-names></name>
</person-group><article-title>Glycogen Storage Disease Because of a PRKAG2 Mutation Causing Severe Biventricular Hypertrophy and High-Grade Atrio-Ventricular Block</article-title><source>Circ Heart Fail</source><year>2016</year><volume>9</volume><issue>8</issue><elocation-id>e003367</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.116.003367</pub-id><pub-id pub-id-type="pmid">27496753</pub-id>
</element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pena</surname><given-names>JLB</given-names></name>
<name><surname>Melo</surname><given-names>FJ</given-names></name>
<name><surname>Santos</surname><given-names>WC</given-names></name>
<name><surname>Moura</surname><given-names>ICG</given-names></name>
<name><surname>Nakashima</surname><given-names>GP</given-names></name>
<name><surname>Freitas</surname><given-names>NC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Right Ventricle Involvement by Glycogen Storage Cardiomyopathy (PRKAG2): Standard and Advanced Echocardiography Analyses</article-title><source>Arq Bras Cardiol</source><year>2022</year><volume>119</volume><issue>6</issue><fpage>902</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.36660/abc.20210801</pub-id><pub-id pub-id-type="pmid">36417616</pub-id>
</element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Zhou</surname><given-names>N</given-names></name>
<name><surname>Jiang</surname><given-names>Y</given-names></name>
<name><surname>Pan</surname><given-names>C</given-names></name>
<name><surname>Shu</surname><given-names>X</given-names></name>
</person-group><article-title>Echocardiographic Characteristics of PRKAG2 Syndrome: A Research using Three-Dimensional Speckle Tracking Echocardiography compared with Sarcomeric Hypertrophic Cardiomyopathy</article-title><source>Cardiovasc Ultrasound</source><year>2022</year><volume>20</volume><issue>1</issue><size units="pages">14</size><pub-id pub-id-type="doi">10.1186/s12947-022-00284-3</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casazza</surname><given-names>F</given-names></name>
<name><surname>Morpurgo</surname><given-names>M</given-names></name>
</person-group><article-title>The Varying Evolution of Friedreich's Ataxia Cardiomyopathy</article-title><source>Am J Cardiol</source><year>1996</year><volume>77</volume><issue>10</issue><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(97)89194-1</pub-id><pub-id pub-id-type="pmid">8623752</pub-id>
</element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riba&#x000ef;</surname><given-names>P</given-names></name>
<name><surname>Pousset</surname><given-names>F</given-names></name>
<name><surname>Tanguy</surname><given-names>ML</given-names></name>
<name><surname>Rivaud-Pechoux</surname><given-names>S</given-names></name>
<name><surname>Le Ber</surname><given-names>I</given-names></name>
<name><surname>Gasparini</surname><given-names>F</given-names></name>
<etal>et al</etal>
</person-group><article-title>Neurological, Cardiological, and Oculomotor Progression in 104 Patients with Friedreich Ataxia during Long-Term Follow-Up</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><issue>4</issue><fpage>558</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.4.558</pub-id><pub-id pub-id-type="pmid">17420319</pub-id>
</element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dedobbeleer</surname><given-names>C</given-names></name>
<name><surname>Rai</surname><given-names>M</given-names></name>
<name><surname>Donal</surname><given-names>E</given-names></name>
<name><surname>Pandolfo</surname><given-names>M</given-names></name>
<name><surname>Unger</surname><given-names>P</given-names></name>
</person-group><article-title>Normal Left Ventricular Ejection Fraction and Mass but Subclinical Myocardial Dysfunction in Patients with Friedreich's Ataxia</article-title><source>Eur Heart J Cardiovasc Imaging</source><year>2012</year><volume>13</volume><issue>4</issue><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1093/ejechocard/jer267</pub-id><pub-id pub-id-type="pmid">22127629</pub-id>
</element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raman</surname><given-names>SV</given-names></name>
<name><surname>Phatak</surname><given-names>K</given-names></name>
<name><surname>Hoyle</surname><given-names>JC</given-names></name>
<name><surname>Pennell</surname><given-names>ML</given-names></name>
<name><surname>McCarthy</surname><given-names>B</given-names></name>
<name><surname>Tran</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Impaired Myocardial Perfusion Reserve and Fibrosis in Friedreich Ataxia: A Mitochondrial Cardiomyopathy with Metabolic Syndrome</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>5</issue><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq443</pub-id><pub-id pub-id-type="pmid">21156720</pub-id>
</element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weidemann</surname><given-names>F</given-names></name>
<name><surname>Rummey</surname><given-names>C</given-names></name>
<name><surname>Bijnens</surname><given-names>B</given-names></name>
<name><surname>St&#x000f6;rk</surname><given-names>S</given-names></name>
<name><surname>Jasaityte</surname><given-names>R</given-names></name>
<name><surname>Dhooge</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Heart in Friedreich Ataxia: Definition of cardiomyopathy, Disease Severity, and Correlation with Neurological Symptoms</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>13</issue><fpage>1626</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.059477</pub-id><pub-id pub-id-type="pmid">22379112</pub-id>
</element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weidemann</surname><given-names>F</given-names></name>
<name><surname>Breunig</surname><given-names>F</given-names></name>
<name><surname>Beer</surname><given-names>M</given-names></name>
<name><surname>Sandstede</surname><given-names>J</given-names></name>
<name><surname>St&#x000f6;rk</surname><given-names>S</given-names></name>
<name><surname>Voelker</surname><given-names>W</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Variation of Morphological and Functional Cardiac Manifestation in Fabry Disease: Potential Implications for the Time Course of the Disease</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><issue>12</issue><fpage>1221</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehi143</pub-id><pub-id pub-id-type="pmid">15728649</pub-id>
</element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Zhai</surname><given-names>N</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Jiang</surname><given-names>M</given-names></name>
<name><surname>Sun</surname><given-names>Z</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiovascular Magnetic Resonance Findings in Danon Disease: A Case Series of a Family</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><size units="pages">1159576</size><pub-id pub-id-type="doi">10.3389/fcvm.2023.1159576</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danon</surname><given-names>MJ</given-names></name>
<name><surname>Oh</surname><given-names>SJ</given-names></name>
<name><surname>DiMauro</surname><given-names>S</given-names></name>
<name><surname>Manaligod</surname><given-names>JR</given-names></name>
<name><surname>Eastwood</surname><given-names>A</given-names></name>
<name><surname>Naidu</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Lysosomal Glycogen Storage Disease with Normal Acid Maltase</article-title><source>Neurology</source><year>1981</year><volume>31</volume><issue>1</issue><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1212/wnl.31.1.51</pub-id><pub-id pub-id-type="pmid">6450334</pub-id>
</element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>J</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Ji</surname><given-names>K</given-names></name>
<name><surname>Fan</surname><given-names>X</given-names></name>
<name><surname>Zhao</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Clinical Features and Cardiovascular Magnetic Resonance Characteristics in Danon Disease</article-title><source>Clin Radiol</source><year>2020</year><volume>75</volume><issue>9</issue><fpage>712.e1</fpage><lpage>712.e11</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2020.04.012</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>X</given-names></name>
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Xie</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Du</surname><given-names>Z</given-names></name>
<name><surname>Zhong</surname><given-names>X</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiac Phenotype Characterization at MRI in Patients with Danon Disease: A Retrospective Multicenter Case Series</article-title><source>Radiology</source><year>2021</year><volume>299</volume><issue>2</issue><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1148/radiol.2021203996</pub-id><pub-id pub-id-type="pmid">33754825</pub-id>
</element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nucifora</surname><given-names>G</given-names></name>
<name><surname>Miani</surname><given-names>D</given-names></name>
<name><surname>Piccoli</surname><given-names>G</given-names></name>
<name><surname>Proclemer</surname><given-names>A</given-names></name>
</person-group><article-title>Cardiac Magnetic Resonance Imaging in Danon Disease</article-title><source>Cardiology</source><year>2012</year><volume>121</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1159/000336448</pub-id><pub-id pub-id-type="pmid">22378182</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="TRen" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20240529i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Complex Puzzle of Hypertrophic Phenotype: A Practical Approach for the Clinician</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7046-8707</contrib-id><name><surname>Felix</surname><given-names>Alex dos Santos</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2001" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3001" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4001" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0711-7995</contrib-id><name><surname>Barberato</surname><given-names>Silvio Henrique</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff5001" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6001" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8809-8783</contrib-id><name><surname>Melo</surname><given-names>Marcelo Dantas Tavares de</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff7001" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8812-2330</contrib-id><name><surname>Rosa</surname><given-names>S&#x000ed;lvia Aguiar</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff8001" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff9001" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3812-4872</contrib-id><name><surname>Cardim</surname><given-names>Nuno</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito e Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff9001" ref-type="aff">
<sup>9</sup>
</xref><xref rid="aff10001" ref-type="aff">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="aff1001">
<label>1</label>
<country country="BR"/>
<institution content-type="original">Instituto Nacional de Cardiologia, Rio de Janeiro, RJ &#x02013; Brazil</institution>
</aff><aff id="aff2001">
<label>2</label>
<country country="BR"/>
<institution content-type="original">DASA - Diagn&#x000f3;sticos da Am&#x000e9;rica SA, Rio de Janeiro, RJ &#x02013; Brazil</institution>
</aff><aff id="aff3001">
<label>3</label>
<country country="BR"/>
<institution content-type="original">Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ &#x02013; Brazil</institution>
</aff><aff id="aff4001">
<label>4</label>
<country country="BR"/>
<institution content-type="original">Complexo Hospitalar Am&#x000e9;ricas - Vit&#x000f3;ria / Samaritano Barra, Rio de Janeiro, RJ &#x02013; Brazil</institution>
</aff><aff id="aff5001">
<label>5</label>
<country country="BR"/>
<institution content-type="original">CardioEco Centro de Diagn&#x000f3;stico Cardiovascular, Curitiba, PR &#x02013; Brazil</institution>
</aff><aff id="aff6001">
<label>6</label>
<country country="BR"/>
<institution content-type="original">Quanta Diagn&#x000f3;stico - Ecocardiografia, Curitiba, PR &#x02013; Brazil</institution>
</aff><aff id="aff7001">
<label>7</label>
<country country="BR"/>
<institution content-type="original">Universidade Federal da Para&#x000ed;ba, Jo&#x000e3;o Pessoa, PB &#x02013; Brazil</institution>
</aff><aff id="aff8001">
<label>8</label>
<country country="PT"/>
<institution content-type="original">Hospital of Santa Marta, Lisboa &#x02013; Portugal</institution>
</aff><aff id="aff9001">
<label>9</label>
<country country="PT"/>
<institution content-type="original">NOVA Medical School, Lisboa &#x02013; Portugal</institution>
</aff><aff id="aff10001">
<label>10</label>
<country country="PT"/>
<institution content-type="original">Hospital CUF Descobertas, Lisboa &#x02013; Portugal</institution>
</aff><author-notes><corresp id="c01001">
<label>Mailing Address:</label> Alex dos Santos Felix &#x02022; Instituto Nacional de Cardiologia - Rua das Laranjeiras, 374. Postal Code 20521-290, Rio de Janeiro, RJ - Brazil. E-mail: alexsfelix@gmail.com </corresp><fn fn-type="COI-statement"><p><bold>Potential conflict of interest:</bold> No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="edited-by"><p><bold>Editor responsible for the review:</bold> Gl&#x000e1;ucia Maria Moraes de Oliveira</p></fn></author-notes><abstract abstract-type="graphical"><p>
<fig position="float" id="f01001"><label>Central Illustration:</label><caption><title>The Complex Puzzle of Hypertrophic Phenotype: A Practical Approach for the Clinician</title><p>The correct diagnosis of a patient with a left ventricular hypertrophic phenotype relies on an integrative approach, using clues from clinical history, physical examination and use of multimodality imaging. LV: left ventricular; LVH: left ventricular hypertrophy; HCM: hypertrophic cardiomyopathy; LGE: late gadolinium enhancement; RV: right ventricular.</p></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf01-en" position="float"/></fig>
</p></abstract><abstract><title>Abstract</title><p>Left ventricular hypertrophy (LVH) represents a frequent observation in clinical practice. Nonetheless, the hypertrophic phenotype emerges as a common manifestation of diverse conditions, thereby presenting a diagnostic conundrum for clinicians. Differentiation among the etiologies of LVH is imperative for therapy decision-making, as different approaches must be implemented for distinct conditions, such as LVH secondary to loading changes, hypertrophic cardiomyopathy (HCM), or HCM mimics.</p><p>In some instances, an erroneous or late diagnosis may lead to a progression of the underlying disease with worsening functional capacity, high morbidity and mortality.</p><p>The rational use of cardiovascular multimodality imaging is of great importance when carried out in addition to a thorough clinical assessment and correlated with electrocardiographic findings, providing clues to fill the gaps, being, most of the time, the missing piece to solve this challenging puzzle.</p><p>An integrative approach is of paramount importance for the evaluation of these patients, as they are often followed by several specialties, with varied systemic manifestations. Although a multidisciplinary team is needed for an optimized follow-up of these patients, the most important player in this journey is the clinician, whose mission is to bring together all the red flags and coordinate all the data for an assertive diagnosis.</p><p>The objective of this review is to provide a pragmatic methodology, highlighting important clues for discriminating among the diverse conditions that result in LVH.</p></abstract><kwd-group><kwd>Left Ventricular Hypertrophy</kwd><kwd>Diagnosis</kwd><kwd>Differential Diagnosis</kwd><kwd>Cardiac Imaging Techniques</kwd><kwd>Heart Function Tests</kwd></kwd-group></front-stub><body><sec sec-type="intro"><title>Introduction</title><p>Left ventricular hypertrophy (LVH) consists of an increased LV wall thickness, representing a frequent observation in clinical practice. Nonetheless, the hypertrophic phenotype emerges as a common manifestation of diverse conditions, thereby presenting a diagnostic conundrum for clinicians.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Differentiation among the etiologies of LVH (<xref rid="f02001" ref-type="fig">Figure 1</xref>) is imperative for devising precise management approaches. LVH frequently originates from secondary adaptive mechanisms, such as arterial hypertension (AH), aortic stenosis (AS), and athlete&#x02019;s heart, or from a spectrum of other pathological states, encompassing both genetic and acquired diseases, that may concurrently exist. Hypertrophic cardiomyopathy (HCM) is characterized by LV wall thickening (&#x02265; 15 mm anywhere in the left ventricle) that is not solely attributable to abnormal loading conditions. It is crucial to differentiate (a) the sarcomeric variant, which accounts for the principal etiology of unexplained LVH (40-60%), from (b) other HCM forms (variants of non-sarcomeric genes or unresolved genetic etiology) and (c) other genetic and non-genetic causes, collectively termed as HCM mimics (genocopies or phenocopies).<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref></sup> The objective of this article is to provide a pragmatic methodology for discriminating among the diverse conditions that result in LVH. This differentiation considers an array of factors, including the patient&#x02019;s clinical profile, family history, electrocardiogram (ECG) attributes, laboratory profile, echocardiography (ECHO), and cardiac magnetic resonance (CMR) features, and in selected cases, genetic study and even endomyocardial biopsy. A rational and comprehensive use of cardiovascular multimodality imaging is particularly important to point to a specific diagnosis, providing clues to fill the gaps, being most of the time, the missing piece to solve this challenging puzzle.</p><p>
<fig position="float" id="f02001"><label>Figure 1</label><caption><title>&#x02013; Challenging puzzle of differential diagnosis in patients with left ventricular hypertrophic phenotype.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf02-en" position="float"/></fig>
</p><sec><title>Clinical presentation</title><p>To aid in the differential diagnosis of LVH, the clinician should keep in mind a focused approach, considering age at first presentation, symptoms, personal and family history, and specific clinical markers on physical examination (&#x0201c;red flags&#x0201d;) (<xref rid="t1001" ref-type="table">Table 1</xref>). The primary investigative step in adults exhibiting LVH involves screening for frequent etiologies, notably pressure overload conditions, like chronic AH and AS, or physiological adaptations associated with athletic training. Individuals with LVH may be asymptomatic or exhibit nonspecific symptoms, such as exertional dyspnea, fatigue, chest discomfort, palpitations, syncope, and/or presyncope. The investigation of LVH is often precipitated by incidental findings identified during an ECG or ECHO, which are often conducted for other screening objectives. Conversely, a variety of noncardiac symptoms and signs may occasionally be indicative of specific diagnoses.</p><p>
<table-wrap position="float" id="t1001"><label>Table 1</label><caption><title>&#x02013; Genetics, epidemiological and clinical aspects of possible differential diagnosis of left ventricular hypertrophic phenotype</title></caption><table frame="hsides" rules="groups"><colgroup width="11%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Hypertrophic Cardiomyopathy</th><th rowspan="1" colspan="1">Fabry Disease</th><th rowspan="1" colspan="1">Cardiac Amyloidosis</th><th rowspan="1" colspan="1">Danon Disease</th><th rowspan="1" colspan="1">Pompe Disease</th><th rowspan="1" colspan="1">PRKAG2</th><th rowspan="1" colspan="1">RASopathies</th><th rowspan="1" colspan="1">Friedreich&#x02019;s Ataxia</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Genetics</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Autosomal dominant inheritance</p></list-item><list-item><p>&#x02022; Great variety of gene mutations, most prevalent: MYH7(cardiac myosin heavy chain beta) - 30-50%, MYBPC3 (Myosin binding protein C) -20-40%, TNNT2(Cardiac troponin T -5-20%</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; X-linked inheritance</p></list-item><list-item><p>&#x02022; Mutation in GLA gene</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Hereditary ATTR (mutant or familiar): an autosomal-dominant disease with variable penetrance</p></list-item><list-item><p>&#x02022; Mutation in transthyretin (TTR) gene</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; X-linked inheritance</p></list-item><list-item><p>&#x02022; Mutations in the lysosome-associated membrane 2(LAMP2) gene</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Autosomal recessive lysosomal storage disorder</p></list-item><list-item><p>&#x02022; Mutations in the GAA gene</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Autosomal dominant inheritance</p></list-item><list-item><p>&#x02022; Mutations in thePRKAG2 gene</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Autosomal dominant inheritance</p></list-item><list-item><p>&#x02022; Mutations in the RAS/MAPK signaling pathway</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Autosomal recessive inheritance</p></list-item><list-item><p>&#x02022; Mutations in the Frataxin gene (FXN)</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Epidemiological Clinical aspects</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Most common LVH among genetic causes</p></list-item><list-item><p>&#x02022; Young and older patients (broad age spectrum)</p></list-item><list-item><p>&#x02022; History of syncope</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Corneal opacity</p></list-item><list-item><p>&#x02022; Angiokeratoma</p></list-item><list-item><p>&#x02022; Hypohidrosis</p></list-item><list-item><p>&#x02022; Albuminuria</p></list-item><list-item><p>&#x02022; Acroparesthesia</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Adults &#x0003e; 55 years old</p></list-item><list-item><p>&#x02022; Bilateral carpal tunnel syndrome</p></list-item><list-item><p>&#x02022; Biceps tendon rupture.</p></list-item><list-item><p>&#x02022; Peripheral polyneuropathy</p></list-item><list-item><p>&#x02022; Sensory involvement, autonomic dysfunction</p></list-item><list-item><p>&#x02022; Skin bruising</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Male individuals from 10-20 years old</p></list-item><list-item><p>&#x02022; Intellectual disability</p></list-item><list-item><p>&#x02022; Muscle weakness</p></list-item><list-item><p>&#x02022; Hepatomegaly</p></list-item><list-item><p>&#x02022; Women with almost exclusive cardiomyopathy</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Children (at birth and first year of life) / Adolescents</p></list-item><list-item><p>&#x02022; Muscle weakness</p></list-item><list-item><p>&#x02022; Macroglossia</p></list-item><list-item><p>&#x02022; Pigmentary retinitis</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Young patients(I-IV decade)</p></list-item><list-item><p>&#x02022; Myalgia</p></list-item><list-item><p>&#x02022; Epilepsia</p></list-item><list-item><p>&#x02022; Early onset arterial hypertension</p></list-item><list-item><p>&#x02022; Ventricular preexcitation(pseudo Wolff-Parkinson White)</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; Children /Adolescents and young patients &#x0003c; 20 years old</p></list-item><list-item><p>&#x02022; Facial dysmorphism</p></list-item><list-item><p>&#x02022; Multiple lentigines</p></list-item><list-item><p>&#x02022; Pectus carinatum</p></list-item><list-item><p>&#x02022; Deafness</p></list-item><list-item><p>&#x02022; Kyphosis</p></list-item><list-item><p>&#x02022; Hypertelorism</p></list-item></list>
</td><td align="center" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02022; &#x0003e; 15 years old</p></list-item><list-item><p>&#x02022; Symmetric gait ataxia.</p></list-item><list-item><p>&#x02022; Kyphoscoliosis</p></list-item><list-item><p>&#x02022; Sensory neuropathy</p></list-item><list-item><p>&#x02022; Dysarthria</p></list-item><list-item><p>&#x02022; Deafness</p></list-item><list-item><p>&#x02022; Vertigo</p></list-item></list>
</td></tr></tbody></table></table-wrap>
</p><p>Concerning the onset age, an elevated prevalence of glycogen storage diseases (e.g., Pompe disease) and RASopathies (including Noonan syndrome) is noted as underlying etiologies for unexplained LVH in children and adolescents. Conversely, in adults aged over 55 years, cardiac amyloidosis (CA) can be found at a higher frequency, and awareness of the possible diagnosis of this treatable disease is very important.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> HCM represents the most common etiology for LVH among genetic causes across a broad age spectrum, spanning from young to elderly patients.<sup><xref rid="B4" ref-type="bibr">4</xref></sup></p><p>Severe LVH observed at birth or during the first year of life, coupled with muscle weakness, macroglossia, and pigmentary retinitis, should prompt clinical suspicion of Pompe disease. In male individuals aged between 10 and 20 years presenting with substantial LVH, intellectual disability, muscle weakness, and ventricular pre-excitation, an evaluation for Danon disease is warranted. Similarly, up to the age of 20, the presence of facial dysmorphism, multiple lentigines, pectus carinatum, deafness, kyphosis, and hypertelorism should alert clinicians to the possibility of RASopathies, such as Noonan syndrome and Noonan syndrome with multiple lentigines. In individuals over 15 years old, the co-occurrence of neurological symptoms like ataxia, imbalance, and alterations in gait may indicate Friedreich&#x02019;s ataxia. Additionally, mitochondrial diseases, alongside LVH, often manifest with sensorial abnormalities as well as neurological and myopathic symptoms. In individuals aged between 30 and 40 years, Fabry disease and PRKAG2 cardiomyopathy (CM) should be included in the differential diagnosis.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> The manifestation of gastrointestinal symptoms, neuropathic pain, angiokeratomas, hypohidrosis, cornea verticillata, proteinuria, conduction disturbances, juvenile or cryptogenic transient ischemic attack or stroke, and hearing loss, coupled with a history of X-linked hereditary transmission, prompt to the investigation of Fabry disease.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> In patients aged over 55-60 years, CA (either light chain or wild-type transthyretin) should be considered, particularly in the presence of clinical indicators such as carpal tunnel syndrome, spontaneous biceps tendon rupture (Popeye&#x02019;s sign), back pain (indicative of spinal stenosis), polyneuropathy (manifesting as neuropathic pain, ambulatory difficulties, or frequent falls), intolerance to antihypertensive or heart failure medications due to postural hypotension, disproportionate low voltage QRS in ECG to LV mass, heart failure with preserved ejection fraction (HFpEF), and bradyarrhythmia.<sup><xref rid="B7" ref-type="bibr">7</xref></sup></p><p>When a genetic etiology is suspected, it is crucial to conduct a detailed inquiry into the three-generation family history, focusing on the diagnosis of HCM, presence of sudden death, arrhythmia, intracardiac device implantation, and reports of early stroke.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> HCM and PRKAG2 mutations are typically associated with autosomal dominant inheritance. An X-linked pattern should prompt consideration of Fabry or Danon disease, whereas an autosomal recessive pattern suggests Friedreich&#x02019;s ataxia<sup><xref rid="B8" ref-type="bibr">8</xref></sup>(<xref rid="t1001" ref-type="table">Table 1</xref>). During the physical examination, the presence of signs indicative of dynamic LV outflow tract obstruction (LVOT), such as a systolic murmur that increases in standing position or bifid pulse, may suggest intraventricular obstruction caused by HCM. A history of pacemaker implantation, numerous affected family members, and the presence of Wolff-Parkinson-White syndrome lend support to the diagnosis of PRKAG2, with Fabry disease as a potential alternative diagnosis.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p><p>Clinical data alone, while informative, is insufficient for the differentiation of the etiology of LVH, and additional diagnostic tests are essential for confirming the underlying cause. Nonetheless, a comprehensive clinical judgment and a tailored assessment of each patient are critical in guiding the judicious selection of appropriate diagnostic methodologies.</p><p>In summary, based on the aforementioned criteria, three principal findings should prompt suspicion of, and initiate the investigation for HCM mimics:</p><list list-type="simple"><list-item><p>&#x02022; The age at which LVH onset occurs, whether early or late in life.</p></list-item><list-item><p>&#x02022; The presence of extracardiac manifestations.</p></list-item><list-item><p>&#x02022; Patterns of inheritance that are not consistent with autosomal dominant transmission.</p></list-item></list></sec><sec><title>Electrocardiography</title><p>Electrocardiographic anomalies may manifest years before the development of a hypertrophic phenotype. While ECG changes are generally non-specific, they can provide diagnostic hints, especially when interpreted in conjunction with other clinical and laboratory findings and correlated with multimodality imaging (<xref rid="f03001" ref-type="fig">Figure 2</xref>). HCM may exhibit a wide range of patterns, including left ventricular strain and ST- and T-wave abnormalities, although, in some cases, the ECG can be normal.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Deep negative T-waves in precordial leads may suggest apical HCM. An extreme LVH pattern is suggestive of Danon, Pompe, and PRKAG2 cardiomyopathies. Low QRS voltage (absolute or relative, e.g., disproportionate QRS voltage to LV wall thickness), atrioventricular block and a pseudoinfarction pattern are hallmarks of CA. A short PR interval/ventricular pre-excitation (notably in younger patients) and atrioventricular blocks (in adult patients) are observed in Fabry, Danon, and PRKAG2 diseases. Bifascicular blocks may also point to Fabry disease as a possible diagnosis.<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p><p>
<fig position="float" id="f03001"><label>Figure 2</label><caption><title>&#x02013; Electrocardiographic clues for the differential diagnosis of LVH. HCM: hypertrophic cardiomyopathy; AV: atrioventricular; AH: arterial hypertension; AS: aortic stenosis; LVH: left ventricular hypertrophy.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf03-en" position="float"/></fig>
</p><p>Patients with LVH may experience a wide range of arrhythmias, from asymptomatic atrial and/or ventricular premature beats to life-threatening ventricular arrhythmias (VAs). Atrial fibrillation (AF) is a common complication in the clinical progression of HCM, Fabry disease, and amyloidosis. Similarly, sarcomeric HCM, Danon, and PRKAG2 cardiomyopathies are associated with a risk of life-threatening VAs.<sup><xref rid="B8" ref-type="bibr">8</xref></sup></p></sec><sec><title>Laboratory tests</title><p>Within the framework of a hypertrophic phenotype and its clinical manifestations, the application of routine and targeted laboratory investigations can provide indications for specific diagnoses. Although non-specific, disproportionately high levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and minor elevations in serum troponin may point to a diagnosis of amyloidosis or specific forms of sarcomeric HCM. Sustainedly high serum creatine kinase (CK) levels could indicate Pompe disease, neuromuscular diseases or athlete&#x02019;s heart. Liver dysfunction, characterized by raised serum levels of hepatic transaminases, may be observed in Pompe, Danon, and PRKAG2 cardiomyopathies. The finding of light-chain immunoglobulin in serum and urine immunofixation assays and an abnormal free-light-chain ratio are consistent with a diagnosis of AL amyloidosis.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> For Fabry disease, the &#x0201c;dry spot test&#x0201d; is a useful screening tool in males, in whom the diagnosis is established through the assessment of alpha-galactosidase A (&#x003b1;-GalA) activity and lyso-Gb3 measurements. In female patients, genetic testing is typically required to confirm the diagnosis.</p></sec><sec><title>Echocardiography</title><p>ECHO plays a pivotal role in the diagnosis and management of LVH, not only due to its broad availability, non-invasive nature, and relative affordability but predominantly because of the comprehensive information it provides. This includes anatomical visualization of structures (LVH phenotype, thickness of LV walls, and geometric distribution of hypertrophy), assessment of left and right ventricular (RV) function, and hemodynamic evaluations (such as LV end-diastolic pressure, pulmonary artery systolic pressure, stroke volume, and vena cava collapsibility). ECHO is also valuable for identifying fixed obstructions, like AS, or dynamic LV obstructions, like obstructive HCM.<sup><xref rid="B12" ref-type="bibr">12</xref></sup></p><p>Recent advances in echocardiographic techniques, particularly in myocardial deformation analysis, have enhanced our understanding of pathophysiology, myocardial mechanics and myocardial function beyond ejection fraction. Speckle-tracking echocardiography (STE) has emerged as a sensitive tool for the early detection of myocardial disease, as global longitudinal strain (GLS) often deteriorates before LV ejection fraction (LVEF) decreases in various clinical contexts, with the advantage of being less load dependent. It is important for diagnosing subclinical cardiac diseases in genotype-positive relatives of patients with HCM, Friedreich&#x02019;s ataxia, and CA, as well as for monitoring patients with metabolic, infiltrative, or myocardial storage diseases. STE helps in characterizing myocardial involvement patterns, acting as a sort of visual &#x0201c;fingerprint&#x0201d; and serving as an echo-based &#x0201c;tissue characterization tool&#x0201d; (<xref rid="f04001" ref-type="fig">Figure 3</xref>).<sup><xref rid="B13" ref-type="bibr">13</xref></sup> There is a strong correlation between GLS values and late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR), pointing to myocardial fibrosis and higher risk of mortality and malignant VAs in patients with HCM.<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref></sup> This parameter also has prognostic value in infiltrative diseases like CA.<sup><xref rid="B16" ref-type="bibr">16</xref></sup></p><p>
<fig position="float" id="f04001"><label>Figure 3</label><caption><title>&#x02013; Longitudinal strain patterns in left ventricular (LV) hypertrophic phenotype (bulls-eye parametric display). A) Hypertrophic cardiomyopathy (HCM) showing regional deformation alterations according to the distribution of hypertrophy (in this case, a septal asymmetric HCM), B) Cardiac amyloidosis, with a pattern of &#x0201c;apical sparing,&#x0201d; an echocardiographic red flag for its diagnosis, C) Fabry disease, with typical alteration of deformation in basal anterolateral wall, D) PRKAG2 cardiomyopathy, with massive biventricular hypertrophy in this case, with marked global alteration in GLS showing diffuse pattern, E) Friedreich&#x02019;s ataxia, with concentric LV hypertrophy, showing alteration of deformation mainly in basal and medial segments, highlighting that &#x0201c;relative apical sparing&#x0201d; is not specific for the diagnosis of CA (this case: courtesy - Dr. Thiago Santos Rosa - Brazil).</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf04-en" position="float"/></fig>
</p><p>Myocardial work has been developed as a new promising echocardiographic tool for the evaluation of myocardial mechanics, incorporating afterload (arterial blood pressure) as an estimate of LV pressure and using longitudinal strain (LS) for the construction of a &#x0201c;pressure x strain&#x0201d; loop, generated by a specific software.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> The additional value of this technique over conventional echocardiographic parameters for the evaluation of cardiomyopathies is still to be proved in larger studies. Still, some data are showing prognostic value for evaluation of HCM<sup><xref rid="B18" ref-type="bibr">18</xref></sup> and CA<sup><xref rid="B19" ref-type="bibr">19</xref></sup> for example.</p><p>While still not universally available, three-dimensional echocardiography (3DE) has become a valuable tool for assessing myocardial diseases, particularly for direct volumetric measurements of cardiac chambers. It provides accurate EF and LV mass values, correlating well with the gold standard CMR.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> 3DE also enables 3D myocardial strain measurement, is less affected by technical limitations like out-of-plane movement, and allows for the simultaneous evaluation of the entire LV, which is useful for synchronization analysis.</p><p>Contrast echo using ultrasound-enhancing agents is important for LV border delineation, especially in patients with suboptimal acoustic windows. It increases sensitivity in detecting conditions like apical HCM and apical aneurysms and differentiating intracavitary thrombus from other structures such as tendons or trabeculations.<sup><xref rid="B21" ref-type="bibr">21</xref></sup></p></sec><sec><title>Cardiovascular magnetic resonance</title><p>CMR has assumed an unquestionable role in the evaluation of LVH, mainly by assessing cardiac morphology, function, and tissue characterization.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Although CMR may give essential clues for the final diagnosis in entities with extreme abnormalities in tissue characterization, such as CA or Fabry disease, the significant overlap of imaging findings in many entities makes necessary a comprehensive integration of imaging findings in the clinical context. No imaging finding should be interpreted in isolation, without integration of clinical history, electrocardiographic data and family history.<sup><xref rid="B22" ref-type="bibr">22</xref></sup></p><p>Beyond the anatomical and functional evaluation of the LV, the main advantage of CMR compared to ECHO is the possibility of tissue characterization. Parametric mapping techniques that measure the T1 and T2 relaxation times have been increasingly incorporated in acquisition protocols, allowing for the quantitative evaluation of intracellular and extracellular components.<sup><xref rid="B23" ref-type="bibr">23</xref></sup>LGE imaging can identify replacement fibrosis and has well-established prognostic value, although it is less sensitive to detect diffuse interstitial collagen deposition than T1 mapping techniques.<sup><xref rid="B24" ref-type="bibr">24</xref></sup></p></sec><sec><title>Diagnosis of left ventricular hypertrophy</title><p>Despite the existence of established gender-specific normal reference values for LV mass in clinical guidelines,<sup><xref rid="B25" ref-type="bibr">25</xref></sup> technical challenges can introduce variability and difficulties in the echocardiographic measurement of LV wall thickness. Suboptimal acoustic window, incorrect measurements (oblique or foreshortening, use of apical window &#x02013; poor lateral resolution), and inclusion of confounding structures may affect accuracy. Some structures, such as a prominent RV moderator band, tricuspid valve apparatus, crista supraventricularis or LV fibromuscular false tendons inserted in the interventricular septum, may erroneously be interpreted as part of the septum, overestimating septal thickness. In pediatric patients, Z-scores, which represent the number of standard deviations from mean values, are used as reference standards. These scores adjust LV mass and wall thickness according to the child&#x02019;s age and body size, providing a more tailored assessment in this population.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> Thresholds for carriers of genetic pathogenic variants may be lower<sup><xref rid="B12" ref-type="bibr">12</xref></sup> and some presentations may cause confusion and misdiagnosis, such as late and already dilated phenotypes.<sup><xref rid="B26" ref-type="bibr">26</xref></sup> To ensure an accurate diagnosis, it is essential to correlate these measurements with the clinical background, the presence of other associated structural cardiac diseases, GLS values, and diastolic function. In certain cases, CMR may be necessary to confirm the diagnosis.</p></sec><sec><title>Hypertrophic cardiomyopathy</title><p>HCM is defined by an increased LV wall thickness of &#x02265; 15mm, or &#x02265; 13mm (in individuals with a positive genotype or relatives of HCM patients), in the absence of conditions that would justify secondary LVH such as severe AH, AS, or aortic coarctation, and excluding any infiltrative systemic diseases.<sup><xref rid="B27" ref-type="bibr">27</xref></sup> It is crucial to recognize that HCM is not merely a myocardial disease; other features supporting the diagnosis include MV and subvalvular apparatus abnormalities like mitral leaflet elongation, papillary muscle hypertrophy, abnormal secondary MV chords, and muscle bundles (<xref rid="f05001" ref-type="fig">Figure 4</xref>).<sup><xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref></sup></p><p>
<fig position="float" id="f05001"><label>Figure 4</label><caption><title>&#x02013; Echocardiographic clues for the differential diagnosis of left ventricular hypertrophic phenotype. HCM: hypertrophic cardiomyopathy; SAM: systolic anterior motion of the mitral valve; MR: mitral regurgitation; RV: right ventricular.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf05-en" position="float"/></fig>
</p><p>Asymmetric septal LVH is the most classic pattern of HCM. Still, other phenotypic expressions like apical, concentric, lateral wall, midventricular, and less typical presentations involving any segment of the LV are common. The classical diagnostic criteria for diagnosing HCM, which are the same for both ECHO and CMR,<sup><xref rid="B8" ref-type="bibr">8</xref></sup> have recently been brought into question (&#x0201c;one size fits all&#x0201d;) and in the future, probably gender, body surface and race will be considered for the definition of new thresholds. In particular, these criteria may not be reached in the apical variant, characterized by the loss or reversal of usual apical myocardial tapering. For instance, new cut-off values and diagnostic criteria were recently suggested for the detection of apical HCM, being the upper limit of normal apically 11 mm or 5.6 mm/m<sup><xref rid="B2" ref-type="bibr">2</xref></sup>. <sup><xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B30" ref-type="bibr">30</xref></sup></p><p>RV hypertrophy is also frequent in HCM patients, found in 30-44% of cases, usually alongside LVH.<sup><xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref></sup> RV dynamic obstruction may occur, either intraventricular or in the RV outflow tract.<sup><xref rid="B33" ref-type="bibr">33</xref></sup> Conventional echocardiographic indices of RV systolic function, such as tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), and tissue Doppler velocities, are typically normal. Still, subclinical systolic dysfunction may be identified through alterations in RV-LS.<sup><xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref></sup></p><p>ECHO has also played an important role in the risk assessment and stratification of HCM patients,<sup><xref rid="B36" ref-type="bibr">36</xref></sup> with studies showing higher mortality in HCM patients with LV septal thickness &#x02265; 30mm, apical aneurysm, or LV dysfunction (LVEF &#x0003c;50%).<sup><xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B37" ref-type="bibr">37</xref></sup> 2D LV GLS strongly correlates with fibrosis in HCM patients. Absolute GLS values and mechanical dispersion have a good correlation with the percentage of LGE and are independent predictors of VAs.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> In the study of Reant et al.,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> GLS absolute values &#x0003c; 15,4% were associated with heart failure, death and hospital admissions in a cohort of HCM patients. The parametric 2D LS bull&#x02019;s eye plot derived from 2D STE may offer an intuitive visual overview of the global and regional LV myocardial deformation in HCM and is characterized by severely reduced segmental strain values in the most hypertrophied walls, usually more pronounced than other etiologies such as hypertensive or LVH secondary to AS.<sup><xref rid="B38" ref-type="bibr">38</xref></sup></p><p>Hemodynamic evaluation to identify those with LVOT obstruction is crucial for treating HCM patients. Approximately one-third of HCM patients have rest LVOT obstruction (&#x0003e; 30 mmHg), with another third showing latent obstruction, revealed through bedside provocative maneuvers (Valsalva, standing, squatting-elevation, amyl nitrite inhalation) or exercise echocardiography.<sup><xref rid="B39" ref-type="bibr">39</xref></sup>Mitral regurgitation is a common finding in patients with HCM, especially in patients with systolic anterior mitral movement (SAM), and can be a major determinant of symptoms. It is very important to highlight that SAM is not a result solely of septal asymmetric hypertrophy (LVOT high velocities and Venturi effect). In fact, primary abnormalities of the MV apparatus, such as hypertrophy and anterior displacement of papillary muscles, leaflet elongation, and alteration in chordal insertion, may have a great role in LVOT obstruction (<xref rid="f06001" ref-type="fig">Figure 5</xref>).<sup><xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B40" ref-type="bibr">40</xref></sup></p><p>
<fig position="float" id="f06001"><label>Figure 5</label><caption><title>&#x02013; Example of a patient with obstructive Hypertrophic Cardiomyopathy. A) septal thickness: 4,1cm, B) Longitudinal strain pattern (bulls-eye) showing regional alteration mainly in septal and segments, C) 3D transthoracic echo (TTE) acquisition, rendered 3D images longitudinal showing systolic anterior motion (SAM) of the mitral valve in systole (*), D) 3D TTE acquisition, rendered color 3D images (longitudinal view) showing mitral regurgitation secondary to SAM (*), E) Continuous Doppler showing late peak rest gradient in left ventricular outflow tract of 96mmHg, classic dagger shape pattern, F) 3D TTE acquisition, rendered 3D images (short axis view) showing papillary muscles anomaly with 4 heads (*) and anteriorly positioned, G) Cardiac MR showing massive septal hypertrophy, and in H- late gadolinium enhanced images showing septal fibrosis with midwall pattern.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf06-en" position="float"/></fig>
</p><p>HCM typically presents with normal or increased LVEF, the classic phenotype of HFpEF, associated with diastolic dysfunction in various degrees. Some patients may exhibit apical aneurysms and progressive LV dysfunction, which may lead to end-stage cardiac disease or the &#x0201c;burned-out&#x0201d; HCM variant, associated with a worse prognosis.<sup><xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref></sup></p><p>CMR also allows for a detailed anatomical characterization regarding the pattern of LVH, variations in MV apparatus and their contributions to LVOT obstruction.<sup><xref rid="B43" ref-type="bibr">43</xref></sup>Considering this detailed evaluation, CMR plays an important role in planning septal reduction therapies.<sup><xref rid="B44" ref-type="bibr">44</xref></sup></p><p>Regarding tissue characterization, native T1 and ECV correlate with diffuse fibrosis, elevated even in areas without LGE.<sup><xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref></sup> Typical replacement fibrosis with a midwall pattern, more frequent in hypertrophic areas, is well depicted by LGE, with a well-recognized prognostic value.<sup><xref rid="B47" ref-type="bibr">47</xref></sup>Using recent advances, diffusion tensor acquisition allows the study of myocyte disarray, a premature marker of the disease,<sup><xref rid="B48" ref-type="bibr">48</xref></sup> and stress perfusion CMR allows the study of microvascular dysfunction.<sup><xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref></sup></p></sec><sec><title>HCM Mimics</title><sec><title>Cardiac amyloidosis</title><p>CA is an infiltrative CM caused by extracellular deposition of amyloid fibrils, with a classic phenotype of LVH (&#x0201c;pseudo-hypertrophy&#x0201d;) and HFpEF. ECHO, particularly in the early stages,<sup><xref rid="B51" ref-type="bibr">51</xref></sup> lacks specificity to precisely distinguish amyloid from nonamyloid infiltrative or hypertrophic heart diseases, reinforcing the need to correlate with other clinical &#x0201c;red flags&#x0201d; and complement with other imaging modalities. Classical ECHO findings may be observed only in advanced stages of amyloid infiltration, with biatrial enlargement, valves and interatrial septal thickening, pleural and pericardial effusion, low myocardial velocities, and biventricular hypertrophy with a bright and sparkling appearance. Usually, these patients present with preserved LVEF and marked diastolic dysfunction with increased LV filling pressures (type II-III diastolic dysfunction), although reduced LVEF is a frequent finding in late-stage disease.<sup><xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref></sup> It is important to notice that CA patients may present with reduced stroke volume even before a reduction in LVEF, caused by different factors, including alteration in myocardial deformation, impaired LV diastolic performance, atrial mechanic dysfunction and reduced LV volumes due to wall thickening.<sup><xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref></sup></p><p>ECHO is a vital instrument for the early diagnosis of CA, particularly when encountering patients with the hypertrophic phenotype (defined as LV wall thickness &#x02265; 12mm) combined with other clinical or echocardiographic &#x0201c;red flags.&#x0201d; These findings (<xref rid="f05001" ref-type="fig">Figure 4</xref>) should prompt the clinician to direct these patients toward a specialized investigative pathway. This pathway typically includes CMR, scintigraphy with bone tracers, and the quantification of serum-free light chains, along with serum and urine immunofixation tests. These diagnostic modalities help in confirming the diagnosis of CA and differentiating monoclonal immunoglobulin light chain (AL) from transthyretin (ATTR) types, and also assess the staging of the disease and prognosis.<sup><xref rid="B56" ref-type="bibr">56</xref></sup></p><p>GLS is notably impaired in patients with CA, demonstrating a strong correlation with the extent of amyloid burden, as shown in studies comparing GLS with LGE and extracellular volume (ECV) measured by CMR.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B54" ref-type="bibr">54</xref></sup> A characteristic regional pattern of preserved longitudinal deformation in the apical segments, forming a basal-to-apical gradient or a relative apical sparing pattern (RASp), has been identified in CA (<xref rid="f07001" ref-type="fig">Figure 6</xref>). There are many ways to identify this pattern by STE, using different formulas and quantitative criteria or even considering a &#x0201c;cherry on top&#x0201d; visual appearance a qualitative visual sign derived from LS parametric (&#x0201c;bulls-eye&#x0201d;) analysis. RASp has shown good accuracy in distinguishing CA from other causes of LVH and myocardial diseases.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref></sup>Although RASp is not specific for the diagnosis of CA,<sup><xref rid="B59" ref-type="bibr">59</xref></sup> and may be found in other causes of LVH, it can be used as a valuable echocardiographic &#x0201c;red flag&#x0201d; to warrant further investigation in patients with a compatible clinical background,<sup><xref rid="B60" ref-type="bibr">60</xref></sup> and also to determine prognosis in these patients.<sup><xref rid="B61" ref-type="bibr">61</xref></sup> It is important to emphasize that RASp can be observed across different types of CA, including AL, hereditary ATTR, and wild-type ATTR amyloidosis, and is not helpful in distinguishing among them. This pattern may not be present in a significant proportion of patients because, in the initial stages of the disease, only mild grades of amyloid infiltration in basal segments may be present. On the other hand, a diffuse pattern of involvement of the myocardium may occur in the late-stage disease without a significant gradient between the apex and base of the heart.<sup><xref rid="B62" ref-type="bibr">62</xref></sup> Considering the disproportionate and early drop in GLS and relatively preserved EF in patients with CA, the ratio of LVEF divided by GLS showed good accuracy in differentiating CA from HCM, with a cutoff of 4,1.<sup><xref rid="B63" ref-type="bibr">63</xref></sup></p><p>
<fig position="float" id="f07001"><label>Figure 6</label><caption><title>&#x02013; Example of a patient with Cardiac Amyloidosis. A) ECG with low voltage in frontal leads, first-degree atrioventricular block, and &#x0201c;pseudoinfarction&#x0201d; pattern in precordial leads, B) a clinical red flag of the ruptured biceps tendon, C) apical 4-chamber showing biatrial enlargement, thickening of interatrial septum and atrioventricular valves, concentric left ventricular (LV) hypertrophy, D) atrial strain with reduced reservoir component (+15%) usually caused by atrial myopathy and diastolic dysfunction, E) LV longitudinal strain (LS) bulls-eye (parametric display) showing altered regional strain in basal and medial segments, relatively preserved in apical segments (&#x0201c;apical sparing&#x0201d; or &#x0201c;cherry on top&#x0201d;). F) reduced right ventricular (RV) LS (free wall strain = -13%) showing infiltration of amyloid in RV wall, G) Cardiac MR showing biventricular wall thickening, interatrial septum, biatrial enlargement, H) Cardiac MR with late gadolinium enhancement showing subendocardial global pattern, with altered gadolinium kinetics.</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf07-en" position="float"/></fig>
</p><p>RV myocardial deformation is typically impaired in patients with CA, which can be a helpful diagnostic feature in differentiating CA from other causes of hypertrophic phenotypes. Interestingly, a pattern of RV relative apical sparing, similar to that observed in the LV, has also been identified in these patients. The identification of this RV pattern, along with LV findings, enhances the diagnostic specificity for CA, as referenced in some publications.<sup><xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref></sup></p><p>CMR is particularly useful for CA once the T1 values are notably extreme and LGE has typical kinetics<sup><xref rid="B22" ref-type="bibr">22</xref></sup> (<xref rid="f08001" ref-type="fig">Figure 7</xref>). Amyloidotic myocardium has a singular avidity for the gadolinium leading to a myocardial &#x0201c;null point&#x0201d; earlier than the LV blood pool. As an extracellular contrast, gadolinium accumulates in the presence of extracellular space expansion secondary to amyloid deposition.<sup><xref rid="B66" ref-type="bibr">66</xref></sup> LGE pattern is typically global and subendocardial, becoming transmural in advanced stages.<sup><xref rid="B67" ref-type="bibr">67</xref></sup>Due to the extracellular accumulation of amyloid fibrils, ECV is markedly increased, frequently higher than 40%.<sup><xref rid="B68" ref-type="bibr">68</xref></sup></p><p>
<fig position="float" id="f08001"><label>Figure 7</label><caption><title>&#x02013; Use of cardiac magnetic resonance (CMR) in patients with left ventricular (LV) hypertrophic phenotype, with EKG, cine CMR, late gadolinium enhancement (LGE) images and T1-sequence mapping. In A) a patient with asymmetric septal hypertrophic cardiomyopathy; in B) a patient with apical hypertrophic cardiomyopathy; C) a patient with ATTR cardiac amyloidosis (CA); D) a patient with Fabry&#x02019;s disease. Arrows show areas of fibrosis, and a (*) points to a typical diffuse pattern in CA. Of note, T1 mapping shows an increased native T1 in a CA patient (C) and reduced T1 time in a Fabry patient (D).</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf08-en" position="float"/></fig>
</p><p>When used alone, CMR does not allow an accurate distinction between AL and ATTR amyloidosis, although some features are more in line with each type: RV LGE is apparent in most patients with ATTR amyloidosis, but only in about 70% of patients with AL amyloidosis; LV mass and ECV are higher in ATTR while native T1 and T2 are higher in AL amyloidosis secondary to light chain toxicity in cardiomyocytes.<sup><xref rid="B67" ref-type="bibr">67</xref>,<xref rid="B68" ref-type="bibr">68</xref></sup>Furthermore, the calculation of ECV in the liver and spleen may identify systemic involvement in AL, which is very rare in ATTR.<sup><xref rid="B69" ref-type="bibr">69</xref></sup></p><p>Combining multimodality imaging and observing their characteristics may provide important clues to identify potential differential diagnoses. Characteristic features of amyloidosis on CMR with grade 0 or 1 on bone scintigraphy point toward the diagnosis of AL amyloidosis, or rarely TTR variants, AApoAI and AApoAIV-amyloidosis.<sup><xref rid="B70" ref-type="bibr">70</xref></sup> When combined with unremarkable monoclonal protein studies, the presence of characteristic features on CMR shows a high specificity for the diagnosis of ATTR CA.<sup><xref rid="B71" ref-type="bibr">71</xref></sup></p><p>Fabry Disease</p><p>Fabry disease is a rare lysosomal storage disorder caused by a deficiency in &#x003b1;-GalA. LVH is the main cardiac manifestation of Fabry disease, and this entity accounts for 0.9% of the cases of HCM.<sup><xref rid="B72" ref-type="bibr">72</xref></sup> In men, the chronic accumulation of globotriaosylceramide is responsible for 2% of the total cardiac hypertrophy, but its storage triggers sarcomeric protein expression via myocyte hypertrophy. On the other hand, in women, LVH consists of balanced sphingolipid and myocyte hypertrophy in proportion. It is often underdiagnosed and can lead to poor outcomes if left untreated. Cardiac involvement is the most crucial prognostic factor in Fabry disease and significantly impacts the quality of life.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Cardiac alterations in Fabry disease may be subtle in young patients. Still, they typically develop HFpEF, arrhythmias, and LVH mimicking HCM later in life, generally after 30 years in men and 40 years in women. Early diagnosis is vital, especially because enzyme replacement therapy is available and can limit disease progression.<sup><xref rid="B73" ref-type="bibr">73</xref></sup></p><p>The typical echocardiographic features of Fabry disease are concentric LVH with preserved EF and disproportionate hypertrophy of the papillary muscles (<xref rid="f05001" ref-type="fig">Figure 4</xref>). However, some patients may exhibit asymmetric LVH and even dynamic LVOT obstruction, leading to misdiagnosis as HCM. Dilatation of the aortic root and thickening of the mitral and aortic valves may occur, usually without significant dysfunction. RV hypertrophy with preserved systolic function is common in Fabry disease patients with LVH, and these patients usually exhibit better systolic function compared to CA patients with similar levels of RV wall thickening.<sup><xref rid="B74" ref-type="bibr">74</xref></sup> GLS is significantly reduced in patients with overt Fabry disease, and regional strain alterations are often more pronounced in the basal inferolateral wall, correlating with LGE in this region on CMR. For carriers of pathogenic GLA gene variants, GLS facilitates early detection of cardiac involvement, independent of LVH.<sup><xref rid="B75" ref-type="bibr">75</xref></sup></p><p>CMR shows native T1 characteristically low,<sup><xref rid="B76" ref-type="bibr">76</xref></sup> reflecting the sphingolipid deposition. Once the storage is mainly an intracellular phenomenon, the extracellular space is spared by accumulation, resulting in a normal ECV measured by pre- and post-contrast T1.<sup><xref rid="B76" ref-type="bibr">76</xref></sup> In fact, CMR may depict the three phases of the natural history of the disease. In the initial accumulation phase, a low native T1 is noted in the absence of LVH. The progression of the disease is documented by the appearance of hypertrophy, inflammation and LGE, mainly in the basal inferolateral wall. Finally, in the presence of extensive LGE there is a pseudonormalization of native T1.<sup><xref rid="B76" ref-type="bibr">76</xref></sup></p></sec></sec></sec><sec><title>Noonan Syndrome</title><p>Noonan syndrome is an autosomal dominant genetic disorder, part of a group known as RASopathies, which affects multiple body systems. It is characterized by a range of features, including congenital cardiac abnormalities, short stature, webbed neck, craniofacial dysmorphism, skeletal malformations, bleeding diathesis, hypertelorism, and mild intellectual disability. Mutations causing Noonan syndrome impact genes that encode proteins of the RAS-MAPK (mitogen-activated protein kinase) pathway. This leads to dysregulation of critical cellular processes, including proliferation, differentiation, survival, and metabolism, characteristic of RASopathies.</p><p>In over 80% of Noonan syndrome patients, cardiac abnormalities are observed, with pulmonary stenosis being prevalent in approximately 50% of cases and HCM occurring in 25%.<sup><xref rid="B77" ref-type="bibr">77</xref></sup>Additionally, Noonan syndrome is associated with a wide spectrum of other cardiac malformations.<sup><xref rid="B78" ref-type="bibr">78</xref></sup>LVH typically manifests early and is often diagnosed within the first six months of life.<sup><xref rid="B79" ref-type="bibr">79</xref></sup>LVH observed in Noonan syndrome can present as either concentric or asymmetric, sometimes accompanied by dynamic obstruction of the LVOT. MV anomalies and subvalvular complications, such as SAM, anomalous MV insertion leading to subaortic obstruction, and myxomatous degeneration resulting in valve prolapse, are commonly noted in Noonan syndrome patients with HCM.<sup><xref rid="B80" ref-type="bibr">80</xref></sup> The presence of HCM in Noonan syndrome significantly influences patient outcomes, correlating with increased morbidity and mortality.<sup><xref rid="B81" ref-type="bibr">81</xref></sup> The progression of LVH is variable; in some cases, it may emerge later in childhood and progress slowly, remain stable for several years, or rapidly evolve during infancy. In a subset of patients, representing 17% of a cohort of 46 subjects followed for seven years, regression and stabilization of LVH have been observed.<sup><xref rid="B82" ref-type="bibr">82</xref></sup></p></sec><sec><title>Pompe Disease</title><p>Pompe disease is classified as an autosomal recessive lysosomal storage disorder of rare incidence arising from mutations in the acid &#x003b1;-glucosidase gene. This genetic alteration results in an accumulation of lysosomal glycogen across various tissues, notably the myocardium, respiratory system, and skeletal muscles. The onset of Pompe disease varies, with a potential diagnosis occurring in infancy, childhood, or adulthood. The classic form of the disease, predominantly observed in infants, is characterized by rapid progression and typically presents with HCM, often prognosticating unfavorably. In such cases, untreated infants frequently succumb to cardiorespiratory failure within the first year of life. Phenotypically, Pompe disease is marked by LVH, predominantly with asymmetric septal thickening, although concentric hypertrophy involving both the septal and free walls of the LV and RV is also noted. In CMR, LGE is rare and can be seen in the subendocardium of the lateral and anterior walls. Severe septal hypertrophy often leads to SAM and LVOT obstruction, exacerbating clinical symptoms. These pathologies can progress to diastolic and systolic dysfunction, culminating in HF. Notably, enzyme replacement therapy has been observed to induce rapid regression of LVH and enhance systolic ventricular function, as assessed by myocardial deformation analysis.<sup><xref rid="B83" ref-type="bibr">83</xref></sup></p><sec><title>PRKAG2 cardiomyopathy</title><p>PRKAG2 CM, an autosomal dominant glycogen storage disease that primarily affects the heart muscle and conduction system, presents with a unique clinical profile and prognosis. PRKAG2 CM is characterized by LVH, Wolff-Parkinson-White syndrome, and progressive conduction system disease.<sup><xref rid="B84" ref-type="bibr">84</xref></sup>HCM in patients with PRKAG2 gene mutations typically emerges in the teenage years or adulthood, with few cases reported in infancy. PRKAG2 CM is associated with worse outcomes compared to sarcomeric HCM, with patients potentially experiencing early cardiac failure and sudden death.<sup><xref rid="B85" ref-type="bibr">85</xref></sup> The echocardiographic phenotype often shows concentric LVH, preserved LVEF, diastolic dysfunction, and, less commonly, RV hypertrophy<sup><xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B87" ref-type="bibr">87</xref></sup> (<xref rid="f09001" ref-type="fig">Figure 8</xref>). LVOT obstruction is rare in these patients, compared to patients with sarcomeric HCM. A study showed that patients with PRKAG2 CM may have more preserved GLS, associated with bradycardia, although having similar LV mass and thickening of ventricular walls.<sup><xref rid="B88" ref-type="bibr">88</xref></sup></p><p>
<fig position="float" id="f09001"><label>Figure 8</label><caption><title>&#x02013; Example of a young patient (25y old male) with PRKAG2 cardiomyopathy. In A) parasternal long axis view showing a remodeled left ventricle (LV) with hypertrophy. In B) EKG showing delta waves, short PR interval (Wolff-Parkinson-White syndrome) and LV hypertrophy pattern. In C) short axis view depicting concentric LV hypertrophy. In D) LV longitudinal strain (LS) bulls-eye (parametric display) showing diffuse alteration of myocardial deformation. E) biventricular concentric hypertrophy and an ICD inside right cavities. F) altered right ventricular longitudinal strain (medium free wall strain = -9,33%).</title></caption><graphic xlink:href="0066-782X-abc-122-1-e20240529-gf09-en" position="float"/></fig>
</p></sec><sec><title>Friedreich&#x02019;s Ataxia</title><p>Friedreich&#x02019;s ataxia is an autosomal recessive degenerative disease, affecting the frataxin gene, leading to mitochondrial iron storage and affecting glucose metabolism, the nervous system and the heart.<sup><xref rid="B89" ref-type="bibr">89</xref></sup> Cardiac disease usually manifests as an HCM phenotype that may evolve into dilated cardiomyopathy, the most important cause of death.<sup><xref rid="B90" ref-type="bibr">90</xref></sup>Myocardial involvement may be detected subclinically before the development of LVH or LVEF reduction, either by STE<sup><xref rid="B91" ref-type="bibr">91</xref></sup>or CMR.<sup><xref rid="B92" ref-type="bibr">92</xref></sup></p><p>Echocardiographic typical features are concentric LVH without LVOT or midventricular obstruction (although asymmetric hypertrophy may also occur), with LV dysfunction (reduced EF) and heart failure in advanced disease<sup><xref rid="B93" ref-type="bibr">93</xref></sup>with altered perfusion reserve.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> The morphological aspect of LVH in these patients may resemble CA, even with a sparkling granular texture of myocardium. Still, usually, there is no bi-atrial enlargement, pericardial effusion or severe diastolic dysfunction in patients with Friedreich&#x02019;s ataxia.<sup><xref rid="B94" ref-type="bibr">94</xref></sup></p></sec><sec><title>Danon Disease</title><p>Danon disease is a rare X-linked dominant genetic disease that manifests with the clinical triad of cardiomyopathy, skeletal myopathy, and intellectual disability. It is caused by mutations in the lysosome-associated membrane 2 (LAMP2) gene. Danon cardiomyopathy is progressive and typically manifests as a hypertrophic phenotype, with alterations in radial, circumferential, and longitudinal strain in early stages, with preserved ejection fraction (HFpEF). With the progression of fibrosis, these patients may evolve with a decline in ejection fraction, worsening of symptoms and a dilated phenotype, particularly in male patients.<sup><xref rid="B95" ref-type="bibr">95</xref></sup> The extent and severity of cardiomyopathy is the major prognostic factor. Most patients are asymptomatic during childhood, progressing to a symptomatic stage during adolescence and culminating in fulminant heart failure and sudden death in adulthood.<sup><xref rid="B96" ref-type="bibr">96</xref></sup> CMR findings have a pivotal role in the diagnosis of this disease and typically include marked LVH, which may be concentric or asymmetric, and distinct patterns of LGE that differ from other forms of hypertrophic cardiomyopathy. LGE often spares the mid-septum and exhibits a base-to-apex gradient with the involvement of the apex.<sup><xref rid="B97" ref-type="bibr">97</xref>,<xref rid="B98" ref-type="bibr">98</xref></sup> Furthermore, cardiac MRI can reveal elevated native T1 and ECV, suggesting myocardial fibrosis.<sup><xref rid="B98" ref-type="bibr">98</xref>,<xref rid="B99" ref-type="bibr">99</xref></sup></p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The association of the different pieces of the LVH puzzle (patient&#x02019;s personal and family history, clinical presentation, physical examination findings, ECG features, and multimodality imaging data) can identify specific &#x0201c;red flags&#x0201d; that help the clinician differentiate between different causes of hypertrophic phenotypes.</p><p>This systematic approach allows for more accurate diagnoses and tailored management strategies. However, it is important to note that further diagnostic tests, such as genetic testing, cardiopulmonary exercise test and endomyocardial biopsy, may be necessary to confirm the underlying etiology. Clinical judgment and individualized patient assessment remain crucial in the diagnostic process.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Study association:</bold> This study is not associated with any thesis or dissertation work.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This article does not contain any studies with human participants or animals performed by any of the authors.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of funding:</bold> There were no external funding sources for this study.</p></fn></fn-group></back></sub-article></article>